0001140361-14-007918.txt : 20140214 0001140361-14-007918.hdr.sgml : 20140214 20140214162250 ACCESSION NUMBER: 0001140361-14-007918 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20131231 FILED AS OF DATE: 20140214 DATE AS OF CHANGE: 20140214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: THERMOGENESIS CORP CENTRAL INDEX KEY: 0000811212 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY APPARATUS & FURNITURE [3821] IRS NUMBER: 943018487 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-82900 FILM NUMBER: 14616995 BUSINESS ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 BUSINESS PHONE: 9168585100 MAIL ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 FORMER COMPANY: FORMER CONFORMED NAME: INSTA COOL INC OF NORTH AMERICA DATE OF NAME CHANGE: 19920703 10-Q 1 form10q.htm THERMOGENESIS CORP 10-Q 12-31-2013
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 10-Q

T Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended December 31, 2013.

or

o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition from _____________ to _______________.

Commission File Number: 333-82900
ThermoGenesis Corp.
(Exact name of registrant as specified in its charter)

Delaware
94-3018487
(State of incorporation)
(I.R.S. Employer Identification No.)

2711 Citrus Road
Rancho Cordova, California 95742
(Address of principal executive offices) (Zip Code)

(916) 858-5100
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes T      No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).
Yes T      No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o
Accelerated filer o
Non-accelerated filer o
Smaller reporting company T

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o      No T

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 
Class
 
Outstanding at February 7, 2014
 
 
Common stock, $.001 par value
 
20,038,547
 
 
 
1

ThermoGenesis Corp.

INDEX

 
 
Page Number
Part I
Financial Information
 
 
 
 
Item 1.
3
 
 
 
Item 2.
13
 
 
 
Item 3.
20
 
 
 
Item 4.
20
 
 
 
Part II
Other Information
 
 
 
 
Item 1.
21
Item 1A.
21
Item 2.
22
Item 3.
22
Item 4.
22
Item 5.
23
Item 6.
24
 
 
 
25
2

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

ThermoGenesis Corp.
Condensed Balance Sheets (Unaudited)

(in thousands, except share and per share amounts)
  
December 31,
    
June 30,
  
 
  
2013
    
2013
  
ASSETS
  
   
 
Current assets:
  
   
 
Cash and cash equivalents
  
$
2,330
    
$
6,884
  
Accounts receivable, net of allowance for doubtful accounts of $29 ($47 at June 30, 2013)
    
5,538
      
4,898
  
Inventories
    
4,180
      
4,259
  
Prepaid expenses and other current assets
    
136
      
232
  
Total current assets
    
12,184
      
16,273
  
 
                
Equipment at cost, less accumulated depreciation of $3,589 ($3,277 at June 30, 2013)
    
2,106
      
2,208
  
Other assets
    
48
      
48
  
 
  
$
14,338
    
$
18,529
  
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
 
                
Current liabilities:
                
Accounts payable
  
$
2,737
    
$
3,106
  
Accrued payroll and related expenses
    
531
      
477
  
Deferred revenue
    
371
      
377
  
Other current liabilities
    
998
      
1,188
  
Total current liabilities
    
4,637
      
5,148
  
 
                
Deferred revenue
    
69
      
63
  
 
                
Commitments and contingencies (Footnote 3)
                
 
                
Stockholders’ equity:
                
 
                
Preferred stock, $0.001 par value; 2,000,000 shares authorized; none outstanding
    
--
      
--
  
Common stock, $0.001 par value; 80,000,000 shares authorized; 16,692,372 issued and outstanding (16,557,627 at June 30, 2013)
    
16
      
16
  
Paid in capital in excess of par
    
127,709
      
127,493
  
Accumulated deficit
    
(118,093
)
    
(114,191
)
 
                
Total stockholders’ equity
    
9,632
      
13,318
  
 
                
 
  
$
14,338
    
$
18,529
  

See accompanying notes.
3

ThermoGenesis Corp.
Condensed Statements of Operations (Unaudited)

(in thousands, except share and per share amounts)
  
Three Months Ended
    
Six Month Ended
  
 
  
December 31,
    
December 31,
  
 
  
2013
    
2012
    
2013
    
2012
  
 
  
   
   
   
 
Net revenues
  
$
4,468
    
$
4,802
    
$
8,112
    
$
8,924
  
 
                                
Cost of revenues
    
2,679
      
2,826
      
4,932
      
5,322
  
 
                                
Gross profit
    
1,789
      
1,976
      
3,180
      
3,602
  
 
                                
 
                                
Expenses:
                                
 
                                
Sales and marketing
    
713
      
735
      
1,428
      
1,391
  
 
                                
Research and development
    
797
      
714
      
1,630
      
1,552
  
 
                                
General and administrative
    
1,882
      
1,085
      
4,024
      
2,225
  
 
                                
Gain on sale of product line
    
--
      
--
      
--
      
(2,000
)
 
                                
Total operating expenses
    
3,392
      
2,534
      
7,082
      
3,168
  
 
                                
Income (loss) from operations
    
(1,603
)
    
(558
)
    
(3,902
)
    
434
  
 
                                
Interest and other income (expense), net
    
--
      
(5
)
    
--
      
(2
)
Net income (loss)
  
$ 
(1,603
)
  
$ 
(563
)
  
$ 
(3,902
)
  
$
432
  
 
                                
Per share data:
                                
 
                                
Basic and diluted net income (loss) per common share
  
$ 
(0.10
)
  
$ 
(0.03
)
  
$ 
(0.23
)
  
$
0.03
  
 
                                
Weighted average common shares outstanding:
                                
 
                                
Basic
    
16,682,730
      
16,522,310
      
16,672,811
      
16,519,078
  
 
                                
Diluted
    
16,682,730
      
16,522,310
      
16,672,811
      
16,519,654
  

See accompanying notes.
4

ThermoGenesis Corp.
Condensed Statements of Cash Flows (Unaudited)

 
  
Six Months Ended
  
(in thousands)
  
December 31,
  
 
  
2013
    
2012
  
Cash flows from operating activities:
  
   
 
Net income (loss)
  
$ 
(3,902
)
  
$
432
  
Adjustments to reconcile net loss to net cash used in operating activities:
                
Depreciation and amortization
    
327
      
266
  
Stock based compensation expense
    
284
      
272
  
Loss on disposal of equipment
    
--
      
7
  
Gain on sale of product line
    
--
      
(2,000
)
Net change in operating assets and liabilities:
                
Accounts receivable, net
    
(640
)
    
(797
)
Inventories
    
7
      
710
  
Prepaid expenses and other current assets
    
96
      
(82
)
Accounts payable
    
(369
)
    
(1,087
)
Accrued payroll and related expenses
    
54
      
(168
)
Deferred revenue
    
--
      
(135
)
Other liabilities
    
(190
)
    
87
  
 
                
Net cash used in operating activities
    
(4,333
)
    
(2,495
)
Cash flows from investing activities:
                
Capital expenditures
    
(153
)
    
(314
)
Proceeds from sale of product line
    
--
      
2,000
  
Proceeds from prepayment from sale of product line
    
--
      
500
  
 
                
Net cash provided by (used in) investing activities
    
(153
)
    
2,186
  
 
                
Cash flows from financing activities:
                
Repurchase of common stock
    
(68
)
    
(54
)
 
                
Net cash used in financing activities
    
(68
)
    
(54
)
 
                
Net decrease in cash and cash equivalents
    
(4,554
)
    
(363
)
 
                
Cash and cash equivalents at beginning of period
    
6,884
      
7,879
  
Cash and cash equivalents at end of period
  
$
2,330
    
$
7,516
  
 
                
Supplemental non-cash financing and investing information:
                
Transfer of inventories to equipment
  
$
57
    
$
214
  

See accompanying notes.
5

ThermoGenesis Corp.
Notes to Condensed Financial Statements
(Unaudited)

1. Basis of Presentation and Summary of Significant Accounting Policies

Organization and Basis of Presentation
ThermoGenesis Corp. (the Company, we or our) designs, develops and commercializes clinical technologies for the processing, storage and administration of stem cells and blood components for sale to users and companies involved in the development and administration of cell therapies.

Interim Reporting
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (SEC) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed financial statements through the date of issuance. Operating results for the six month period ended December 31, 2013, are not necessarily indicative of the results that may be expected for the year ending June 30, 2014. These unaudited condensed financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended June 30, 2013.

Revenue Recognition
Revenues from the sale of our products are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. We generally ship products F.O.B. shipping point. There is no conditional evaluation on any product sold and recognized as revenue. All foreign sales are denominated in U.S. dollars. Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet.

Our sales are generally through distributors. There is no right of return provided for distributors. For sales of products made to distributors, we consider a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are not limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements with us, the level of inventories maintained by the distributor, whether we have a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive. We currently recognize revenue primarily on the sell-in method with our distributors.

Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis. Revenue for each unit of accounting is recognized as the unit of accounting is delivered. Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Estimated selling prices are determined using vendor specific objective evidence of value (VSOE), when available, or an estimate of selling price when VSOE is not available for a given unit of accounting. Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer’s geographic location. We account for training and installation, and service agreements as separate units of accounting.
6

Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement. All other service revenue is recognized at the time the service is completed.

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

Fair Value of Financial Instruments
The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short duration.

Segment Reporting
We operate in a single segment providing medical devices and disposables to hospitals and blood banks throughout the world which utilize the equipment to process blood components.

Net Income (Loss) per Share
Basic net income (loss) per share is calculated in accordance with Accounting Standards Codification (ASC) Topic 260, “Earnings Per Share”, which requires using the average number of shares of common stock outstanding. Diluted net income (loss) per share is computed on the basis of the average number of common shares outstanding plus the dilutive effect of any common stock equivalents using the “treasury stock method”.

The following table provides a reconciliation of weighted-average shares used to determine basic and diluted earnings per share for the six months ended December 31, 2012.

Basic average common shares outstanding
    
16,519,078
  
Effect of dilutive options
    
576
  
Diluted average common shares outstanding
    
16,519,654
  

Common stock equivalents consist of stock options, warrants and common stock restricted awards. For the three and six months ended December 31, 2013, 2,263,671 common stock equivalents were excluded from the computation of earnings per share because their effect would have been anti-dilutive, and 2,622,712 and 2,577,712 for the three and six months ended December 31, 2012.

Comprehensive Loss
ASC 220, “Comprehensive Income” establishes standards for the reporting and communication of comprehensive income (loss) and its components in the financial statements. As of December 31, 2013, the Company has no items of other comprehensive income (loss) and, therefore, has not included a schedule of comprehensive income (loss) in the financial statements.
7

Recently Adopted Accounting Pronouncements
In February 2013, the FASB issued ASC 2013-02, which is an update to improve the reporting of reclassifications out of accumulated other comprehensive income (AOCI). Companies are also required to present reclassifications by component when reporting changes in AOCI balances. We adopted ASC 2013-02 effective July 1, 2013. The adoption of ASC 2013-02 did not have a material impact on our results of operations or financial condition.

Recently Issued Accounting Pronouncements
In July 2013, the FASB issued ASU 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”. This amendment requires entities to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward or a similar tax loss or a tax credit carryforward, unless certain conditions exist. This guidance is effective prospectively for annual reporting periods (and the interim periods within) beginning after December 15, 2013. Early adoption and retrospective application are permitted. We expect to adopt this guidance effective July 2014. We are currently assessing the potential impact, if any, the adoption of ASU 2013-11 may have on our financial statements.

2. Inventories

Inventories consisted of the following at:

 
  
December 31,
2013
    
June 30,
2013
  
 
  
   
 
Raw materials
  
$
709,000
    
$
981,000
  
Work in process
    
1,963,000
      
2,066,000
  
Finished goods
    
1,508,000
      
1,212,000
  
 
  
$
4,180,000
    
$
4,259,000
  

3. Commitments and Contingencies

Financial Covenants
In June 2010, we entered into a License and Escrow Agreement which granted a customer a non-exclusive, royalty-free license to certain intellectual property necessary for the potential manufacture and supply of AXP devices and certain AXP disposables. The license is for the sole and limited purpose of manufacturing and supplying the AXP and related disposables for use by the customer. The licensed intellectual property will be maintained in escrow and will be released to and used by the customer if and only if the Company defaults under the Agreement. Originally, default occurred if the Company (1) fails to meet certain positive cash flow metrics for each rolling quarterly measurement period except where the following two measures are met, (2) failure to meet cash balance and short-term investments of at least $6,000,000 at the end of any given month, or (3) failure to meet a quick ratio of 2 to 1 at the end of any given month.

On December 31, 2013 we amended and restated the License and Escrow Agreement to delete all of the financial covenants except the minimum cash and short-term investments balance covenant, (2) above, which was reduced to $2,000,000 at the end of any given month. We are in compliance with this covenant at January 31, 2014.
8

Contingencies
On April 11, 2013, we filed an answer and counter-claims in response to the complaint Harvest Technologies Corp. (Harvest) filed on October 24, 2012 against the Company in the case captioned as Harvest Technologies Corp. v. ThermoGenesis Corp., 12-cv-01354, U.S. District Court, District of Delaware (Wilmington), with the complaint being amended on February 15, 2013 to name the Company’s customer Celling Technologies, LLC as a defendant. In the complaint, Harvest contends that our Res-Q 60 System infringes certain Harvest patents. The counter-claims are based on anti-trust and other alleged improper conduct by Harvest and further seek declarations that the Res-Q 60 System does not infringe the patents and that the patents are invalid. The Company is vigorously defending itself against the Harvest claims, while aggressively pursuing its separate claims against Harvest. The Company is unable to ascertain the likelihood of any liability and has not made an accrual as of December 31, 2013.

During the three months ended September 30, 2012, we were notified by a third party who believes that the Res-Q system infringes upon certain of its US and European patents. The Company is in the process of gathering information; however, it has not yet collected enough information to assess the validity of the alleged infringement or estimate any potential financial impact; therefore, it has not made an accrual as of December 31, 2013.

Warranty
We offer a warranty on all of our products of one to two years, except disposable products which we warrant through their expiration date. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.

The warranty liability is included in other current liabilities in the unaudited balance sheet. The change in the warranty liability for the six months ended December 31, 2013 is summarized in the following table:

 
  
 
Balance at July 1, 2013
  
$
489,000
  
Warranties issued during the period
    
90,000
  
Settlements made during the period
    
(75,000
)
Changes in liability for pre-existing warranties during the period
    
(142,000
)
Balance at December 31, 2013
  
$
362,000
  

4. Stockholders’ Equity

Stock Based Compensation
We recorded stock-based compensation of $115,000 and $284,000 for the three and six months ended December 31, 2013, and $129,000 and $272,000 for the three and six months ended December 31, 2012.
9

The following is a summary of option activity for our stock option plans:

 
  
Number of Shares
    
Weighted- Average Exercise Price
    
Weighted- Average Remaining Contractual Life
    
Aggregate Intrinsic Value
  
 
  
   
   
   
 
Outstanding at June 30, 2013
    
1,063,750
    
$
2.36
    
   
 
 
                  
   
 
Granted
    
48,750
    
$
1.39
    
   
 
Forfeited
    
(6,750
)
  
$
2.21
    
   
 
Expired
    
(158,750
)
  
$
3.67
    
   
 
 
                  
   
 
Outstanding at December 31, 2013
    
947,000
    
$
2.09
      
1.9
    
$
27,000
  
 
                                
Vested and Expected to Vest at December 31, 2013
    
861,767
    
$
2.04
      
1.8
    
$
21,000
  
 
                                
Exercisable at December 31, 2013
    
602,214
    
$
2.41
      
1.6
    
$
7,000
  

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no options exercised during the six months ended December 31, 2013 and 2012.

Common Stock Restricted Awards
The following is a summary of restricted stock activity during the six months ended December 31, 2013:

 
  
Number of Shares
    
Weighted Average Grant Date Fair Value
  
Balance at June 30, 2013
    
390,003
    
$
1.81
  
Granted
    
--
      
--
  
Vested
    
(164,998
)
  
$
1.93
  
Forfeited
    
(33,334
)
  
$
1.81
  
Outstanding at December 31, 2013
    
191,671
    
$
1.70
  

In connection with the vesting of the restricted stock awards, the election was made by some of the employees to satisfy the applicable federal income tax withholding obligation by a net share settlement, pursuant to which the Company withheld 57,680 shares and used the deemed proceeds from those shares to pay the income tax withholding. The net share settlement is deemed to be a repurchase by the Company of its common stock.
10

5. Merger with TotipotentRX

On July 15, 2013, we entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), with TotipotentRX providing for the merger of TotipotentRX into the Company, with the Company surviving. TotipotentRX is a privately held biomedical technology company specializing in human clinical trials in the field of regenerative medicine and is the exclusive provider of cell-based therapies to the Fortis Healthcare System.

At the February 13, 2014 Special Meeting, the Company’s stockholders voted in favor of the merger and the TotipotentRX stockholders have also approved the merger. The merger is expected to become effective on February 18, 2014. The combined company will be called Cesca Therapeutics Inc. to better reflect the combined products and services of the two companies.

Upon consummation of the merger, a TotipotentRX stockholder will receive, in exchange for each share of TotipotentRX common stock held by such stockholder immediately before the closing of the Merger, approximately 30 shares of Company common stock, subject to adjustment. After the merger, the former shareholders of TotipotentRX will own approximately 12,490,800 shares of the Company’s common stock. Additionally, TotipotentRX’s Chief Executive Officer will become President of and a director of our Company.

The Merger Agreement contains certain termination rights for both the Company and TotipotentRX, and further provides that, upon termination of the Merger Agreement under specified circumstances, including, but not limited to, termination due to a failure by one party to recommend approval of the merger, a party soliciting an acquisition proposal in breach of the Merger Agreement, or a party entering into an agreement with a third party related to an acquisition proposal, that breaching party may be required to pay to the other party a termination fee of $500,000.

11

6. Sale of Product Lines
 
Thermoline
On December 31, 2012, the Company entered into an Asset Purchase Agreement for the sale of certain of the assets, rights and properties of the ThermoLine product line for $500,000. The $500,000 was received upon signing the agreement and was included in other current liabilities on the December 31, 2012 balance sheet. The Company recognized the gain on sale upon delivery of the assets which occurred during the quarter ended March 31, 2013.
 
CryoSeal
In June 2010, the Company and Asahi entered into an amendment (the "Amendment") of their Distribution and License Agreement. Under the terms of the Amendment, Asahi obtained exclusive rights to distribute the CryoSeal System in South Korea, North Korea, Taiwan, the People’s Republic of China, the Philippines, Thailand, Singapore, India and Malaysia. These rights included the exclusive right to market, distribute and sell the processing disposables and Thrombin Reagent for production of thrombin in a stand-alone product.

In connection with the above-described Amendment, the Company and Asahi also entered into an Option Agreement ("Option Agreement") and on June 30, 2012, Asahi exercised the option to purchase certain intangible assets related to this product line, including all associated patents and engineering files for $2,000,000. In connection with the notice of exercise, the Amendment automatically terminated. Payment of the $2,000,000 was based upon completion of certain provisions of the Option Agreement. As such, the Company recognized the gain on sale upon completion of those provisions which occurred in July 2012. The $2,000,000 payment was received in August 2012.

7. Subsequent Event

On January 30, 2014, the Company completed a private placement of the sale of 3,336,800 shares of its common stock at $2.00 per share, together with warrants to purchase up to an aggregate of 1,668,400 shares of common stock. The warrants may be exercised by the holders at a price of $2.81 per share starting July 30, 2014 continuing through January 29, 2019.
12

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward‑Looking Statements
This report contains forward-looking statements. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained herein. When used in this report, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company or its management are intended to identify such forward-looking statements. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by these forward-looking statements. We wish to caution readers of the important factors, among others, that in some cases have affected, and in the future could affect our actual results and could cause actual results for fiscal year 2014 and beyond, to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company. These factors include without limitation, the ability to obtain capital and other financing in the amounts and at the times needed to complete clinical trials and product marketing for new products, market acceptance of new products, regulatory approval and time frames for such approval of new products and new claims for existing products, realization of forecasted income and expenses, initiatives by competitors, price pressures, failure to meet FDA regulations governing our products and operations and recalls associated with such regulations, the risks associated with initiating manufacturing for new products, failure to meet FCPA regulations, legal proceedings, and the risk factors listed from time to time in our SEC reports, including, in particular, the factors and discussion in our Form 10-K for fiscal year 2013.

Overview
ThermoGenesis designs, develops and commercializes devices and disposable tools for use by customers to automate the processing, separation and storage of certain cells, and stem cell fractions sourced from cord blood, peripheral blood and bone marrow. These cells can be used for research and development or the practice of regenerative medicine depending upon the application and the specific regulatory approval granted. The Company was founded in 1986 and is located in Rancho Cordova, California. Our growth strategy is to expand our offerings in the development of regenerative medicine tools and partner with other pioneers in the stem cell arena to accelerate our clinical evaluations and our worldwide penetration in this market.

In October 2013, we effected a strategic reorganization designed to better align resources with our expected cord blood revenue streams, increase our internal clinical resource capabilities and provide greater focus on new application development to improve our market competitiveness and to speed AXP AutoXpress Platform (AXP) adoption in developed and emerging markets. As a result of eliminating a total of eleven positions in connection with the reorganization, coupled with other targeted savings in operating costs, we expect to realize approximately $1.5 million in annual expense savings. One-time severance costs of approximately $210,000 were recorded in the quarter ended December 31, 2013.

Our Products
Cord Blood
· The AXP System is a medical device with an accompanying disposable bag set that isolates and retrieves stem cells from umbilical cord blood. The AXP System provides cord blood banks with an automated method to separate and capture adult stem cells which reduces the overall processing and labor costs with a reduced risk of contamination under cGMP conditions. The AXP System retains over 97% of the mononuclear cells (MNCs). High MNC recovery has significant clinical importance to patient transplant survival rates. Self-powered and microprocessor-controlled, the AXP device contains flow control optical sensors that achieve precise separation of the cord blood fractions.
13

· The BioArchive System is a robotic cryogenic medical device used to cryopreserve and archive stem cells for future transplant and treatment. Launched in fiscal 1998, our BioArchive Systems have been purchased by over 110 umbilical cord blood banks in over 35 countries to archive, cryopreserve and store stem cell preparations extracted from human placentas and umbilical cords for future use.

Bone Marrow
· The MarrowXpress® or MXP System, a derivative product of the AXP and its accompanying disposable bag set, isolates and concentrates stem cells from bone marrow. The product is an automated, closed, sterile system that volume-reduces blood from bone marrow to a user-defined volume in 30 minutes, while retaining over 90% of the MNCs, a clinically important cell fraction. Self-powered and microprocessor-controlled, the MXP System contains flow control optical sensors that achieve precise separation. In June 2008, we received the CE-Mark, enabling commercial sales in Europe. In July 2008, we received authorization from the FDA to begin marketing the MXP as a Class I device in the U.S. for the preparation of cell concentrate from bone marrow. However, the safety and effectiveness of this device for in vivo use has not been established.

· The Res-Q 60 BMC, is a rapid, reliable, and easy to use product for cell processing. The product is a centrifuge-based disposable device designed for the isolation and extraction of specific stem cell populations from bone marrow. The product was launched in 2009. The key advantages of the Res-Q 60 BMC include (a) delivering a high number of target cells from a small sample of bone marrow, and (b) providing a disposable that is highly portable and packaged for the sterile field. These features allow users to process bone marrow to isolate and capture certain cells in 15 minutes. However, the safety and effectiveness of this device for in vivo use has not been established.

PRP
· The Res-Q 60 PRP is designed to be used for the safe and rapid preparation of autologous platelet rich plasma (PRP) from a small sample of blood at the point of care. The product allows PRP to be mixed with autograft and/or allograft bone prior to application to a bony defect in the body. The Res-Q 60 PRP received FDA 510(k) clearance in June of 2011.

The following is management’s discussion and analysis of certain significant factors which have affected our financial condition and results of operations during the period included in the accompanying financial statements.

Merger with TotipotentRX
On July 15, 2013, we entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), with TotipotentRX providing for the merger of TotipotentRX into the Company, with the Company surviving. TotipotentRX is a privately held biomedical technology company specializing in human clinical trials in the field of regenerative medicine and is the exclusive provider of cell-based therapies to the Fortis Healthcare System.

At the February 13, 2014 Special Meeting, the Company’s stockholders voted in favor of the merger and the TotipotentRX stockholders have also approved the merger. The merger is expected to become effective on February 18, 2014. The combined company will be called Cesca Therapeutics Inc. to better reflect the combined products and services of the two companies.
14

Upon consummation of the merger, TotipotentRX stockholder will receive, in exchange for each share of TotipotentRX common stock held by such stockholder immediately before the closing of the Merger, approximately 30 shares of Company common stock, subject to adjustment. After the merger, the former shareholders of TotipotentRX will own approximately 12,490,800 shares of the Company’s common stock. Additionally, TotipotentRX’s Chief Executive Officer will become President of and a director of our Company.

The Merger Agreement contains certain termination rights for both the Company and TotipotentRX, and further provides that, upon termination of the Merger Agreement under specified circumstances, including, but not limited to, termination due to a failure by one party to recommend approval of the merger, a party soliciting an acquisition proposal in breach of the Merger Agreement, or a party entering into an agreement with a third party related to an acquisition proposal, that breaching party may be required to pay to the other party a termination fee of $500,000.
 
Critical Accounting Policies
Management’s discussion and analysis of its financial condition and results of operations is based upon the condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these condensed financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a full discussion of our accounting estimates and assumptions that we have identified as critical in the preparation of our condensed financial statements, please refer to our 2013 Annual Report on Form 10-K.
15

Results of Operations for the Three Months Ended December 31, 2013 as Compared to the Three Months Ended December 31, 2012

Net Revenues
Revenues for the three months ended December 31, 2013 were $4,468,000 compared to $4,802,000 for the three months ended December 31, 2012, a decrease of $334,000. The decrease is primarily due to a decrease in BioArchive device revenues as there was one less BioArchive device sold during the quarter ended December 31, 2013 as compared to the quarter ended December 31, 2012. Additionally, other revenues decreased as we were still selling ThermoLine products during the quarter ended December 31, 2012 prior to the sale of the product line. These decreases were offset by an increase in revenues from Res-Q disposables.

The following represents the Company’s revenues by product platform for the three months ended:

 
  
December 31,
  
 
  
2013
    
2012
  
 
  
   
 
AXP
  
$
2,126,000
    
$
2,163,000
  
BioArchive
    
1,084,000
      
1,345,000
  
Manual Disposables
    
457,000
      
546,000
  
Bone Marrow
    
654,000
      
467,000
  
Other
    
147,000
      
281,000
  
 
  
$
4,468,000
    
$
4,802,000
  

Gross Profit
The Company’s gross profit was $1,789,000 or 40% of net revenues for the three months ended December 31, 2013, compared to $1,976,000 or 41% for the corresponding fiscal 2013 period. Gross profit declined commensurate with the decline in revenues.

Sales and Marketing Expenses
Sales and marketing expenses were $713,000 for the three months ended December 31, 2013, compared to $735,000 for the comparable fiscal 2013 period, a decrease of $22,000 or 3%. The slight decrease is primarily due to a decline in sales commissions as a result of the decrease in revenues.

Research and Development Expenses
Research and development expenses were $797,000 for the three months ended December 31, 2013, compared to $714,000 for the comparable fiscal 2013 period, an increase of $83,000 or 12%. The increase is primarily due to costs associated with developing our Vascular Xpress, or VXP, which is an advancement of the AXP system to treat vascular indications.

General and Administrative Expenses
General and administrative expenses were $1,882,000 for the three months ended December 31, 2013, compared to $1,085,000 for the comparable fiscal 2013 period, an increase of $797,000 or 73%. The increase is primarily due to expenses of $563,000 associated with the proposed merger with TotipotentRX, $220,000 of legal fees associated with the Harvest patent litigation and $130,000 of severance costs related to the October reorganization. Without these costs, general and administrative expenses remained consistent.
16

Non-GAAP Measures
In addition to the results reported in accordance with US GAAP, we also use a non-GAAP measure, adjusted EBITDA, to evaluate operating performance and to facilitate the comparison of our historical results and trends. This financial measure is not a measure of financial performance under US GAAP and should not be considered in isolation or as a substitute for loss as a measure of performance. The calculation of this non-GAAP measure may not be comparable to similarly titled measures used by other companies. Reconciliations to the most directly comparable GAAP measure are provided below.

 
  
Three Months Ended December 31,
  
 
  
2013
    
2012
  
Loss from operations
  
$ 
(1,603,000
)
  
$ 
(558,000
)
 
                
Add (subtract):
                
Depreciation and amortization
    
171,000
      
132,000
  
Stock-based compensation expense
    
115,000
      
129,000
  
Adjusted EBITDA loss
  
$ 
(1,317,000
)
  
$ 
(297,000
)

Adjusted EBITDA
The adjusted EBITDA loss was $1,317,000 for the three months ended December 31, 2013 compared to $297,000 for the three months ended December 31, 2012. The adjusted EBITDA loss increased compared to the second quarter in the prior year due to our expenses associated with our proposed merger with TotipotentRX, legal fees regarding the Harvest patent litigation and a decrease in revenues associated with our BioArchive devices and ThermoLine products, as discussed above.
17

Results of Operations for the Six Months Ended December 31, 2013 as Compared to the Six Months Ended December 31, 2012

Net Revenues
Revenues for the six months ended December 31, 2013 were $8,112,000 compared to $8,924,000 for the six months ended December 31, 2012, a decrease of $812,000. The decrease is primarily due to the anticipated decrease in AXP disposable revenues that occurred in the first quarter of fiscal 2014 due to the termination of the GE distribution agreement and the related wind-down of their product inventory offset by an increase in shipments to Golden Meditech. Also, other revenues decreased as we were still selling ThermoLine products during the six months ended December 31, 2012 prior to the sale of the product line.

The following represents the Company’s revenues by product platform for the six months ended:

 
  
December 31,
  
 
  
2013
    
2012
  
 
  
   
 
AXP
  
$
3,330,000
    
$
4,034,000
  
BioArchive
    
2,195,000
      
2,180,000
  
Manual Disposables
    
1,020,000
      
967,000
  
Bone Marrow
    
1,319,000
      
1,003,000
  
Other
    
248,000
      
740,000
  
 
  
$
8,112,000
    
$
8,924,000
  

Gross Profit
The Company’s gross profit was $3,180,000 or 39% of net revenues for the six months ended December 31, 2013, compared to $3,602,000 or 40% for the corresponding fiscal 2013 period. Gross profit declined commensurate with the decline in revenues.

Sales and Marketing Expenses
Sales and marketing expenses were $1,428,000 for the six months ended December 31, 2013, compared to $1,391,000 for the comparable fiscal 2013 period, an increase of $37,000 or 3%. The increase is primarily due to expenses associated with establishing direct representation in Asia.

Research and Development Expenses
Research and development expenses were $1,630,000 for the six months ended December 31, 2013, compared to $1,552,000 for the comparable fiscal 2013 period, an increase of $78,000 or 5%. The increase is primarily due to costs associated with developing our VXP system and ensuring our products comply with the European Union Restriction of Hazardous Substances in Electrical and Electronic Equipment (“RoHS”) Directive.

General and Administrative Expenses
General and administrative expenses were $4,024,000 for the six months ended December 31, 2013, compared to $2,225,000 for the comparable fiscal 2013 period, an increase of $1,799,000 or 81%. The increase is primarily due to expenses of $1,240,000 associated with the proposed merger with TotipotentRX, $485,000 of legal fees associated with the Harvest patent litigation and $130,000 of severance costs related to the October reorganization. Without these costs, general and administrative expenses remained consistent.
18

Gain on Sale of Product Line
During the six months ended December 31, 2012, the Company recognized a gain of $2,000,000 on the sale of certain intangible assets related to the CryoSeal product line, including all associated patents and engineering files.

Non-GAAP Measures
In addition to the results reported in accordance with US GAAP, we also use a non-GAAP measure, adjusted EBITDA, to evaluate operating performance and to facilitate the comparison of our historical results and trends. This financial measure is not a measure of financial performance under US GAAP and should not be considered in isolation or as a substitute for loss as a measure of performance. The calculation of this non-GAAP measure may not be comparable to similarly titled measures used by other companies. Reconciliations to the most directly comparable GAAP measure are provided below.

 
  
Six Months Ended December 31,
  
 
  
2013
    
2012
  
Income (loss) from operations
  
$ 
(3,902,000
)
  
$
434,000
  
 
                
Add (subtract):
                
Depreciation and amortization
    
327,000
      
266,000
  
Stock-based compensation expense
    
284,000
      
272,000
  
Gain on sale of product line
    
--
      
(2,000,000
)
Adjusted EBITDA loss
  
$ 
(3,291,000
)
  
$ 
(1,028,000
)

Adjusted EBITDA
The adjusted EBITDA loss was $3,291,000 for the six months ended December 31, 2013 compared to $1,028,000 for the six months ended December 31, 2012. The adjusted EBITDA loss increased compared to the first six months in the prior year due to our temporary decrease in AXP disposable revenues and expenses associated with our proposed merger with TotipotentRX and legal fees regarding the Harvest patent litigation.

Liquidity and Capital Resources
At December 31, 2013, we had cash and cash equivalents of $2,330,000 and working capital of $7,547,000. This compares to cash and cash equivalents of $6,884,000 and working capital of $11,125,000 at June 30, 2013. The Company has primarily financed operations through private and public placement of equity securities and the sale of certain non-core assets. On January 30, 2014, we completed a private placement of 3,336,800 shares of common stock, plus 1,668,400 warrants for net proceeds of $6.1 million.

Net cash used in operating activities for the six months ended December 31, 2013 was $4,333,000 compared to $2,495,000 for the six months ended December 31, 2012. The increase is primarily due to the net loss of $3,902,000.

Based on our cash balance after the January 30, 2014 private placement, historical trends, cost reductions and future revenue projections, we believe our current funds are sufficient to provide for our projected needs to maintain operations and working capital requirements for at least the next 12 months. However, in order to maximize the value of our clinical trials and accelerate the planned commercialization of our products in connection with the proposed merger with TotipotentRX, we intend to raise approximately $10 to $15 million for investing in the planned clinical development strategy over 36 months. Effective December 31, 2013, we amended the Technology License and Escrow Agreement with Cord Blood Registry Systems, Inc. The amendment deleted all of the financial covenants, except the minimum cash and short-term investments balance covenant which it reduced to $2,000,000 at any month end. Our ability to fund our longer-term cash needs is subject to various risks, many of which are beyond our control. Should we require additional funding, such as additional capital investments, we may need to raise the required additional funds through bank borrowings or public or private sales of debt or equity securities. We cannot assure that such funding will be available in needed quantities or on terms favorable to us, if at all see Part I Item 1A – Risk Factors.
19

Off-Balance Sheet Arrangements
As of December 31, 2013, we had no off-balance sheet arrangements.

Backlog
Our cancelable backlog at December 31, 2013 was $505,000. Our backlog consists of product orders for which a customer purchase order has been received and is scheduled for shipment within the next twelve months. Orders are subject to cancellation or rescheduling by the customer, sometimes with a cancellation charge. Due to timing of order placement, product lead times, changes in product delivery schedules and cancellations, and because sales will often reflect orders shipped in the same quarter received, our backlog at any particular date is not necessarily indicative of sales for any succeeding period.

Item 3. Quantitative and Qualitative Disclosures about Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Securities and Exchange Act of 1934 and are not required to provide information under this item.

Item 4. Controls and Procedures
We carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer along with our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined by Exchange Act Rule 13a-15(e) and 15d-15(e)) as of the end of our fiscal quarter pursuant to Exchange Act Rule 13a-15. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective.

There were no changes in our internal controls over financial reporting that occurred during the three months ended December 31, 2013 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company have been detected.
20

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.
In the normal course of operations, we may have disagreements or disputes with distributors, vendors or employees. Such potential disputes are seen by management as a normal part of business.
 
On December 17, 2013, the Company filed a lawsuit against OriGen Bimedical, Inc. ThermoGenesis Corp. v. Origen Biomedical, Inc., 2:13-cv-02619, U.S. District Court, Eastern District of California (Sacramento) claiming that OriGen’s freezer bag products are infringing on one of our patents and a patent developed from our partnership with New York Blood Center, which although owned by the New York Blood Center, has had all rights thereunder assigned to us. On January 28, 2014, a Stipulation and Order, was signed to extend Origen’s deadline to file a response until February 28, 2014.

On October 24, 2012, Harvest Technologies Corp. filed suit against us in the case Harvest Technologies Corp. v. ThermoGenesis Corp., 12-cv-01354, U.S. District Court, District of Delaware (Wilmington) claiming our Res-Q 60 System infringes certain Harvest patents. The Company has been served, and on April 11, 2013, we filed an answer and counter-claims in response. The counter-claims are based on anti-trust and other alleged improper conduct by Harvest and further seek declarations that the Res-Q 60 System does not infringe the patents and that the patents are invalid. The Company intends to vigorously defend itself against the Harvest claims, while aggressively pursuing its separate claims against Harvest.

Item 1A. Risk Factors.
In addition to the risk factors discussed below and other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2013, which could materially affect our business, financial condition or future results. There have been no material changes from those risk factors, other than the risk factors listed below. The risks described in our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known or knowable to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.
 
An Inability to Successfully Integrate Operations with TotipotentRX Could Adversely Affect the Combined Business. The ability of ThermoGenesis and TotipotentRX to fulfill our strategy and business plan is dependent on our ability to successfully integrate our operations. Failure to quickly and adequately integrate operations and personnel could adversely affect the combined company’s business and its ability to achieve its objectives and strategy.
21

We May Not Be Able to Successfully Integrate our Business with TotipotentRX, or to Realize the Anticipated Synergies of the Combined Businesses. Our proposed merger with TotipotentRX represents a significant investment by both companies. The merger will require significant attention and resources of both our companies which could reduce the likelihood of achievement of other corporate goals. The additional financing needs created by the combined company will also require additional management time to address. There is no assurance that we will realize synergies in the scientific, clinical, regulatory, or other areas as we currently contemplate.

Upon Completion of the Merger, We Will Need to Raise Additional Capital in Furtherance of our Business Plan. Upon completion of the merger, management estimates a need for $10 million to $15 million of additional growth capital to execute the Cesca business plan over the next 24 to 36 months. The proposed financing may include shares of common stock and warrants to purchase additional shares of common stock, equity investments from strategic development partners or some combination of each. Any additional equity financings may be financially dilutive to, and will be dilutive from an ownership perspective to, the combined company’s stockholders.

Lack of Demonstrated Clinical Utility of Cord Blood Derived Stem Cells Beyond Hematopoietic Transplantation May Result in a Decline in Demand for Cord Blood Banking Services, Adversely Affecting Sales of Our Products. Transplants using stem cells derived from cord blood and cord tissue have become a standard procedure for treating blood cell lineage disorders including leukemia, lymphoma and anemia. However, clinical research demonstrating the utility of cord blood stem cells for use in treating other diseases or injury has been minimal, leaving claims of broad clinical utility of cord blood stem cells by cord blood banks largely unsubstantiated. The low utilization rate of banked cord blood samples coupled with the lack of demonstrated clinical results for multiple treatment indications has led to consumer skepticism regarding the benefits of cord blood banking and in turn, a significant reduction in collection rates in a number of geographies in Europe and the US. A continued lack of investment in the research and development of supporting clinical data for additional applications may lead to greater skepticism globally, further adversely affecting demand for cord blood banking services and our revenues.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.

Item 3. Defaults upon Senior Securities.
None.

Item 4. Mine Safety Disclosure.
Not applicable.
22

Item 5. Other Information.

Voting Results of Special Meeting of Stockholders

On February 13, 2014, we held a special meeting of stockholders (the “Special Meeting”). The results of the Special Meeting, based on the presence in person or by proxy of holders of 11,303,241 shares of the Company’s common stock entitled to vote, are described below.

Proposal 1: To consider and vote upon a proposal to approve and adopt the Agreement and Plan of Merger and Reorganization dated July 15, 2013, by and among ThermoGenesis Corp., TotipotentRX Corporation, Kenneth Harris and Mitchel Sivilotti, and related transactions therein, pursuant to which among other things ThermoGenesis will issue shares of common stock to the shareholders of TotipotentRX Corporation and TotipotentRX Corporation will merge with and into ThermoGenesis, with ThermoGenesis surviving the merger and changing its name to Cesca Therapeutics Inc. The proposal was approved as follows:
 
For
Against
Abstain
8,852,015
2,413,090
38,136
23

Item 6. Exhibits.
10.1 Extension Addendum to Escrow Agreement dated October 30, 2013 (1)
10.16 Employment Agreement with Matthew T. Plavan (2)
10.17 Employment Agreement with Dan T. Bessey (2)
10.18* Sales and Purchase Agreement between ThermoGenesis Corp and CBR Systems, Inc.dated December 31, 2013 (3)
10.2.4 Forbearance Agreement to Technology License and Escrow Agreement dated November,26, 2013 (4)
31.1 Certification by the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification by the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32 Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101.INS XBRL Instance Document‡
101.SCH XBRL Taxonomy Extension Schema Document‡
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document‡
101.LAB XBRL Taxonomy Extension Label Linkbase Document‡
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document‡

Footnotes to Exhibit Index
(1) Incorporated by reference to ThermoGenesis Current Report on Form 8-K filed with the SEC on October 31, 2013.
(2) Incorporated by reference to ThermoGenesis Current Report on Form 8-K filed with the SEC on October 30, 2013.
(3) Incorporated by reference to ThermoGenesis Current Report on Form 8-K filed with the SEC on January 7, 2014.
(4) Incorporated by reference to ThermoGenesis Current Report on Form 8-K filed with the SEC on November 27, 2013.
‡ XBRL information is furnished and not filed for purpose of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.
* Portions of this exhibit have been redacted and filed separately with the SEC pursuant to a request for confidential treatment.
24

ThermoGenesis Corp.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
ThermoGenesis Corp.
 
 
(Registrant)
 
 
 
 
Dated: February 14, 2014
/s/ Matthew T. Plavan
 
 
Matthew T. Plavan
 
 
Chief Executive Officer
 
 
(Principal Executive Officer)
 
 
 
 
Dated: February 14, 2014
/s/ Dan T. Bessey
 
 
Dan T. Bessey
 
 
Chief Financial Officer
 
 
(Principal Financial Officer and Principal Accounting Officer)
 

 
25
 EX-31.1 2 ex31_1.htm EXHIBIT 31.1
Exhibit 31.1

PRINCIPAL EXECUTIVE OFFICER’S CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Matthew T. Plavan, certify that:

1. I have reviewed this report on Form 10-Q of ThermoGenesis Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusion about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: February 14, 2014
/s/ Matthew T. Plavan
 
Matthew T. Plavan
Chief Executive Officer
(Principal Executive Officer)
 
 
 EX-31.2 3 ex31_2.htm EXHIBIT 31.2
Exhibit 31.2

PRINCIPAL FINANCIAL OFFICER’S CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Dan T. Bessey, certify that:

1. I have reviewed this report on Form 10-Q of ThermoGenesis Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: February 14, 2014
/s/ Dan T. Bessey
 
Dan T. Bessey
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
 
 
 EX-32 4 ex32.htm EXHIBIT 32
Exhibit 32

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of ThermoGenesis Corp. (the "Company") on Form 10-Q for the period ended December 31, 2013, as filed with the Securities and Exchange Commission (the "Report"), we, Matthew T. Plavan, Chief Executive Officer and Dan T. Bessey, Chief Financial Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge:

(1)      the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)      the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 14, 2014
/s/ Matthew T. Plavan
 
Matthew T. Plavan
Chief Executive Officer
(Principal Executive Officer)
 
 
Dated: February 14, 2014
/s/ Dan T. Bessey
 
Dan T. Bessey
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)


EX-101.INS 5 kool-20131231.xml XBRL INSTANCE DOCUMENT 0000811212 2013-07-01 2013-12-31 0000811212 2014-02-07 0000811212 2013-12-31 0000811212 2013-06-30 0000811212 2013-10-01 2013-12-31 0000811212 2012-10-01 2012-12-31 0000811212 2012-07-01 2012-12-31 0000811212 2012-06-30 0000811212 2012-12-31 0000811212 2010-06-30 0000811212 us-gaap:StockOptionsMember 2013-06-30 0000811212 us-gaap:StockOptionsMember 2013-07-01 2013-12-31 0000811212 us-gaap:StockOptionsMember 2013-12-31 0000811212 us-gaap:RestrictedStockMember 2013-06-30 0000811212 us-gaap:RestrictedStockMember 2013-07-01 2013-12-31 0000811212 us-gaap:RestrictedStockMember 2013-12-31 0000811212 kool:MergerWithTotipotentrxCorporationRxMember 2013-07-15 0000811212 kool:CryoSealMember 2012-09-30 0000811212 kool:CryoSealMember 2012-07-01 2012-08-31 0000811212 kool:ThermolineMember 2012-10-01 2012-12-31 0000811212 us-gaap:SubsequentEventMember 2014-01-29 2014-01-30 0000811212 us-gaap:SubsequentEventMember 2014-01-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares false --06-30 2013-12-31 No No Yes Smaller Reporting Company THERMOGENESIS CORP 0000811212 20038547 2014 Q2 10-Q 5538000 4898000 2737000 3106000 3589000 3277000 127709000 127493000 29000 47000 2263671 2622712 2263671 2577712 12184000 16273000 14338000 18529000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Organization and Basis of Presentation</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ThermoGenesis Corp. (the Company, we or our) designs, develops and commercializes clinical technologies for the processing, storage and administration of stem cells and blood components for sale to users and companies involved in the development and administration of cell therapies.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold; align: right;">5.</td><td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold;"><u>Merger with TotipotentRX</u></td></tr></table></div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On July 15, 2013, we entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), with TotipotentRX providing for the merger of TotipotentRX into the Company, with the Company surviving. TotipotentRX is a privately held biomedical technology company specializing in human clinical trials in the field of regenerative medicine and is the exclusive provider of cell-based therapies to the Fortis Healthcare System.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">At the February 13, 2014 Special Meeting, the Company&#8217;s stockholders voted in favor of the merger and the TotipotentRX stockholders have also approved the merger. The merger is expected to become effective on February 18, 2014. The combined company will be called Cesca Therapeutics Inc. to better reflect the combined products and services of the two companies.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Upon consummation of the merger, a TotipotentRX stockholder will receive, in exchange for each share of TotipotentRX common stock held by such stockholder immediately before the closing of the Merger, approximately 30 shares of Company common stock, subject to adjustment. After the merger, the former shareholders of TotipotentRX will own approximately 12,490,800 shares of the Company&#8217;s common stock. Additionally, TotipotentRX&#8217;s Chief Executive Officer will become President of and a director of our Company.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The Merger Agreement contains certain termination rights for both the Company and TotipotentRX, and further provides that, upon termination of the Merger Agreement under specified circumstances, including, but not limited to, termination due to a failure by one party to recommend approval of the merger, a party soliciting an acquisition proposal in breach of the Merger Agreement, or a party entering into an agreement with a third party related to an acquisition proposal, that breaching party may be required to pay to the other party a termination fee of $500,000.</div></div> 2330000 6884000 7879000 7516000 -4554000 -363000 2.81 1668400 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold; align: right;">3.</td><td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold;"><u>Commitments and Contingencies</u></td></tr></table></div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Financial Covenants</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In June 2010, we entered into a License and Escrow Agreement which granted a customer a non-exclusive, royalty-free license to certain intellectual property necessary for the potential manufacture and supply of AXP devices and certain AXP disposables. The license is for the sole and limited purpose of manufacturing and supplying the AXP and related disposables for use by the customer. The licensed intellectual property will be maintained in escrow and will be released to and used by the customer if and only if the Company defaults under the Agreement. Originally, default occurred if the Company (1) fails to meet certain positive cash flow metrics for each rolling quarterly measurement period except where the following two measures are met, (2) failure to meet cash balance and short-term investments of at least $6,000,000 at the end of any given month, or (3) failure to meet a quick ratio of 2 to 1 at the end of any given month.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On December 31, 2013 we amended and restated the License and Escrow Agreement to delete all of the financial covenants except the minimum cash and short-term investments balance covenant, (2) above, which was reduced to $2,000,000 at the end of any given month. We are in compliance with this covenant at January 31, 2014.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Contingencies</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On April 11, 2013, we filed an answer and counter-claims in response to the complaint Harvest Technologies Corp. (Harvest) filed on October 24, 2012 against the Company in the case captioned as Harvest Technologies Corp. v. ThermoGenesis Corp., 12-cv-01354, U.S. District Court, District of Delaware (Wilmington), with the complaint being amended on February 15, 2013 to name the Company&#8217;s customer Celling Technologies, LLC as a defendant. In the complaint, Harvest contends that our Res-Q 60 System infringes certain Harvest patents. The counter-claims are based on anti-trust and other alleged improper conduct by Harvest and further seek declarations that the Res-Q 60 System does not infringe the patents and that the patents are invalid. The Company is vigorously defending itself against the Harvest claims, while aggressively pursuing its separate claims against Harvest. The Company is unable to ascertain the likelihood of any liability and has not made an accrual as of December 31, 2013.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">During the three months ended September 30, 2012, we were notified by a third party who believes that the Res-Q system infringes upon certain of its US and European patents. The Company is in the process of gathering information; however, it has not yet collected enough information to assess the validity of the alleged infringement or estimate any potential financial impact; therefore, it has not made an accrual as of December 31, 2013.</div><div><br /></div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Warranty</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We offer a warranty on all of our products of one to two years, except disposable products which we warrant through their expiration date. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The warranty liability is included in other current liabilities in the unaudited balance sheet. The change in the warranty liability for the six months ended December 31, 2013 is summarized in the following table:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 78%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Balance at July 1, 2013</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">489,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Warranties issued during the period</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">90,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Settlements made during the period</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(75,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Changes in liability for pre-existing warranties during the period</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(142,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Balance at December 31, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">362,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div> 16692372 16557627 16000 16000 16692372 16557627 0.001 0.001 80000000 80000000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Comprehensive Loss</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ASC 220, &#8220;Comprehensive Income&#8221; establishes standards for the reporting and communication of comprehensive income (loss) and its components in the financial statements. As of December 31, 2013, the Company has no items of other comprehensive income (loss) and, therefore, has not included a schedule of comprehensive income (loss) in the financial statements.</div></div> 2679000 2826000 5322000 4932000 69000 63000 371000 377000 327000 266000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold; align: right;">4.</td><td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold;"><u>Stockholders&#8217; Equity</u></td></tr></table></div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Stock Based Compensation</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We recorded stock-based compensation of $115,000 and $284,000 for the three and six months ended December 31, 2013, and $129,000 and $272,000 for the three and six months ended December 31, 2012.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following is a summary of option activity for our stock option plans:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Number of Shares</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Weighted- Average Exercise Price</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Weighted- Average Remaining Contractual Life</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Aggregate Intrinsic Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: top;">&#160;</td><td valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: top;">&#160;</td><td valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: top;">&#160;</td><td valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: top;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding at June 30, 2013</div></td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,063,750</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2.36</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #cceeff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #cceeff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #ffffff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #ffffff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">48,750</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.39</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #cceeff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #cceeff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td></tr><tr style="height: 18px;"><td valign="bottom" style="background-color: #ffffff; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(6,750</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2.21</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #ffffff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #ffffff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expired</div></td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(158,750</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">3.67</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #cceeff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #cceeff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #ffffff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #ffffff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 52%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding at December 31, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">947,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2.09</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.9</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">27,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 52%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Vested and Expected to Vest at December 31, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">861,767</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2.04</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.8</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">21,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 52%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Exercisable at December 31, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">602,214</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2.41</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.6</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">7,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company&#8217;s common stock. There were no options exercised during the six months ended December 31, 2013 and 2012.</div><div><br /></div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Common Stock Restricted Awards</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following is a summary of restricted stock activity during the six months ended December 31, 2013:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Number of Shares</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Weighted Average Grant Date Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Balance at June 30, 2013</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">390,003</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.81</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">--</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">--</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Vested</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(164,998</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.93</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(33,334</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.81</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding at December 31, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">191,671</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.70</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In connection with the vesting of the restricted stock awards, the election was made by some of the employees to satisfy the applicable federal income tax withholding obligation by a net share settlement, pursuant to which the Company withheld 57,680 shares and used the deemed proceeds from those shares to pay the income tax withholding. The net share settlement is deemed to be a repurchase by the Company of its common stock.</div></div> -0.10 -0.03 0.03 -0.23 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Net Income (Loss) per Share</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Basic net income (loss) per share is calculated in accordance with Accounting Standards Codification (ASC) Topic 260, &#8220;Earnings Per Share&#8221;, which requires using the average number of shares of common stock outstanding. Diluted net income (loss) per share is computed on the basis of the average number of common shares outstanding plus the dilutive effect of any common stock equivalents using the &#8220;treasury stock method&#8221;.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following table provides a reconciliation of weighted-average shares used to determine basic and diluted earnings per share for the six months ended December 31, 2012.</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="background-color: #cceeff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Basic average common shares outstanding</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">16,519,078</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Effect of dilutive options</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">576</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Diluted average common shares outstanding</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">16,519,654</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Common stock equivalents consist of stock options, warrants and common stock restricted awards. For the three and six months ended December 31, 2013, 2,263,671 common stock equivalents were excluded from the computation of earnings per share because their effect would have been anti-dilutive, and 2,622,712 and 2,577,712 for the three and six months ended December 31, 2012.</div></div> 531000 477000 2.00 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value of Financial Instruments</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short duration.</div></div> 0 -7000 0 0 2000000 0 1882000 1085000 2225000 4024000 1789000 1976000 3602000 3180000 -369000 -1087000 0 -135000 640000 797000 54000 -168000 -96000 82000 -7000 -710000 -190000 87000 576 1508000 1212000 709000 981000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold; align: right;">2.</td><td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold;"><u>Inventories</u></td></tr></table></div><div><br /></div><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Inventories consisted of the following at:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td colspan="2" style="border-bottom: #000000 2px solid; white-space: nowrap; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">December 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">June 30,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td valign="bottom" style="width: 66%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Raw materials</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">709,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">981,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Work in process</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,963,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,066,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Finished goods</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,508,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,212,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 66%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4,180,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4,259,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div> 4180000 4259000 1963000 2066000 4637000 5148000 14338000 18529000 -153000 2186000 -68000 -54000 432000 -1603000 -563000 -3902000 -4333000 -2495000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Recently Adopted Accounting Pronouncements</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In February 2013, the FASB issued ASC 2013-02, which is an update to improve the reporting of reclassifications out of accumulated other comprehensive income (AOCI). Companies are also required to present reclassifications by component when reporting changes in AOCI balances. We adopted ASC 2013-02 effective July 1, 2013. The adoption of ASC 2013-02 did not have a material impact on our results of operations or financial condition.</div></div> 0 -5000 -2000 0 3168000 3392000 7082000 2534000 434000 -1603000 -558000 -3902000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold; align: right;">1.</td><td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold;"><u>Basis of Presentation and Summary of Significant Accounting Policies</u></td></tr></table></div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Organization and Basis of Presentation</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ThermoGenesis Corp. (the Company, we or our) designs, develops and commercializes clinical technologies for the processing, storage and administration of stem cells and blood components for sale to users and companies involved in the development and administration of cell therapies.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Interim Reporting</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (SEC) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed financial statements through the date of issuance. Operating results for the six month period ended December 31, 2013, are not necessarily indicative of the results that may be expected for the year ending June 30, 2014. These unaudited condensed financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended June 30, 2013.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Revenue Recognition</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenues from the sale of our products are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. We generally ship products F.O.B. shipping point. There is no conditional evaluation on any product sold and recognized as revenue. All foreign sales are denominated in U.S. dollars. Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Our sales are generally through distributors. There is no right of return provided for distributors. For sales of products made to distributors, we consider a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are not limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements with us, the level of inventories maintained by the distributor, whether we have a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive. We currently recognize revenue primarily on the sell-in method with our distributors.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis. Revenue for each unit of accounting is recognized as the unit of accounting is delivered. Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Estimated selling prices are determined using vendor specific objective evidence of value (VSOE), when available, or an estimate of selling price when VSOE is not available for a given unit of accounting. Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer&#8217;s geographic location. We account for training and installation, and service agreements as separate units of accounting.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement. All other service revenue is recognized at the time the service is completed.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value of Financial Instruments</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short duration.</div><div><br /></div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Segment Reporting</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We operate in a single segment providing medical devices and disposables to hospitals and blood banks throughout the world which utilize the equipment to process blood components.</div><div><br /></div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Net Income (Loss) per Share</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Basic net income (loss) per share is calculated in accordance with Accounting Standards Codification (ASC) Topic 260, &#8220;Earnings Per Share&#8221;, which requires using the average number of shares of common stock outstanding. Diluted net income (loss) per share is computed on the basis of the average number of common shares outstanding plus the dilutive effect of any common stock equivalents using the &#8220;treasury stock method&#8221;.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following table provides a reconciliation of weighted-average shares used to determine basic and diluted earnings per share for the six months ended December 31, 2012.</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="background-color: #cceeff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Basic average common shares outstanding</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">16,519,078</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Effect of dilutive options</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">576</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Diluted average common shares outstanding</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">16,519,654</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Common stock equivalents consist of stock options, warrants and common stock restricted awards. For the three and six months ended December 31, 2013, 2,263,671 common stock equivalents were excluded from the computation of earnings per share because their effect would have been anti-dilutive, and 2,622,712 and 2,577,712 for the three and six months ended December 31, 2012.</div><div><br /></div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Comprehensive Loss</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">ASC 220, &#8220;Comprehensive Income&#8221; establishes standards for the reporting and communication of comprehensive income (loss) and its components in the financial statements. As of December 31, 2013, the Company has no items of other comprehensive income (loss) and, therefore, has not included a schedule of comprehensive income (loss) in the financial statements.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Recently Adopted Accounting Pronouncements</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In February 2013, the FASB issued ASC 2013-02, which is an update to improve the reporting of reclassifications out of accumulated other comprehensive income (AOCI). Companies are also required to present reclassifications by component when reporting changes in AOCI balances. We adopted ASC 2013-02 effective July 1, 2013. The adoption of ASC 2013-02 did not have a material impact on our results of operations or financial condition.</div><div><br /></div><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Recently Issued Accounting Pronouncements</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In July 2013, the FASB issued ASU 2013-11, &#8220;Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists&#8221;. This amendment requires entities to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward or a similar tax loss or a tax credit carryforward, unless certain conditions exist. This guidance is effective prospectively for annual reporting periods (and the interim periods within) beginning after December 15, 2013. Early adoption and retrospective application are permitted. We expect to adopt this guidance effective July 2014. We are currently assessing the potential impact, if any, the adoption of ASU 2013-11 may have on our financial statements.</div></div> 48000 48000 998000 1188000 68000 54000 153000 314000 0 0 2000000 2000000 0 0 0.001 0.001 0 0 136000 232000 0 2000000 2000000 90000 489000 362000 -142000 75000 2106000 2208000 797000 714000 1552000 1630000 -118093000 -114191000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Revenue Recognition</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenues from the sale of our products are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. We generally ship products F.O.B. shipping point. There is no conditional evaluation on any product sold and recognized as revenue. All foreign sales are denominated in U.S. dollars. Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Our sales are generally through distributors. There is no right of return provided for distributors. For sales of products made to distributors, we consider a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are not limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements with us, the level of inventories maintained by the distributor, whether we have a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive. We currently recognize revenue primarily on the sell-in method with our distributors.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis. Revenue for each unit of accounting is recognized as the unit of accounting is delivered. Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Estimated selling prices are determined using vendor specific objective evidence of value (VSOE), when available, or an estimate of selling price when VSOE is not available for a given unit of accounting. Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer&#8217;s geographic location. We account for training and installation, and service agreements as separate units of accounting.</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">&#160;</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement. All other service revenue is recognized at the time the service is completed.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.</div></div> 7000 P1Y9M18D P1Y7M6D P1Y10M24D 4468000 4802000 8924000 8112000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The warranty liability is included in other current liabilities in the unaudited balance sheet. The change in the warranty liability for the six months ended December 31, 2013 is summarized in the following table:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="width: 78%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Balance at July 1, 2013</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">489,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Warranties issued during the period</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">90,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Settlements made during the period</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(75,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Changes in liability for pre-existing warranties during the period</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(142,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Balance at December 31, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">362,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following is a summary of option activity for our stock option plans:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Number of Shares</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Weighted- Average Exercise Price</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Weighted- Average Remaining Contractual Life</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Aggregate Intrinsic Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: top;">&#160;</td><td valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: top;">&#160;</td><td valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: top;">&#160;</td><td valign="bottom" style="vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: top;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding at June 30, 2013</div></td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,063,750</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2.36</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #cceeff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #cceeff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #ffffff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #ffffff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">48,750</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.39</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #cceeff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #cceeff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td></tr><tr style="height: 18px;"><td valign="bottom" style="background-color: #ffffff; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(6,750</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2.21</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #ffffff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #ffffff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Expired</div></td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(158,750</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">3.67</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #cceeff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #cceeff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #ffffff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="background-color: #ffffff; vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 52%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding at December 31, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">947,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2.09</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.9</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">27,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 52%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Vested and Expected to Vest at December 31, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">861,767</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2.04</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.8</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">21,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 52%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 52%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Exercisable at December 31, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">602,214</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2.41</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.6</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">7,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Inventories consisted of the following at:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td colspan="2" style="border-bottom: #000000 2px solid; white-space: nowrap; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">December 31,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: top;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">June 30,</div><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2013</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td valign="bottom" style="width: 66%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: top;">&#160;</td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: top;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Raw materials</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">709,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">981,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Work in process</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,963,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">2,066,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Finished goods</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,508,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1,212,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 66%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4,180,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">4,259,000</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following is a summary of restricted stock activity during the six months ended December 31, 2013:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="padding-bottom: 2px; width: 66%; vertical-align: top;"><div>&#160;</div></td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Number of Shares</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;">&#160;</td><td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"><div style="text-align: center; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">Weighted Average Grant Date Fair Value</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Balance at June 30, 2013</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">390,003</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.81</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #ffffff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Granted</div></td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">--</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">--</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Vested</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(164,998</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.93</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Forfeited</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">(33,334</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">)</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.81</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 66%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Outstanding at December 31, 2013</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">191,671</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">$</div></td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">1.70</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The following table provides a reconciliation of weighted-average shares used to determine basic and diluted earnings per share for the six months ended December 31, 2012.</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="width: 90%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td valign="bottom" style="background-color: #cceeff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Basic average common shares outstanding</div></td><td valign="bottom" style="background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">16,519,078</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Effect of dilutive options</div></td><td valign="bottom" style="padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">576</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 1%; vertical-align: bottom;">&#160;</td></tr><tr><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 78%; vertical-align: top;"><div style="text-align: left; text-indent: -7.2pt; font-family: ''Times New Roman'', Times, serif; margin-left: 7.2pt; font-size: 10pt;">Diluted average common shares outstanding</div></td><td valign="bottom" style="padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td><td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 9%; vertical-align: bottom;"><div style="font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">16,519,654</div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 1%; vertical-align: bottom;">&#160;</td></tr></table></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Segment Reporting</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">We operate in a single segment providing medical devices and disposables to hospitals and blood banks throughout the world which utilize the equipment to process blood components.</div></div> 1391000 713000 735000 1428000 2.21 33334 1.81 1.70 48750 390003 191671 164998 1.81 1.39 3.67 0 2.41 158750 1.93 602214 6750 861767 2.36 2.09 27000 21000 1063750 947000 2.04 57680 3336800 9632000 13318000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold; align: right;">7.</td><td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold;"><u>Subsequent Event</u></td></tr></table></div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">On January 30, 2014, the Company completed a private placement of the sale of 3,336,800 shares of its common stock at $2.00 per share, together with warrants to purchase up to an aggregate of 1,668,400 shares of common stock. The warrants may be exercised by the holders at a price of $2.81 per share starting July 30, 2014 continuing through January 29, 2019.</div></div> 16519078 16682730 16522310 16672811 16682730 16522310 16519654 16672811 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Recently Issued Accounting Pronouncements</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In July 2013, the FASB issued ASU 2013-11, &#8220;Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists&#8221;. This amendment requires entities to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward or a similar tax loss or a tax credit carryforward, unless certain conditions exist. This guidance is effective prospectively for annual reporting periods (and the interim periods within) beginning after December 15, 2013. Early adoption and retrospective application are permitted. We expect to adopt this guidance effective July 2014. We are currently assessing the potential impact, if any, the adoption of ASU 2013-11 may have on our financial statements.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-style: italic; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; font-weight: bold;">Interim Reporting</div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (SEC) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed financial statements through the date of issuance. Operating results for the six month period ended December 31, 2013, are not necessarily indicative of the results that may be expected for the year ending June 30, 2014. These unaudited condensed financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended June 30, 2013.</div></div> P1Y P2Y 6000000 2000000 284000 272000 115000 129000 57000 214000 0 500000 500000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left;">&#160; <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><tr><td style="width: 18pt; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold; align: right;">6.</td><td style="text-align: left; width: auto; font-family: ''Times New Roman'', Times, serif; font-size: 10pt; vertical-align: top; font-weight: bold;"><u>Sale of Product Lines</u></td></tr></table></div><div>&#160;</div><div><u><font style="font-weight: bold;">ThermoLine</font></u></div></div><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><br />On December 31, 2012, the Company entered into an Asset Purchase Agreement for the sale of certain of the assets, rights and properties of the ThermoLine product line for $500,000.&#160;The $500,000 was received upon&#160;signing the agreement and was included in&#160;other current liabilities on the December 31, 2012 balance sheet.&#160;The company recognized the gain on sale upon delivery of the assets which occured during the quarter ended March 31, 2013.</div><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><u>CryoSeal</u></div><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In June 2010, the Company and Asahi entered into an amendment (the "Amendment") of their Distribution and License Agreement. Under the terms of the Amendment, Asahi obtained exclusive rights to distribute the CryoSeal System in South Korea, North Korea, Taiwan, the People&#8217;s Republic of China, the Philippines, Thailand, Singapore, India and Malaysia. These rights included the exclusive right to market, distribute and sell the processing disposables and Thrombin Reagent for production of thrombin in a stand-alone product.</div><div><br /></div><div style="text-align: justify; font-family: ''Times New Roman'', Times, serif; font-size: 10pt;">In connection with the above-described Amendment, the Company and Asahi also entered into an Option Agreement ("Option Agreement") and on June 30, 2012, Asahi exercised the option to purchase certain intangible assets related to this product line, including all associated patents and engineering files for $2,000,000. In connection with the notice of exercise, the Amendment automatically terminated. Payment of the $2,000,000 was based upon completion of certain provisions of the Option Agreement. As such, the Company recognized the gain on sale upon completion of those provisions which occurred in July 2012. The $2,000,000 payment was received in August 2012.</div></div></div> 30 12490800 500000 2000000 EX-101.SCH 6 kool-20131231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Merger with TotipotentRX link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Sale of Product Lines link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 070100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 080100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Merger with TotipotentRX (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Sale of Product Lines (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 kool-20131231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 kool-20131231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 kool-20131231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Award Type [Axis] Accounts receivable, net of allowance for doubtful accounts of $29 ($47 at June 30, 2013) Accounts payable Accounts Payable, Current Equipment, accumulated depreciation Paid in capital in excess of par Adjustments to reconcile net loss to net cash used in operating activities: Accounts receivable, allowance for doubtful accounts Anti-dilutive securities not included in diluted net loss per common share (in shares) Current assets: ASSETS Assets [Abstract] Total current assets Assets, Current Total Assets Assets Organization and Basis of Presentation Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Merger with TotipotentRX [Abstract] Business Acquisition [Line Items] Merger with TotipotentRX Business Combination Disclosure [Text Block] Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Exercise price of warrants issued (in dollars per share) Issued warrants to purchase common stock (in shares) Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies [Abstract] Commitments and contingencies (Footnote 3) Common stock, shares outstanding (in shares) Common stock, $0.001 par value; 80,000,000 shares authorized; 16,692,372 issued and outstanding (16,557,627 at June 30, 2013) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Common stock, shares authorized (in shares) Comprehensive Loss Cost of revenues Deferred revenue Deferred Revenue, Noncurrent Deferred revenue Deferred Revenue, Current Depreciation and amortization Stockholders' Equity Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stockholders' Equity [Abstract] Disposal Groups, Including Discontinued Operations, Name [Domain] Per share data: Basic and diluted net income (loss) per common share (in dollars per share) Net Income (Loss) per Share Earnings Per Share, Policy [Policy Text Block] Weighted average common shares outstanding: Accrued payroll and related expenses Employee-related Liabilities, Current Sale of common stock in a private placement (in dollars per share) Fair Value of Financial Instruments Loss on disposal of equipment Gain (Loss) on Disposition of Property Gain on sale of product line Gain (Loss) on Sale of Other Assets General and administrative Gross profit Gross Profit Consolidated Statements of Operations (Unaudited) [Abstract] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Accounts payable Deferred revenue Increase (Decrease) in Deferred Revenue Accounts receivable, net Increase (Decrease) in Accounts Receivable Net change in operating assets and liabilities: Accrued payroll and related expenses Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other assets Increase (Decrease) in Other Operating Assets Inventories Increase (Decrease) in Inventories Other liabilities Effect of dilutive options Inventories [Abstract] Inventory, Net [Abstract] Finished goods Inventory, Finished Goods, Net of Reserves Raw materials Inventory, Raw Materials, Net of Reserves Inventories Inventory Disclosure [Text Block] Inventories Total Inventory, Net Inventories [Abstract] Work in process Inventory, Work in Process, Net of Reserves Total current liabilities Liabilities, Current Current liabilities: LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES AND STOCKHOLDERS' EQUITY Total liabilities and stockholders equity Liabilities and Equity Schedule of changes in product liability included in accrued liabilities [Roll Forward] Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward] Cash flows from financing activities: Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from investing activities: Cash flows from operating activities: Net income (loss) Income (Loss) from operations Net Income (Loss) Attributable to Parent Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Recently Adopted Accounting Pronouncements Interest and other income (expense), net Expenses: Total operating expenses Operating Expenses Income (loss) from operations Operating Income (Loss) Basis of Presentation and Summary of Significant Accounting Policies [Abstract] Basis of Presentation and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Other assets Other Assets, Noncurrent Other current liabilities Supplemental non-cash financing and investing information: Other non-current liabilities Repurchase of common stock Payments for Repurchase of Common Stock Capital expenditures Payments to Acquire Property, Plant, and Equipment Preferred stock, $0.001 par value; 2,000,000 shares authorized; none outstanding Preferred Stock, Value, Issued Preferred stock, shares authorized (in shares) Preferred stock, shares issued (in shares) Preferred stock, par value (in dollars per share) Preferred stock, shares outstanding (in shares) Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Proceeds from sale of product line Proceeds from Divestiture of Businesses Payments received Warranties issued during the period Product Warranty Accrual, Warranties Issued Warranty [Abstract] Product Warranties Disclosures [Abstract] Balance at December 31, 2013 Balance at July 1, 2013 Product Warranty Accrual Changes in liability for pre-existing warranties during the period Product Warranty Accrual, Preexisting, Increase (Decrease) Settlements made during the period Product Warranty Accrual, Payments Equipment at cost, less accumulated depreciation of $3,589 ($3,277 at June 30, 2013) Property, Plant and Equipment, Net Research and development Restricted Stock [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Revenue Recognition Exercisable at December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Vested and Expected to Vest at December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Exercisable at December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Outstanding at December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Net revenues Schedule of changes in product liability included in accrued liabilities Schedule of Product Warranty Liability [Table Text Block] Option activity for stock option plans Inventories Schedule of Inventory, Current [Table Text Block] Restricted stock activity granted to employees Reconciliation of weighted-average shares Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Segment Reporting Sales and marketing Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Balance at June 30, 2013 (in dollars per share) Outstanding at December 31,2013 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted-Average Exercise Price Per Share [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Weighted-Average Grant Date Fair Value [Roll Forward] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Outstanding (in shares) Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Stock Compensation Expense [Abstract] Forfeited (in dollars per share) Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Exercisable at December 31, 2013 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Exercisable at December 31, 2013 (in shares) Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Vested and Expected to Vest at December 31, 2013 (in shares) Balance at June 30, 2013 (in dollars per share) Outstanding and exercisable at December 31, 2013 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested and Expected to Vest at December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Outstanding at June 30, 2013 (in shares) Outstanding at December 31, 2013 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Award Type [Domain] Vested and Expected to Vest at December 31, 2013 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Number of shares withheld to pay income tax withholding (in shares) Consolidated Statements of Cash Flows (Unaudited) [Abstract] Consolidated Balance Sheets (Unaudited) [Abstract] Stock Options [Member] Sale of common stock in a private placement (in shares) Stock Issued During Period, Shares, New Issues Stockholders' equity: Stockholders' equity: Total stockholders' equity Stockholders' Equity Attributable to Parent Subsequent Events [Text Block] Subsequent Events [Abstract] Subsequent Event Type [Domain] Subsequent Events [Line Items] Subsequent Event Type [Axis] Subsequent Events [Table] Subsequent Event [Member] Basic average common shares outstanding Basic (in shares) Dilutive average common shares outstanding Diluted (in shares) Disclosure of the new accounting pronouncements that may impact the entity's financial reporting. Recently Issued Accounting Pronouncements [Policy Text Block] Recently Issued Accounting Pronouncements Policy disclosure for the quarterly financial data in the annual financial statements. It may also indicate if the information in the financial statements is unaudited and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished. Interim Reporting [Policy Text Block] Interim Reporting Document and Entity Information [Abstract] This line item represents the minimum period of warranty that an entity offers on all of its products. Period of Warranty on Products Period of warranty on products, minimum This line item represents the maximum period of warranty that an entity offers on all of its products. Period of Warranty on Products Maximum Period of warranty on products, maximum License and Escrow Agreement [Abstract] License and Escrow Agreement [Abstract] Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios, and adherence to certain clauses which must be met in order to avoid default. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants. Short Term Investment Minimum Minimum cash balance and short-term investments The aggregate amount of noncash, equity-based remuneration. This may include the value of stock or unit options and amortization of restricted stock or units. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Stock Based Compensation Stock based compensation expense Weighted Average Remaining Contractual Life [Abstract] Weighted-Average Remaining Contractual Life [Abstract] Common Stock Restricted Awards [Abstract] Aggregate Intrinsic Value [Abstract] Value of inventories transferred to equipment in noncash transactions. Transfer of inventories to equipment Transfer of inventories to equipment The cash inflow associated with the prepayment amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. Proceeds from prepayment from sale of product line Proceeds from the prepayment from sale of product line Sale of Product Lines [Abstract] The entire disclosure for Gain on sale of product line. Sale of Product Lines [Text Block] Sale of Product Lines Represents the number of shares of Company common stock to be issued in exchange of each share of RX common stock. Number of shares of Company common stock to be issued in exchange of each share of RX common stock Number of shares of Company common stock to be issued in exchange of each share of RX common stock (in shares) Represents the reporting of the amounts of merger with TotipotentRX Corporation ("RX") that were completed during the period. Merger with TotipotentRX Corporation ("RX") [Member] Merger with TotipotentRX Corporation ("RX") [Member] Represents the aggregate number of shares of Company's common stock to be owned by former shareholders of RX after the merger. Aggregate number of shares of Company's common stock to be owned by former shareholders of RX after merger Aggregate number of shares of Company's common stock to be owned by former shareholders of RX after merger (in shares) Represents the amount that a breaching party may be required to pay to the other party upon termination of the Merger Agreement under specified circumstances. Termination Fee Termination fee Represents the percentage of Company's shares of common stock to be owned by former shareholders of RX after the merger. Percentage of Company's shares of common stock to be owned by former shareholders of RX after merger Percentage of Company's shares of common stock to be owned by former shareholders of RX after merger (in hundredths) Company involved in Asset purchase agreement. ThermoLine [Member] The amount of the option agreement for the future sale of assets. Option Agreement For Future Sale Of Assets Option agreement amount Transaction related to Distribution and License Agreement and Option Agreement. Cryo Seal [Member] EX-101.PRE 10 kool-20131231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#ZP-;3N@$``-<0```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/@S`4AN]-_`^DMP9* M4>#T;*N M@@486RJ9$A;%)`"9*5'*:4H^)B]AGP36<2EXI22D9`66C(:7%X/)2H,-?+6T M*2FFYL[?FBG5/)OQ*=`DCGLT4]*!=*%K>I#AX`ER M/J]<\+STC]2KA1B'QEN\86I;97'H/0 M3H5FYG>!3=V;WQI3"@C&W+A77GL,NJSHES*S3Z5FT>$F'90JS\L,A,KFM=^! MR&H#7-@"P-55U(Y1S4NYY3Z@WRZVM!W8F4&:]VL;G\B1(.&X1L)Q@X3C%@E' M#PG''1*./A*.>R0<+,8"@L51&19+95@\E6$Q58;%51D66V58?)5A,5:&Q5D3 M+,Z:8''6!(NS)EB<-?DO9W4^-@)MKW__.MHV1W*+=:L*[)G_-=9-CRD7W(!X M=\8'[+,#_.Q]B,/'S[%1VOH@;N#T7=@F[:8ZU+X1&%?"+FMW9=:=H@_QIPON MA69HC@D$B`YMVAY+#+\!``#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P" M```+``@"7W)E;',O+G)E;',@H@0"**```@`````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````````````C)+/ M3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?/ M/UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBD ME)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&74"T\ MU<%J"`=[!ZH^^CSYLK$SO+=N5#9@NIS]NHFD++28,5 M\YS3$$ MX4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`$ MM^X'F$1-0E,[V-Y'__U,UZ4M=-HEZ!*P0^271Z\4>;'ZVC?)!SI?6Y,)&*0B M09/;HC9E)MXVSP\SD?B@3:$;:S`3!_1BM;R_6[Q@HT/\R%=UZY,8Q?A,5"&T MCU+ZO,*]]@/;HHEOMM;M=8A+5\I6YSM=HE1I.I'N,H987L5,UD4FW+J(YV\. M;3SY_]AVNZUS?++Y^QY-N'&$_+1NYRO$$(-J5V+(1+?EY?'-;!`5"WE;#`R9 MU<"0E,,-!T@Z:M(G'1\.331;EZB?-86#.SED;A3T":-SZ9E'MW4RK@**S919 MS902`XI9#2A2#C<<(.FH<9]T0FS%>';-<2F/3](OW!FB$]1K8^D*YTREVSK5 M$DPHOZCXDV3])ZF4DL/=:$C?<&>*3!2PHR'9J!&W;T:4;WIM,UT%_5U48TH, M<*L!4H[BGB44.4P`=\?D-``#__P,`4$L#!!0`!@`(````(0": M6TI+T`(``#L(```/````>&PO=V]R:V)O;VLN>&ULE)5;3^,P$(7?5]K_$.5] MR8V[:)&`KK;27M"VP+Y9)IDV%HX=;(?"O]]QJH9I4JK=IW22^OC,F<_)Q>5K M)8,7,%9H-0J3@S@,0.6Z$&HY"N_F7[^#G^_.EBIE9%F=A-.Z:O#5!`0O>2#?']C;JF%=Z MF*;'_I\^BGL!*_N^R)?!ZX-0A5[YOV*T;UV5H8%5^^A!%*[$YW$<=_>^@5B6 M;G,3Y2.BWR:(^[370+7M;1)A."DV44ZX-S95Z_2%QA'ZU*?861(&YES@#S,M M$F^2$I7T_U30P+L,-MRY:0/_T,W, MH2D_<\OT@OVJ@<@<$I7#O6ZV5:ZY)2K4RU%?Y8I;T>Y\:\"BBQ:X-NQ94U5$ M!6EX;ZDE@[8T52^X6!N!IXC$<$+6G/2WOM95)=RZ=3]=')+#TXFGM*>")[4+ M\[2O,G,Z?RJU+/!@L,ES@X!0!V=D[5E_[0\P2S!L)5S)YMJ)6COLXOX*9OX`&EX&64Q&<"X M?W`4QBRC+0QHW"^$)CJJ,\IC,@"2,,#F_%%N!T$I3`88[F6!40\4PV3`X0X: M=GBA6"8#+O<'@F%V@2243"QZ;QT:R`TX+B2=;T+1Q**W>'\B=+[^_=LABD5/ M:%&PO=V]R:W-H965T&ULG%A=CZI( M$'W?9/\#X5VA0;Z,>G,19O:1NDJ'73V94:I MTX<^=:J[VEY\>R\/QANOFT)42Y--;=/@52XV1;5;FG__]30)3:-ILVJ3'43% ME^8';\QOJY]_6IQ$_=+L.6\-8*B:I;EOV^/;9IAM4'BS'MGVKS(K*5`SS^A$.L=T6.4]$_EKRJE4D-3]D+G7^IB\UM1<<@V^"0=>!;B14)_;.0C&&Q=C7[J'/BC-C9\F[T>VC_% MZ5=>[/8MV.V!(BELOOE(>)-#1H%FZGB2*1<'F`#\-+T)#"B)V'.U`D]YOGW62PU MHTY@DK79:E&+DP%5`^]LCIFL038'YK,R-8^+UL^D@D9)\EVR=%R@H@%_WE9^ ML+#>(*5Y#XD5)#"-`1)BR/H,D0F4M,GYP3"&X2'I&2'=`T4769`L*LL%VV\; M=E8A!V$5GH_?%U]#'(Q87R/\"$.2:P@A2:\1&@D2ZOX?H7(0U*#F16#C.<8* M,M,@'D:L[R*2NXAT#(%DPD1T/\=]E."E"3F\E%I`ZB96D+`KU=G,IY6(PJ%- M[$GT<,@8":Q$#\\B MEY"G>MASG2&,)/E?D23!1))[R52W_F,%49)8$%))*!P%5)(>=EE(*CQ%85_S M&$F"#>MQER28K*O!?"5)0:!"+K5)U]5=1'(7D8XAD#QY0M&V__%U)<'$,3+Y M6$%F71$&C/BY1E&7C$U4M'=[YI`UF:*P&PTK&@F*OB)(@HD@4D2Q@O2"(M+4 MUBC*B->)BO:"?)<6(`I[WB=KBD';>MRB#DTDD4G'/::?5Q@.+^Y*=(WC=DA] M0O&9K>UOW?@4Q1W'&<8CIYCLW0_77H<1JQ-,X$;:]MT7X?EH(0^C,RTS M6)ELU9HR>?R]?TYDJL$CA<-VI/;Y'O-)+2J"LSK<]9*QH2D*3H:"P+)DN]9D MC6_K\I<,V09II<0]1AV8)K<,4R0]P/.)H0DFN&683C#3#B!8F>S:CRM3/1Y* MX=)M0S*QF"G,6$>^#TGN0])1"!8IV[4CB<.Y9[K4S?3C(!NVX-D*U M!4ZB&"/>,E6*=EW@GS^6=V.,C*5M21O5\@(_VD"B>4,M^#>UZ,R)3;);Z"35FVUWQY3L@&(E&F&?/2E&DDV>UJW2 M=-5`[D.247;B]HL7]%(PK8RJ;`1T)!A]F?F>W!-@FDU+`0E`E5(;!WTJW2LH)B^JEWX`WS0J M>46WC?VN]I^Y6-<6IIU#()=K4CXON&'04*")TMPQ,=6``;@B*=S.@(;0@[_O M16GK`@^&43Z*!PG`T8H;NQ2.$B.V-5;)WP&4'*D"27HD@?N1)$FB+,U'XQM8 M2'#D`RZHI;.I5GL$FP8T34?=%DPFP.R296\F@TBNYM$5^5)`&YC&;I:.DBG9 M00O9$3-_#9/V&`+RO0?0O?8P@!F]WMV3!U=48+B>>1CT_-[G/&"R,TS>(RX< M#"X=O*_LP##!,]9TE/6\03E@;E`&R'7VX3^SNZ+K['^3!0WD5L M&/3_B[NB:_%ASQ_$`R;WXDF:W@:^E1U?2`3/VTGGL?CT@ M9`^G/!R"CJ[Y5ZK7HC6HX15LI3@:@7D=SGA86-7YS;Y2%LZF?ZSA4\SA),01 M@"NE[&GAOB+]QWWV!P``__\#`%!+`P04``8`"````"$`*;1JMJH'``"H*@`` M&0```'AL+W=O?'G_^Z>&MK+[6+WG>C(S#H5X%+TUSO)],ZO5+OL_J<7G,#^;*MJSV66-^ MK9XG];'*LTU[TWXWD=-I/-EGQ2$`A_OJ%H]RNRW6N2K7K_O\T(!)E>^RQO2_ M?BF.]3I83X_3XL"D,@1WV495O5\%G<:^C,)@\ M/K0#]&^1O]6=?X_JE_+MEZK8_%X<]TU?Y5OO^;%\TMCRCTS1!;L?O-#Y?7:C*BQ&5U\Z6PEL%H_5HWY?X_$`EG!2;2 MF82F]^ZZ',O%3,SB`2Z14@[HWS:9!A2,[#_MZHF^&V)I^MRRJ8!R,SH+69*M\>9;A\F'PS MY5T[3=+7Q`LL24\26TSKJTX?7'P%OD6?%'8F&:0SEREQ-9M9W*:(I[D(" M&C,QSZ0SK$B]"N55:$Z!.$U'NIP\GQ6O`C.(Y[XO0]SY!"2+=DH*,9M."7^* M!'+9$ZBN0"ZBGD`CP=P\)"Y-(#13KBZ:+6%H-D4>T=Y$2TB60`(:TXWS,-`2 M>A7*J]"<`G'&'^&T-^%2RHBLE@0T'*=7H4`Q:^?#;!XO+K5J-QS-.2!*L]=U MJ\E7T8HI'9VIH.'HO`KE56A.@?ALBNH\%W@^*Z:S-"(K$30AO`K-*1#? M<@B?%=/ZD366@(;C\RH4*&!VBFDB$^8K>7V`K9J2AB3"CH1A^B7 M*"[C0D9SR@@BEM$K4:XI8+R+KS!R'IC19H3; M&2%18$:2LA(!(I;1*U'.Q3&*V;5*B61/,:K/#<%9('&8F MG].;G-'D([A8XB:Q5Z+\+IJ58%J;)(;30O[`E:5)2'`AQ=%Z)L'..U= MM*0T&TD0G3G)PDW==9:3M]"L!>;\4"J25U+1C-0K<:(39T365>JNLYS0SGL6 MFK7`G*896D__5R/2WD7>.F/ROI0X$<.1^B7*+]&L!-.23,0_3NRWS&36B@69 ME8D3L93@PTC4%1<9DXFAKX@N.S_F_%`>DI!CS!HZYR&QN+30/C@2)V)@4K]$ M79'(F$0O?45TZ0WF)8G(4]=^$A*+W@/&&W-2Z96H*Q(9D]"EKXC>XQP4AR3$ M(91OX][\!1%;3Z]$N:88%\U*<#4')2+93T175BF(X(U%7GD1=2X,@'*2=STT MZX$([0X[?-=M[\)/T?[Z="+72]%_Y78"CM3GH5D/3$IR$;\RPWX>ZJ],)X(_ M+%PII;O.`D([[UEHU@+SV<31R7T>/L@GW1U6QI>U#CML""*F_ZE?HOP2S4HP M)4E#'DI()VC?B>B^$X*(I?1*E-]%LQ),:3HSH)96C5>CC.E3)`012^F5*.<" M:SJT?RBCCQ"V'0PY*`*%_0@DHQZD-]^DSH<9!W66V#]ADRRISQ2R;#`? MB3Z>J=J//)*^!28AB)C.IWZ)6(IX3D)VZA3,,"BOB69- M,"/).K=]^QY"G,$[+"%)G(@A2?T2Y9=H5H)HHP_EGO8NLM/.R`Z8.!%'ZYD#'5K`5&'11\HG[PD9WS*!`,G(A%!!]&HIS+"9$>V]!L*QC1!I6; MLT\$L0:MS]EE$W>((&+ZGSH?1J*-OR-$?S>M%@3AYI MB1.=.DF^]4O=9183FGG'P1X0M+VX[@"4<``0#J7M\^HY3_/=KAZMRU=[N"\T MW]^?/ST?//PL[5DM\GDB[M/V]![Y7)F#BNWGD_,%T3NJ6S,"<'VGR_F1&ANSJ9-QT:\+%>$`P``PPL``!D```!X;"]W M;W)K&ULE)9=;]HP%(;O)^T_1+DO^8+P(:!JJ+I- MVJ1IVL>U20RQFL21;4K[[W><$]+8T)1R`01>OWG\'MLYR]OGLG">J)",5RLW M&/FN0ZN49ZS:K]P_OQ]N9JXC%:DR4O"*KMP7*MW;]>=/RR,7CS*G5#G@4,F5 MFRM5+SQ/ICDMB1SQFE;PSXZ+DBBX%'M/UH*2K!E4%E[H^[%7$E:YZ+`0UWCP MW8ZE])ZGAY)6"DT$+8@"?IFS6I[DZZ4$J7OY#4=!:H4G8FL!G M:Q),1N-P,IU]Q"5J7>#SY`*&PP@>3J=)YYXHLEX*?G1@R0&PK(E>P,$"#$^Q MX"2ZH-[*"0+2)G?:9>5.70$Q0D;34):N"]TP2F8G-2Z#H" M7L<(L^LS7B[9"46+-8HNH69+\(?^?4/KOA<4D=]I#!2(J(^BXXI@+0XCZ4&@ MZ\T\C*RY)Z@9]S23CJ"9QV9(83""R<<9]:"5"TETU0DC*Z<$-3.LK]^\+,:^ M(K84!B/LF3[C<'Y:;.<7F7=.4`/W[_CM_(84!EMLLEU78SW(SF]L,:*FSQA& M-N6YYE5A4,)FZR=X':4>9%/&%B5J3,JIJ=F<:]Z@U(]/ZW@90R&&ZZT'V?6> MF00):OJ4KP2X7X841I)SDW&838O-!(/X]:S`$PYSLQXG/` MY+/V9P*=E%ZF>%1'\26\]Q\GV$MAMU!2L:<;6A322?E!]TD!+._NUZZ'NPN; M+JS[`UJHFNSI#R+VK)).07)UTXMLN8+FJ?F:0[-,X0'N MCT"\XUR=+G1[T+7?Z_\```#__P,`4$L#!!0`!@`(````(0"5GM4$H`(```P' M```9````>&PO=V]R:W-H965TZ7'S\LCE(] MZ8HQ$X!"HW-4&=/.HTC3B@FB0]FR!IZ44@EB8*GVD6X5(X7;).HHB>,L$H0W MR"O,U1`-69:$WK6=HL;><&IDEJ6)@2YR!N]S7D6S2)06BX*#AG8 ML@>*E3EZP/-UAJ+EPM7G%V='W;D/="6/GQ0OOO"&0;&A3;8!.RF?+/I8V+]@ M^L:\$T%!2O)H3;?Y?$SX_O*0+=32,CF-2]>-TQ3*"C(A$EJE:BLP0#\ M!H+;DP$%(2_N>N2%J7*49.$$Q[/1!%1V3)LMMY(HH`=MI/CM(7R2\B+)202N M)Q&JC$XJ<+VH_&MSY--QU=D00Y8+)8\!G#@PK%MBSR^>@^#[ MY8`Z6/;!PFX+9*JAA<_+))DLHF>H.STQJW>8/K&^)4;Q!8G`U\48-`P[U9&$Y,)RX>7T5>>6;JRCJ)9W'\ M5A1G?MT%9E/RZI9Y)G3,\RT;=R-Y:ETCB+.L2/6]PRH=[ ML_"UMVF_7RO/G+RE\;0;V7OK$0F&L?M6V)ZW['^\6;CO+4FNO7G&=W2,K;6W MR-Y;CTC27M.]-S_0_"O;DCW[2M2>-SJH6>F&E9T^RH^S.+0+(UOWBNZD@3'D M;BOXZC!X?^,0GI=2FO/"#LS+=VSY!P``__\#`%!+`P04``8`"````"$`Y)$& MI%D#```!"P``&0```'AL+W=O/7P6A;:"V:4YJWK*5R2UT)6+/A_HN MH64-%#M2$/'6D.I:F?A/^XHRM"M`]ZM]CY*6N[DYHR])PBBGF3"`SE2)GFM> MFDL3F-:KE(`":;O&X8WD0V#[0-QZJYSHW/[(;'!9DCQ*ED"?ZQKXR*%!7M;. M?+$R7Z"JR0FS.-_'&:86GB.\4?:1@@P4+JPAS?829K15?([I;340 M#0U\NV@)'H@>!\)Q(%*!H:)1H;2(KR$&#L`4[CL@GX;9Y-,@%XV=F(^<4!A5I=&,"OO_N1<* M&"G`%1NWDP@X8\@D50*C390#Z@BAWF\E9GL[D\CB3 M(WT4W]@^O(TNQ!U_"ULU;>$<%G#V:GSD<-3&\_RP#P!FEHKV1&W2'U_4_````__\#`%!+`P04 M``8`"````"$`_J`O_\<7N18:0- MZ4K2RHX5^)EI?+GZ^&&YE>I!-XP9!`R=+G!C3+_P?4T;)HCV9,\Z^%)))8B! MI:I]W2M&RB%(M'X4!*DO".^P8UBH6F:`L>IE\R#.`0X6C-M;KFE MQ(ANM)'BMP.%.RI'$NU(X+XC"1-O%B7S[`P6WRD:#-X00U9+);<(-@WDU#VQ M6S!<`//>F=,Q>CUE%3Q:DBO+4N`Y1N!"0WL>5U&6+?U'J"G=8:X=!JX'F'S$ M^*!G%`5"#D6]7>9];@NVN6W9K9AK]^)5HCQX.U'\GD067&!@?S&0AR.OR^TP MLP-,,B)>603(^18M&/;,`6N41R.OR^PP9V2&'7>8V78\AA/Q]R+;H*GW>*+` M89*A_7$&UL[%E/;]LV%+\/ MV'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^ M-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=; M5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_ M2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP M?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.] M*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T M._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_ M7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM? MH5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^ MRIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-" MG9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKL MZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U, M8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU M)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$ MXR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\F_W4`BA M;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD. MVF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2 MU.#9DRD*0Y/L(&,<8[Z4%3]F\=%]2')VDZNZ1 M]DBKU7Y<$^(DJ`%'0)OVW^^8<:C'(83THBG-Z^'Q>#RO8?[M(S\Z[Z*L,EDL M7#;R74<4J=QFQ7[A_O/WR]/$=:HZ*;;)419BX7Z*ROVV_/67^5F6K]5!B-J! M"$6U<`]U?9IY7I4>1)Y4(WD2!7RSDV6>U'!9[KWJ5(IDVPS*CU[@^[&7)UGA M8H19.22&W.VR5#S+]"T718U!2G%,:N"O#MFIND3+TR'A\J1\?3L]I3(_08A- M=LSJSR:HZ^3I[,>^D&6R.<*\/QA/TDOLYN(J?)ZEI:SDKAY!.`]!K^<\]:8> M1%K.MQG,0*7=*<5NX7YGLW40N=YRWB3HWTR<*^-OISK(\V]EMOTC*P1D&]9) MKE M/#M0<@!X+6,D"Z3L9]-B6$.KM.RA:P-V^"O4,(-2405ZSX%08/[#$=3 MXH4+L;_0`GKC%4HFF-,P].&'*M:F(IY,N*D@:#`_$TVM++]9\)>558,LQ)`" MK%`2-8A1%$Y,@":_:U/!)U.B((B`8R+V+ZP26VC<0D,)HG&F[FMGCRB":&HJ M"%I,T8;M"S7(0K0J:X421&1A;-X?DV<*@A!5^[:E!%N2X#8\[%R4(&3"_(WU$$?BW:V]* M$?OSI\06VL1"0XFN/7);3-[M[TGF?,W7]7(W:`KOJQ"KBPM4KR\.N':OC M:,TD"FYO#&8YQAU`[/+0M-J>Q[]J!A>UB0C-R=!8NV;=*Z'Y4ZW;*+T[>-CH MS9;,;;=@J-%%-P['9M7CVA)):-4EQ5/M>S@>-GN"9SL&0PWB17!S8T]J.E/! MQX2?PJG&/1P.VSR!L[V"F580CKO@J*('[B&S4$<[:\=RVRVT!C,WI3:E,V?: M!6,3LJUIZBR_N%-VUT;!K9)?,=,(>-Q9=J8D8KP'[R&W8-=VP:]6UC2#F+0+ MG3LBN&T5K,,K!IQ`K\V"VX[61*9]A5N&LN[7T"5^R#$8]GO8>E^-S[8,K8$= MT&JL*ECW2@A>8!G'L/->,XH:"+<-1&MX<^*SFO?ZQI<4S;(,A1;??<@(T#K, M_A)9=U]IC?:MCN-`CX`BJB8_N/4%2DVS%MFVH34:+8"VV[%);!&?WMXH@6KC MPQ&QZ9/LV=;11+R<#)Z@O_GT]KB1;15G4]+':1Y5.Q\.BFF?PC:SA?4/SYP'>+PEX0/='(-Y)65\N MU)N1]HW5\G\```#__P,`4$L#!!0`!@`(````(0`%;E3HB0,``%`,```8```` M>&PO=V]R:W-H965T&ULG%=-;]LX$+TOL/]!T#V6*5GR!VP7 ME;+9+=`"Q6+;GFF)MHE(HD#2((E7N64/52'2LA96MD`W5<"MWD>HDHY4-:NHH'H^SJ*&\ M#9%A(=_#(;9;7K);41X:UFHDD:RF&O2K/>_4,UM3OH>NH?+^T-V4HNF`8L-K MKI\L:1@TY>++KA62;FK8]R.9T/*9V]Z\HF]X*8426ST"N@B%OM[S/)I'P+1> M5AQV8&P/)-NNPL]D49!)&*V7UJ"?G!W5X'.@]N+XM^355]XR+> M0+]4YA$$1Z^B[VP&OLN@8EMZJ/6_XO@/X[N]AG2GL".SL47U=,M4"8X"S2A. M#5,I:A``_X.&F](`1^BCO1YYI?>K,,E&Z72<$(`'&Z;T'3>485`>E!;-+P21 M$Q62Q"<2N)Y(2#R*9RE)LRM8DA,+7'N6WTF(<#O6G5NJZ7HIQ3&`D@/!JJ.F M@,D""(TM"9C[MBW@AXGY;()L**`5Y/)AG:;+Z`'L+T^0'"'3,.@AL8LH7B.2 M<0^)0%ZO$>RZ7J,)\C1F/;W=1HZ0J4V1V5.`(`&.&`BZ;8\!@XF#G"?&^ M&"&3`<2SK[B$<*0!R5#:^_)G@E8A[+9/3CKU)")D9I,;S]W%8K@X>8ETA,&I M&`J[[)D!>X)F[G?F"$%!23KS)3G+\?2,J.P:40;L)G+BBT((V/%BI"N[N(1P M_(*C,O3K?8DT09YOGC$Y0N8VD>2OF\33=W;9$6?>@E=W"1/DBLM>#CB>0(2D M6&5C^^?INX1P),X_(M$$>1+]LXJ0B97HR2_>7G-D$6BFUUMGHSQA7O_,3YBW ME9U9=*5]K/=CWQXVC\PKJIP@YFS1G5]W!9I^?'79$>SBCL")6U7Y"8.%-\/" M\Y-[&>,*->WZ>J'8Y!VAWGL@)XA!H23+YG$R]0JA\#!I.LWB,_T/)JR/",5^ M[PCUWZ66>15>%HH\SY@WA>(`AR-*P^2.%:RN55"*@QG.8CB&_5,<''.R@!\P(&2OL\ZA=@GNOHCGVC'1(G0KS1HK.3PT9HF.3L MQSU,[@Q&A/$(P%LA]/.-F3G[WP+K_P$``/__`P!02P,$%``&``@````A`&L= M;]T6)@``XG```!0```!X;"]S:&%R9613=')I;F=S+GAM;*R=ZV[DQI7'OR^P M[U`8##`:H"7K,M?$]D+6:!PE'DM1RQD'P7Z@NBF)<8OLD.S1*)_R&@OL`GF6 M/$J>9'__4U4DF^QN:8(8MB%U%^MR[N=_3E%?_]?GVYG[E)955N3?/-G;V7WB MTGQ23+/\^ILG/UV\WW[SQ%5UDD^369&GWSRY3ZLG__7M?_['UU55.Y[-JV^> MW-3U_%=??55-;M+;I-HIYFG.-U=%>9O4_%I>?U7-RS295C=I6M_.OMK?W7WU MU6V2Y4__661'OE/]M^^?O+MUU7V[=?UM^^*R>(VS6O' M-MQQ7F?UO3O)_?QL^^NOZF^__DI#_?!7[D.1US<50Z?IM/_MNW2RXP[V1FY_ M=^^@_^7[]'+'[;ZV+U_TOWQ@&^Y/AY=572:3^K_[3S[K?Q`.<9Y>9WJ$H_V8 MW*;]4<\N?G-\_N'T^^,?C\G[6'Q(F.H(Z93*#*M/TL_M=>M\?]VR7 M?][L[>WO[?>_.EJ4)8^[]UDU88H_IDDIRKEW23W>_5CT/PIS_*&8+?(Z*>_9T`RY7#,L[OH\ MG1=EC;2Z<9W4B\'P9W],!Y^%E6Q^=\0QKXMR2+'Q;3)C`ZY=X:BXG2?Y8&28 MCF]O"PY>%Y-?1FY\DY1IY4X7M6D/&^P?I!&G+N'?(^J#_3Y#5-=+8WC\+"VS M8NI63_#[`=>;U2_NYT,V[^UN_[Z_WT-4<&IJ^'Z6#$[S["J958.)FE7"[M;) MU5&15\4LF\*+J?LNF27Y)(6$F(O*;?V4)XMIQC?/^7G\SCU]WM_:;QCI"15Q72_ZC][E%0W9E@F^B']RR+[E,S2O!YPX7!BQJIR93I)&70Y2T;K_UFT]??':);5COVFSW\%I3O)/ MK%^4V5!RS\ITGF13EW[&QE;(ERQB4=\@II.@QOZ8_5->%#6ZO7G,,6>?>SM; M8YBK>N1F:<4:$\SO8F:\F:98\DF6U-A='?SIP>CE&QWL8+3_^A%G.[6];MKC MH;&IO__(Q%F67&:SK(8V`TXV#)HG]^).?PZ^+Q?(%U^7Q0SN0+LR]>>*!.T_ M\RZ]2C&/&@A3%H,Y_7DB73N[ZT^TS(`-`V5&LEIL\-R=X,NP'CAESNRVWA=% MG1@_5WG+EBSJ&V3TK^GTUR['TKMBO:D+IG'MY&]LYG6S[[T: MO7J[/SIXO>\R.9.IE_IV.;?%D)[3]"!,^D0%GN)LD\DU+P8_IY(D%' MGCEQGX*(34?\K[))5O>'>.;:\7JD7CVRPWX[2_?)P*/^@X^VD&?X':*?M,[P MYFLMYDGN+FZ*184.5",[_[SV/LMAA),1P9CIOMF6NZQ*735'[Z^R84#5J%W7 M+CY@$/NG:TS/:*VUZ3\RD-E&6-T6+)VBX4E9N3FFT21VH"Z#"0:";1/Y3Q_] M=)!0;>$+G^SHSZ:%EW7I2P^]_/07G7CEHP\?=^5CCSYK)RQ0?)=ZNXBBGL)8 M\T*/"A`.'IT2#`*E)<5[U![6YP$_$BT$1S((+XYPN+)`Z[[_OBPP4?.RN!K: MG^,0#@P,^YA0QKN1VZ3\!9LP#$//TXJ(?^)CH"E>;E98$-#7M^_3'(I[KYE, M;[/<,I4D8Q0S">+7^>$3(C#=?'-+N^T8P)>7MR MG2[-@1=K'>.:76TP3N_"9C<,V:`0%DN_)Q1^E%+:Z"L;W64H4D`.G7U:'>1) MA9:HV&?BX?3/BRK$3W6!.A%`3<@DC?ZBN^-3\<+B_44%'26NC01N6/M=-_A5 M])C<*O?\J]FA_C[&BJ3<9:(%8++B=1\U!Q'LCY?026NF634O4!UICK*1E#:QZ\08`S%8Z;*A27]//KKMS-0?8/M0WK2)COV'^GS/R'HQ`*KC7A)4*(5D,9-NVVCDL#[?LR%K\<*`>%R!R%0F1UM(3(1F7X5BK MD;+WED&<(9@\X75=A!@O;G&^]YILG%WGQ-`3`7Y!!T6,,Z`/97=]6OP[YMR` M2IZ6UTD>K)>9C)7K]3=U`=AP6R@:T(&/BG*^X[;(-_C1T+&1NT,DH=VB?.ZF M#+K.R3!"8!%3VMO;M`1%F)$^5FY"8*!DQ=7IY"8O9L6U,ET!*9H6O5)R!IU& M`-&%.3RSO9T8Q&,1%>&AFP!!^E4N9P5XF$POV:FR:XC4S%*1R8`F*Y&;W^CZ=*Y+@69WXIUPPFR&IC-OZ:6>\X[X_/#PCXH)V MF<(JCM-NJ*-$1B%;5!-E.;`V,1\HD?G;]]0"G$!%&W:(TYS@D?=VI12`X`*7 M!"B-MW_>,<4HI^QY=C^"G66M<+*_TE6$07"7$[RZW`%*3\5!Y^*HLX5LL6B2 MYPMHUVZZ0\5-M&L.[UI:MTR1@`/3B%K8X6HAC4:LJ@6!]#@%#[+HQ4Y[_#EX M:A3DEGQ)!]T:'Q\]=^4B1N=E0P,OE*L9EV#@4!2@K25^>$-:[8#^&Q>+.?KD M!?0VR0D0Y=%(K`5Y=8*C+4Z#"IOCA0V>>(YX"2!1$L,>2BA'N&T#`9`X;`[V M654R9Y*(Q%TE62D1;$U>2ZW(A1UW+!M:09W+"@/*SZ*5Y.0R0+U6&5(@G7:H MG0IZ,M312Q\\->(%816-&L5I.;.2T?5-62RN;VQ-6T66'2Q)JK(3)OL9/90H'(X.E9OKVT*L:H0EAL6+9 MJ/:_:\YVY8M,\8BP*T9B4N`[927Z1C0,"5&?]A'C-ER0W(>2 M3]0*!BD98!8P2W=W(]N)$UC@N&%0JN!-508;!,:SLYT>6%NQ:B(20SZ9:9"=O(^SN20!I(;>-XA&&<.T`0F&E."M)*' M^BS?4Q?Z81-STU@DP@QH@.%XY%9UW&Q*R)]]B"R1+D0 M`Q%2#EE&PGN1:$1X06#C5#V.L2J%<5Q#,*V=A4>2-R_P(;TQV5(52Q+%N3$J M[1;,=XX<9&FLVBS#V<&)NN`,85,B?TR7),J*?@F:;93QIK,#FRB>W(^XE#7) MM_'&]!:44Z\FW4=N8`YU65/(*5000<+9XG(N0Z*8%B),:GGYCMI6WKXM4%SM M="9D2W-U`WKU("B\8$>7]_T]MR7#[BP#S7*MMK3ZQO`:I"'4F' M5KLDQ`*GTSC]VCD6G@*]ZM`0D9-I\C`5(GF$S^8C9$<[ M1Q@&NL$$KR`_=<-:42=B;<93UBY8"Q`>*3<<(!S'M%OVU`E\,M+:$/U-"*<0 M@,0HQJ($:-=!-%(;[<(7F2LM\2^Y[Z4%66(.GL-I$@C8J1_.LZ6KBKEDO7\&R MG:5D/L?U.G3M4-OO8@.A0]Q$`"A,W@R"V"2:U(H;$`)L1$*YWHOH M/__V/\K:"DS._`94V00$(V':'33&[ZV$?YI&SRL'0YA,L+S5"6&*2Z[+-%12 M$-EJ@TP,/.K81SJ-_?`^50)GB)E$1+;8D\H[39,7&=I4L);QJ$%1Q)4`HC)% M071E&C3+KFR<1+;9K`\[O)V,)XG10$\/O9E$)F0TL9=ATXQ2RC`C\IH.3A;4 MW1LGL%!Q,>1$V#[?^H%0Q-A*%`:`G9J27:48M1#9H+61;WZN;I2L><.>\4MW M-\*EM6=@?5*C7L/<>/\0=GE@:;C6S?M1\P:H3 MW.6]::(>-6$VS$QGLQ\Z.!\2Y,W>2RUI M]'H]9J7,"TA7RANG"%_8&IQRGUX;-^OR"???/1&CL<7RB.#/JC('`57BN M(XZI7.H,D^3#=AT8)@MW-__$CFZ*RMH#X`9?>BSI,LE_D8FW7)(RB['NKB@) MEF&E/$1-;\I?/4M;&6%-MCOA$3M7E`EY1\?14&>`:.E?U?T M*!1W4D"2/@35"RBT2R`CII2R5=MI=1>J?MNQZA>("))IH4+C7BU^F9C8VE'X M&D#!W$:DRX"B?7D];LC94+B86ZS;'QE9_\5+ M''6EJ(20X-F4D8-24D5*HGN<($I'@F MGGB0?`6YZ_N[\[99XDQ!ZU-%>J==@/PNU#0[:^@HV7Z21! M`K0K#&CJ27QGJ$\+Q"D7V(Y$]Z'`/KU2^Z/7>_MVBOW1R]>O[;][<[(\VAL_-$9!'5J1`0T2HS36*6X0U#OT_4;& M$=(*;,,.>+O2V<*R_=`#/G&,9ECN0O1>A7T1=IAG7('YZ1'M7N9!:0;XBK(. M&Q[SN2XE!MNPU)3>.Z"449C!C)T7`[*2R4TZ!21^Z$2;MM\G_3G8I26#AU.4 M`./0<0)G99$#TP!N"J_M/WD"H)=>@@ECWM0\[Q/K]X?C[PCCK"_/V,HWV[O[ MT1\HP".^GAOJBB?,(`AQGI&[Y2$Y+<+DNMPW<"P%C\^R&F'8D0@X.M`R`%K4$)#SDN#(A(F M/X1@+X0%>8@:RK0=,`)X6N'%VGD486"Z&^:?!(:U`<"#O+>#K./[3_[D>QP4 M+WCFB=QH(Q+P4PZ#8Z)\D7QVWP6(Y*.`V,0I\#G%/?$,_M":(8X4GJ(;,KY8 M+1*R6]*^TNEI#3!8*[%?CX"=2,Z[3[AC@VWE>T&X)(8(M>]?;V(4!,'7:2Q$ M\X(A:>WNM6:U`.>$!#.S<3`608Y<\+.XS1H)$2<0F6%D3&MMT"$/59C3 M-J',U`QBX7DXOQB,/0@4T)YLB'VJWZC4BP#=1YH>SDE$4:)8X.I%FT"7ZP5] M]TK,H)%W(!);M%2)N=)QY%=6-Q326J6`6Q3P05=D4&4+E>.I0!B_\##"<\@7 MR_[)%2/:\LG>2]^R#W*0E"QCFB1::4:0UW8/RA]4^S)*2K%9P]??3`75%8** MB,121G;#89J#M:>*,OS"*R[SM."8N&%U9CO+G$H'TM&H'Y"3Q8'>Z#4;10L/ MQXWP6TG'U%?B@;*V.HD'"[7;@5*>=%H,UO<.=D>%<$8ILP<8VT@RJ0?M#%W/ MU;?IL?K2__P\N>,PW@`-','3_NB/1?F+?"A"HS2G_S4)J=SXU%U3D1]\BP== M:G@_`D/`!OB&]_Y4&P=OZ'5@"\BXV'F$]^'GE>[-J(&)(S`!\X7_!F<;0IFX M'ZC@4)`WV3RN)F5QYPXCD!+R/\.$.6<+W?"C4&X+[10-C5Q9W">S^G[[2B$D M(FUS(KA12Z5$5@<2G@U!$72NNRW77:5LK8!2Y%T(O5_(WRDF52.,X>:'/Y\M MY;AQ#?N\S7>]6XI[07.D[EJ#.I"?,N+_U+I)DBT>:5>5P6[7M72&9[6&5^,9 MH9HP3@`3$7=2^;U]3D+ M-C!_7-$K-6J40S`4O!O18:H3*P8O5,FSKQI^4S.F0H1,T6V@YA8;V=8$>S-M M[=%``61)?EF0$F+I(R,@)@X(<^M[E<@&E3*2=7@>&.RLNRHBZE\(O!!(-GIK M.:8%:<'66C$-NP<\BA#H%*U%J.^TJ++2$!,9@+ZU[_.%]VMZ]V4P4"T;A)_J@2!;P0&X]E/E1Z[BD:/M;C(8"^4"L%P.*;C3#D/L0 MR'KF%/#YF!!B7P%GBM3\6Y'1&A4,.$W+;8+[C,R(K<$&@FRT'RJ+<+95X\TL/*Y)\1-SI66L9VNH MC9$+/PH?M,5JTUJ?S`[UF]Q&;F]_>_)IFP#_)2M:=?N=U8\)/+BT7%*5:GY' M9-YQLXS(E9[UC]D,X;BNBUP%#/5E+1_[,C4+JO"4O7&R)LN*\9%(E2/*W:-9 M4:"Q8T>AW-,EW M5K1LO=IUXWMKKJ,+2V58[$@T8)%E%$9QEY6WX#V>BPB^8,79#(N@-PP^24E\ M0H<93:\YNR6'.#QD(K9#4R'PZ8Q:W457F"KW*>.N,/>FL,(*Y7V3#F!".B,Z M[,A?W+47>U-LN=)K`@9B3(NIK6],G!<6T11A@I[$N<(\@WW0*"C$$+E(JL@+ M'7^6_4(-]$:=C\B@-"""\$374-##%.H]FLJS*[E6DY>DQ&2VU](C+C'K'#L;H)?6.4OXPK&``+)*<$#^SZF)Q^PL-9J9N8BFWN;@H<^BRC M0C]@9-47/*MYQA.S91'OI[&=[7BA:(E#+0EC8PG,^(A&(4K5@:\3/K`3=1H, M?PWX?\=F2F)^9>->?N[EMG'%Y!E(*JTNZB?K/.5YH13"),S$1R\J8!4MVHAX M4"%Y4B5UV#M?%!&OVIBN31Q\]O]K31*1HLZN_E4^?O2PYWT_OOZHV(X4%19A MO-3B8)T![%X'D4V`>KZA2K]S[5-6G`A#'5U5 ML,O/\\QKL_4!6H+F$TF5:M`WGY]Y8DY!=)*)$5=[$K1@G4+-GJ/4&PZ$W/O& M1_]PZ$027V,WXT#.+V#98#+KR0+$:WI+`QRE1C"XV5TS^)VVGS>Z?>MT#&:R MN<`A`5FQ6A.&QR[$J&?=C,[]B($IT,E[;M6=1_9)S6M"+Y:-%$],$GMEZ_5"#9GVAP[_*H1>(B MO>\M7YF7*6D6#ED["\34EA]>>>^%!5C]I3O4&="[/W:L:D]S]?>8B+8>J-:J M,1LRUNYP?+W;,"EO3%!N(TM'-FD827^#Z'6C))4VN^T]LH*O^(PT_.D>,8=N M>+JW_[8SWVNC=)-??L%\PRJ#5+25^(;890!8Q/MWV^XP5#:/ M/^LZ`R'FF=H\A[3W]_7:\>>\)\ MRS>KAOUU\C3YV'/#!YP-/+$QZS'B)D\5G1FT"XT!M MWZ>@[*DMI>,Z9/NHD^,JK6OX,JWO=!M#'Z=1&JSW*@8`"Z$(,VNW\.5$.YK& M_V4!UD@P)-F)HT/4XH/\3E72/`?15`BI@B`+T/42",[2VN:'BY.V!_*WH7:Q M`17FS0HIJ(ZET$-,ZQ##$_'6ZR(Z%!_WZM=HY1=M=N"_HB(V>FB";2\NC-Z^?3/X_.!@='#PHO\Q^1?9#9&' M6:`F'23V-<\5PL4AR8SN'GT&F@A/(XCF7HFI*[6`A*=3M&\.0:4-C-/8J3K1)/S=JYNTGF),;3D[`LU%IEFK]^JC MJ54;5%@4%H`0ER@X7K"Y-\FYNKN%=J$JW'2D#,+"#VEY37!L7./J>N8#]O.? M^TQ>-VZ#OS_-0Q`6:B*6.2U#T(`N#>`LNWB&^Q++PVKZZ#SE=6OMK3Z[F$=! M+HQH'JGU/5AW!'U^.55ID':*Z+*B-$=O>+`"?.]<& M525MLCM>4<*$[!>_:1?=#%^UV6GT-H/'#L3X!I0/QX:Q/#91`[0/CACD;_99 MDL,3>$ATR?TF!<&_H=;&.ZHL/QW(R:%'H5H@AW`(,_O"C=7LBM9]``7F-%Z? M`\7,V)N!#)&D^V2.@1-?)9\4O_A4,K!$[-8QEHB[]+@O)*L";MUWNMJH!_SS M7FO"7!S*E]`T1)HRD35IZV98@?8L;_Q9_`0,O+0&>GZ8BUD1?E?2QFQ'(//4 M:(V2*?UQ(-LG^63'KZ)F>OAT)7MF6VMF:[),G;**UVL"`91O^N4(\`>T_PET M42;6@D$S8$MT4R5Y'KF_M+8/?VIJN1+ML,\/IG+LG+0V$^&'05B=Y?E M>NS".JA%V_:B'_TK5G1M.>^%C@/!?&]DH[SU3V6\U-O\EK>RMS]Z\79W]*9] M&538>=C6BJCE<.H[$I3)CY9(9X./;K+TBCB/RX>FKJ=7W)(V0VO%'HZIV)K+ MQ%.#381L$1H2@,$K+HF(<@KNP_H#D4#\HI%L3*!$1.WN+9:I.@<8OXF,W?_Q M19A+LGQC4YC=UNXRWV;4,XE`DBB2*A M1(P(-XJ>-P=2$3]8UP)YWY6$$XN;3$AL5;#B2#SG7U.!DES2](BDKSE9[)HP MK,\A*Y:7+!/=^QUH7K_O<+5RJ?%',83W61ZV M\2-9L,-V&KEUC*ZE7N(PM6=A M*(&S[4;UI0'T5"85^9C&9XFIJA4_;#\ M98O:^O>I^-#6KGRRL4[2$FJRJE+RQ0=[CU(L/PZ$YZB\+W@MZJS/Y1-%?I#1 M-QYH8Y&[HLEAE=QD+("8&E&"+DA]#4.V$._)8?S]R?/`+2!57X[B'E]LJ8E% MST8L=NC+FF)GM:CTH&%U,]\H;*"X#'>#VJ@IR`H;`NXEP6,A5078?CAH6S9R M8YKY;MSO:'3DW7(_$D8UOUPD&6_.]%)]EA;HS MKDS8[5;9Q(L;W0/*I[QM%7E*Z,O":?,*7%T4@W(?@#?OJRRQ0(5\(NRW$3#- MUSN-+(2_E4-5OSV49M.](ML"HJ\F%TDP0YH[`QIS`:*M<(@PG(9W(&%I1E`5 M\<#T*`QAU/*ULS!N(#:(QZJ$T2K&V[Q@@\MQETA&AV/&@R#RVI87(6N%[,O1 MJ0?"&H%P6T_Z'R%1FH3M=]-E[%"0S`9YT+(!6(.,39H5+0TI`U>J,Y6MO+5! M'6?$0A9Q6L-6UZAT/)X5X7FD('(VH(3_ZRJQ=I4R8Y[Z$HXJP]YEMQ5SJW>N M(A\.-,`M$3KQ`M:0T?&"RX(6J%!]B%Y"]_?.PBW:8!;;U_IV@.'C1?R^OY++JS6L>,>5OB,T[#?Q2B M`_@*JS6\-M[L7;+?R.SAXGH!`K<2,QJW[WY%^KMUW MW'[[9?"&[?[HOHT]17ICQX,O35+#[^I)(!W2V"2G7`E)?"MTY%-TG@)V7O7B MWSYV()#RZ3ZO456)Q(?9K%A<^QO=%NR$*H6'.*++7LPM?E=D%*%?I&1O].K5 MF]&+I8B;+3^TVU6V/W\>^654H MO%?YA07,6;[PKMN7[B)-`?DE$F\'QHO*!+DE!U#TCDCXZ%J:.VZQ^@=>B^2V MX@N2!M6@?\_T%P*)J\'DYT0+C[J#TQ>V;JOFUIK)T>GU78]NW5/C[H6`MA+6 M&L[FY1&=*J75^!'L6"\CHNOO>+RB?K5V$\%:-2"NG)QEN='Z6UFEO\3Y6A`X M=DWB-!K@LO_TOX?1[U*"&-YHTY_]L'M!!D]/4[#O"\^M<:0M^,8+50(;K0%; MNAWU4,6B36]NM6M-:O;[XGM-2P(5#['N9>BDIL,8\P%Q>VA./'_S@O5!(2A& ME=+J06/L^H;F#]V&N( M'T/+7G_F9WO6S=#_^,'9$K":Q6W_L6?[OC>B__F_2Y7=G\[I2A$TR2&G0\>X M4K,?XK<5/@,*BNBT)>+#SJL+\"G=<3$JL@J1^Y/R67>BZU"#/<6ZS7:LGZZL MVSQPL+9*&^H$5KT0]JO@DV2?.%^P4;^PL>'-IF8%N86B@*UR?_I@K4R#W;<+ MV^D9N)$!O;IG-X8^V&0M0I%VTQ!X[@NVFP:%,NVF(;TM]G/JC=O\TC+MIGV` M_ZF,OK9DN^G9@4R%R4)-OKVK_`"[UE4';>V'7RK>Y=K#HY<9^/#X+B\?'KW$ M5N5*CR'OP]/^2QQ_>-I',?_A:09RL+[78D/R$5R`WE!(B*V_);3_@K:T^T'@ M%`>^C>/VWFP<]SJ.>[5RV-IVCPU[[016WH"M,UQ1M#=8P,#;#2.Z0K5A6&>B MAWG6G9/,I&M_2"J\^7EXEH"H#VJS;JOU=FO'J,N<=XM:JK[UY/QG0(](1GJ] MU_S1F=F.BQW:?>_^KRS4G^,[O4)!_:2''>![DU]M/5-PB>1=\MZ"/O&%3;(H M#TDQ/%S:):D'!?-5+AY8+G*=_[S\Y`:6M[*;-PU4@WT\TRV$P4XH,9&?$$^0 M2E""&!2EV(6_.`B31_4FSX]P,` M0YU@WT:@!GM*>85NR+('CP/+A.+`VN=/?*`S)KFVELO1\E]0,IRLK;\)%6[> MF`K)^=474OC=C4(`%-)P<=#TLW:M_K'[`S<3 M.TKSDDH9L!SZ*SH0U@:=^=)I'K;%X7IY@TIVJF"Y9+ M#V_:RU?\C<)O_U\`````__\#`%!+`P04``8`"````"$`"Q&^U^\*``!\70`` M#0```'AL+W-T>6QES$7Y[ZEJOU5CC-O0T,FAV\$V7?744]75W=6V M;[][#0/MJY=L_#B:ZH/W?5WS(C=>^M'35/_+HWTUUK5-ZD1+)X@C;ZJ_>1O] MN[M?_N)VD[X%WI=GSTLU$!%MIOISFJYO>KV-^^R%SN9]O/8BN+**D]!)X3!Y MZFW6B>]Z=923WJ0'DNYN MHVUHA^E&<^-ME$YUHSRE95<^+J?ZM:YE)L_C)8#XS;^V\M__/#;^K4?OM%[A1HB$WQP6.;[_D&Q<#F3W,LMN+M=Q1$Q!+S. M"+IYB>*?(ANO03"`>?BSN]O-S]I7)X`S`X3GQD&<:"EX&>QC9R(G]+)?S)W` M7R0^_FSEA'[PEITV\`0+C/QWH0]NPI.]3,-E]2P036'3&&%P-IEXAMH4@DD. MGCQLD_/C'ILX7<-V7:?PQ^EB5ARV2YJN>ES4.#Q%5^DKHB=Y6DQUVX8<,NCW MD5;JL#,IF\S[H.]BRJZ'%[/,M$U[)-4R+A;K?D.%IBV3RA:%]H?1_<7HE*^L MR;H\#5^J!V"'D\NB#UWW0/\>V?BY1)Q<>$"3ZK%M`XGGL`DC\3+ZV-Q@`Z.N M'P3EI,L;RD='()O3H:[:JP2!(J\2!(J\RF;//0F9/^\I4$A0W%<)`D5>)0@4>74D.0./ ME'N5(%#D58)`D5=9S4=B7X4"G>*^2A`H\BI!H,BKTB:?>0:>*/Y+IS$=]?%5HVP3EW$R1)V4HKM@8$):\3LW-UM MX*U26)$F_M,S_DWC-?R[B-,4]AWN;I>^\Q1'3@!?>T6+XN^!EK`S`YLP4SU] M]MT74,95>S-N,A7GTE!F/0M7$];(ZH^LH7&=+=@DJ0Z]I;\-Z]:5NO?&)="( MW+8;3CB,2B5Y.%3%IQYZ(7>?8`OF:N9IP080$T5("+:086-5B!6UD;00LY$T M$+21M!"U$;K.OLY5,+F,M[`IN.M@VQ[W^VS5USE>]@LDP/=$3&N;.I^M3?8P MVMI&E-."/,@OM;XQ,_##9L=[+&UI4;>SI<$>*UM:B-K(Q\U>B\O2!:;G/4AV M^.9^?AP,4)0U)'A(AL_3$Y;BLV*\)"$>ON]G5%=LYA8QNWEG%C'K]"I3C_FHVNV0'H:FID-#;2 MG/4Z>/N\#1=>8K-[')@*=A8KTM71C$T+JN,/@?\4A1XKP^F9F.^3./7YT(O"C5#\$EK%]F/.#=)GE0 M@PMH4!_"(Q,!+.8+!.`$%0CP[IB<`PA/%0A@D50@@`"M$`"<`U%Q2C\8D&P& M,5"I!/WG4@DYIK"24WE&*YO2+^@_8*7-I=^3:";Y%@*]HAD.#@`X2653BE65 M8HC;H:=5%,#!`0IL&'7E#'F#IIROC!"2=`%#Q0BD@4.,R(M*DG-!9P7@,",S MB?,0$A28BE1#`#A*(!!'#!2-OP.*0=$(3*-!T1!,(7!C\`7[!/4$-T(JP@!X ME/2*:IXPX$:,"])`(*C*D"0:#%4IDF)0E2,K5QBJ4B2!H"I#4D^H2I$4@ZH< M25RA*D42","(D@Q)/:$J15(,JG)DY0I358HD$%1E2.()\\PILD?+IED1E=9/ MQT?53[7756LA=="T:`*_%\VSU5.V<@1?L+4464KC\TA.43O5GN/$_QD6F?A< MD@O%5"_1\3FVU'?IF9\29_WHO<)2--OE>5TUUWH!25'?V`U&'F$CIDH_5+)U MK8MRZ?R<@.5T(EHMQ[I*:UU^)S#XVG9K@+1B8(4%U2"0ZQR#]!"0U$6PYZJF M"09)Y1BHJQ!/7G.&T]P<@L\5-C"'R:3 M*N1@44H$[3"XJ2V0PORK&S=ZBT*DNVC"Z`\9_10/(PTV$[M"8ZS MYNY22&7\2L%R;/QRRK&D>HB)65[)[10K@@'=$"KGQW=B+',`6_AKG,"=%,M< M+H9'Y96Y4"0GU?&))*6C`N\TQX(K#PROC9X\LA\>J4W."'JD\EK0DG40KD,N MGH_K@%J]T1"RASNU2,0V!@@%>5J$\H.]RMS=P"*?F&JY481&!1V?GQO4\Q4_ M73H*H."0V$`K%YQU?/^CM!Z99/@,UR&E>?F@$0YH>0QR071"AV^=-H&B/64QGI]:$//T-(;TL%YP3@/""^0'LGNU-KC4`9R@&XAT69U?.=HU@GXC<=<_?R<(^^PF5! M';XK+FB2R^*Y'PIR;^WS([N;I<*%)HO@HK(J/V*V(++`Y*ZR*C^"XZ@L,+FK MK,J/@)#(LD!)5UF5'\$+5!:$6U=9I1\M$(SX3$KE._A&.,+9@PA'F93*:WR4FX)1GDFI_,7'MR48WYF4RE,@CUAD MP05QBTH?F3R[EB"[,V=99%T^8'"<$8$![U!UMP&\VS;&-^.R6RMPCDL,PAOI MA"0]>^Z+-H(\PO*)8`UXRAO@8QJWT+F+*OL#3@_=6=Q$#K3,T?/SA'*V+&&B= MB>&3*LZ?1,1\C-;;TD-\+L6A6T3$)S]Z\99\Y/`,&P!21-)G;YLF3AE_?)E]R=,WZ&QRD+$O$V#])W<#DF`OQ/VY30B*V($$,P+SWZ M*3QT7G1B3@3"$L'Q&,,M3J6(G8PB*..O3A)A;^&Z[DZ,-EA4W3`&L__E:_6L M+>,]Q3=MLZ=PR_4`$+7T5LXV2!_+BU.]^OY']CH'"*;\5]_[7^.4B9CJU?=/ M^)X,Z,50:(1T\VD#[UZ`O]HV\:?ZOQ]FH\G]@VUL.KR7!V?S6T MYK/[>WO2-_KS_P!E^%KR&WBO]0FO_6:O)X=;Q@;6S2:`EX,GN;$Y^"_5N:E. M#C+X;.<%8,-^>&%$;U.^-OWNOP```/__`P!02P,$%``&``@````A`'D1A(?( M`P``FPT``!@```!X;"]W;W)KDG>N MR.?-[[^M3T*^J`/GV@.%4H7DH'6U\GV5''C!U$14O(1?=D(63,.EW/NJDIRE M]4U%[@?3Z=(O6%82H["28S3$;I:)["SA$/=V0KQ`O>^@6^FD(050,81/UW#O,88!2_#=/_ M?`[Y7&_;5^FE?,>.N?XF3G_R;'_0$&D!:+S!H1>&]$:#`)[A=TL?RU%=\LJ\[8$]-LLY;BY$&]@G%5,:Q^N@+E MC],"^4#V$>&0W,'&A43!WKQNIFO_%;*?-$1D"'AM"6H3\9G`#00/K1'(S7@C M"*,1W"]T%IDO^G$#)^Z0F+6$902RT#>"!3.#6KV>&;P)N-ZZYZVZ<6B(>8]8 MV$1\C;`<@DC?X75G"(<$5M_NR-*.&QFB[^S.)N(AT7FWG$%+C'>&L.WLWHX; M&:+O[,$FXB%QP=GR%F<(V\ZH6^@&Z5NC;J4/D0O>H*'&9PUAQYM3ZI%!+&]= MK=?5&`^1"][PX3GZ?$#8\>:V@4&N>ALB%[P]W.(-8<=;)VM:U""6-Z=7XB'2 MB5B=0.'(&)^XFG;<.4T8-8QESVF8^`/FDC\\AWL;.^Z8H^;T[I\FU&G)J&'Z M/CL/IOH:9%$_0F"*FMTOYMUR[3SBN=WS>?VPH^:4[_L+W,YMF+Z_P&W=#YAN M#;8_/+7'^S-GO.7/[5XZ?`X$;OM^P%SR!^N\P1_2=AT&;@=3PUCYZX(W&SQD M.L3.WTV/#)S<7'].BT8-8_GKBJOQ-_JY`0/M+?D;/CD"IT>C6C$DR[KXYW0Y M;"RVJ>DS<"@WS;?WQ`'^".(Q=TPG`.R'T^0*' MNO9OU>9_````__\#`%!+`P04``8`"````"$``-',@CP#``"^"0``&0```'AL M+W=O2_!#DD`$:I" MZ%9IDZ9I?YY-8L!J$D>V*>VWWW5,`DXH="]`S,_'/O<87V;WKT7NO%`A&2]C M%PV&KD/+E&>LW,;N[U^/=V/7D8J4&)],=+8@<\(J6\,V&BX(H>!1;3U:"DJR>5.0>'@Y#KR"L=(W"5'Q$ M@V\V+*4)3_<%+941$30G"O8O=ZR2C5J1?D2N(.)Y7]VEO*A`8LURIMYJ4=>?,%2P27?J`'(>6:C?<\3;^*!TGR6,7"@R^X( MNHG=!S1=1:XWG]7U^ESG&HYGW`C5-C\RBSX1C&UDVB*Z@UDV:@9,NLJ>L&D+'!Y9: M7U"M]UEGP@G-I+T$6P3JSYQ)F+9\6T[.J;1 MNP>PL:4GP5$[?L^4U MM+U>]ZCAKL=.#@O#0*W;O#MI+V\2R4UBU1#Z-@NBL"VBY0VNO/_/44^R/6)\ MTJ]OOH5AKN9H(Q=SM)&+.=H(Y!@&IYO;>#5]T;2-@HHM7=(\ET[*][KG^?"; M:D?;=OR`]6W:&5^@*=SQ_?$$VG<][K43H'U69$N_$[%EI71RNH&EAH,(CITP M#=@\*%[536S-%33.^N,._B=1Z![#`<`;SE7SH'M$^\]K_@\``/__`P!02P,$ M%``&``@````A`"+DS'!H!```?PX``!D```!X;"]W;W)K&ULK%?);N-&$+T'R#\0O(^X:R$D#4213`9(@""8)&>*:DF$2;;`IBS[ M[U.]T;UX%!O(Q;2>7CW6JZI>M/[ZTK7.,QI(@_N-&\Q\UT%]C8]-?]ZX?WTO MORQ=AXQ5?ZQ:W*.-^XJ(^W7[\T_K.QZ>R`6AT0&%GFS4\\C]05U%9GA M*^KAFQ,>NFJ$C\/9(]Z/MSKZN:WN4*Z?`1#7PZ-37*<7WK4#]R MD0&UU0CYDTMS)5*MJS\BUU7#T^WZI<;=%20.3=N,KTS4=;HZ_7;N\5`=6O#] M$L15+;79!TN^:^H!$WP:9R#G\41MSRMOY8'2=GULP`$MNS.@T\;=!6D9A*ZW M7;,"_=V@.U'^=\@%WW\9FN-O38^@VM`GVH$#QD^4^NU((0CVK.B2=>"/P3FB M4W5KQS_Q_5?4G"\CM#L!1]18>GS-$:FAHB`S"Q.J5.,6$H"_3M?0T8"*5"\; M-X07-\?QLG&C^2Q9^%$`=.>`R%@V5-)UZAL90B18S1:! MOXH6(/(@,!:!\!2!\2Q<)D$RIV]_$`C?LK3A*=^XF"V3))XO_^.5.!HL@5S\#_8HBK4 MEDPHDX#BT_`@&3(D-X'"!$H%T#S`&)H>(EA8[R\)V0D:!,.O=")(?#W'C'-" ME93HE/U$F7Q82&$AI8IH5F!AF%;HZO[DE%$56.+P>!NST#0G2)#*1#+-393) MG(44%E*JB&8.C)CFXL^;HRK,G$PJ$XCJ)$B,5;6?2#(LMY#"0DH5T;S`%J!Z M>3QKE*RG+)!H6C%["\DMI+"04D6T_&"+^7A^E*SG)Y"W]$P@MV(*"RD%PLXA M+3MZ&U$VT\?5HV0].XX$L*=-HQO,C?G>"Q([B_DN*1!M3N*YOJ`+08K9YAPO M5[YO")>"8;M:?<85)>NN.!)`2Q57YM8O2&];;2Z$YE.O"H$LF`5JP'0@"/RF MH9X&`6R;'V\,8^L>!&2T)M1KO)EL1A8`BF"*E()&N56<@(ZBF.,/Y60K;J]Q*,J8+D7KOS.U4 MLI3F26@Y:142@B8IAHPQ+04KA(8IK!_9IB>GLM[8Y06N?<+U=WQEKC]1`GX4 M:R7@$,U+26@Q]8'5;@]78SKV_(8L[BY"2PNTEJ4(#$,VU-$AX8SVJ&V)4^,;O2*O0&M"^?4]7Z2PCT%?#1RN]3LVK0:>T>O^._PL M3.&Z8NMD40J'OXWOXG3'BV*^($[A0+4#LB2%P^D=?)["H0"X-PG!]?]:G='O MU7!N>N*TZ`3>^=`/_`>$6`%B#`YXA(L_FX@+_-!#<,'TZ:R<,![E!_J"Z:?C M]E\```#__P,`4$L#!!0`!@`(````(0"NSJW=9`8``/D:```8````>&PO=V]R M:W-H965T&ULK%G;CMLV$'TOT'\0]![+DF]KPW:PML0V0`H4 M1=H^:V79%M:V#$F;3?Z^,Q1)<3B*LU[T)SHSFS(5#4U45Y M6?GA8.A[^24K=\7EL/+__B(^//A>W:2777HJ+_G*_Y[7_L?UK[\L7\OJN3[F M>>.!A4N]\H]-5SJ<@&@ZG MP3DM+GYK85&]Q4:YWQ=9'I?9RSF_-*V1*C^E#?A?'XMKK:V=L[>8.Z?5\\OU M0U:>KV#BJ3@5S7=IU/?.V>+3X5)6Z=,)>'\+QVFF;Z;`9@+ M6DKDK@`&&W:OR_BD#]$^1O];6_[WZ6+[^5A6[ MS\4EAVA#GC`#3V7YC**?=@B!6/IH/);#@* M0=Q[RNM&%&C2][*7NBG/_[9"H3+5&ADI(_#;8^2&XE@IPJ]2C`:S<#@?S>#A M-_1@57H-OTHOC#JO;RA.E2+\F@>&X^$4R7*UH`V6C'V<-NEZ696O'A0TA*.^ MIM@>X0),Z:"W%DP:?I0%"#\:>40K*W_F>Q#@&DKGZSH3E::?5),:9'8UV;--'KVV(8-B#B4<$@2B;N(TL]S$ M:NI.QV\_:[9#D523@FCDIVXU&2D=YA@/(9C%+AD)AP2!*"6<=A:EGT1>S48[ M\O:X5)%G4!PR*.&0(!!U$P>9Y>9[^UC-0]M_,R*M$\IDYD;>2'619U`2,D@0 MB%+"<>90&D,V[VUC-15M2F90VI0>7$I&JJ/$H"1DD"`0I803T*+TDV)2\]+V MW!ZAJI@8%(<,2C@D"$3^F9.N^P6RT5&2ZQADCYC)TID&BI]H5K_#`?#AW; M0HOTD+MKTN*;JDNNA7"KMLBY;RM*$7:_KL25K:F!$FU^)E\=D0EIH!.&4F^=CI,:N3;N%G/RY9SRE M2/*G%!^L_"D(]F.+D%.O0CL!NZXE]2/:.$(=VB'<@BK67\JK9'U'"-1,MD/0 M0D[FW9$/-\6R/NS,*UNDL7E_*JFHO1"9PBT\*VMEV^K/]E:YO=D\Y]4AW^:G M4^UEY0O>&$-#KY<&;J^S-Q'>9\O;7W]QU:FL");D*W,8$7V*UMY M@!69=K8RAY5YWW.B(?@FN];5`95>C1`TX'VSSV?@"-V!"+J`DU22$FUJIJK;M,T-(@B:$")B9W6_?8WP9VR<[ MW5GMRS#YJZ^OVNK;)Q+6MZEJVA_IZ6MM_?XX_+6VK M'XKKH;BTUVIM?ZUZ^[?-K[^L7MONJ3]7U6"!PK5?V^=AN(6.TY?GJBGZ27NK MKO#FV'9-,<#/[N3TMZXJ#F.AYN)XKCMWFJ*^VDPA[+Y'HST>Z[**VO*YJ:X# M$^FJ2S%`^_MS?>N%6E-^CUQ3=$_/MT]EV]Q`XK&^U,/74=2VFC+,3M>V*QXO MT.\OQ"]*H3W^0/)-779MWQZ'"<@YK*&XSX$3.*"T61UJZ`&UW>JJX]I^(&%. M9K:S68T&_5-7K[WRO]6?V]>DJP^_U]<*W(9QHB/PV+9/-#0[4`2%'50Z'D?@ MS\XZ5,?B^3+\U;ZF57TZ#S#<,^@1[5AX^!I5?0F.@LS$&YM1MA=H`/RUFIJF M!CA2?!F?K_5A.*]MSYW,%NZ40+CU6/5#7%-)VRJ?^Z%M_F5!A#9*BGAW@LXY$A)(!#&4K'HY MN-\:6Q@/JO)`9=;VPK9@V'I(R)?-U%\Y+Y!#)0_9XA"B1^Q$!!UEJAJ98&^" MV`2)"5(39";(%>"`*](:2*R?80V5H=:(7FT%>//*,XP0$:)(9(*]"6(3)"9( M39"9(%>`9@3,CI]A!)59V_!7Y@CQC138LAA/#9H9YL@0Z0XB>T1B1!)$4D0R M1'*5:";!]/\9)E$96`[A(5U",XG'0%-DC&F2#)$F(;)')$8D021%)$,D5XEF M$JQKFDGW-PRQJ-#HT0O1B2TC_KC`F).&O:-KF'1%<4YKQOQ#S:#1>C,XFE-2)8]KTN;U] MRR8XDTN?V'D+MCA1YY9P),D.D8B3Z5P&[3&*13GVU4$/D8E`LER*RV48Y:+< M**4;00]*JA%W\D+M,#M7:1UFB%:AS`YS$R<\RI--CP32%]ZY,:U$%-LH%V[@ MNJX>$HL0U2A472JBWJTN$U&LNF!)4'6Y"+EC)FA_Q$P:KDVI+6&(P"ZHF+G0 M.[P346\'\8@C3TTI+K\89PP)YE/4EU@4&[^1Q[F?8/%41+V)9P(Q<<^=SY%X M+F+8![CZ.4+HJ4K-.G/Z?=\JQ<]FZNQCR$C&I>D?CU*3D6LM97[NQT;"\`3, MOYF[1%V,>0R[H.#^(?%4*+V)9P)Q<8_`M8^1U[DFKL]:>D!$_LTG8I$7J]<' M5GQVY-0F-D.0BV)QV]&+$0U/UK$I\-(MY%!F]]`FUTNANS,4]-1=1 M?2F/>K^^3$3Q^KP97C;HK=(X_93T9+=$[%*AJ;I3M:LNE]XJVV=Z`P0MVZPD M9M=36S^$3P0PR.3S$(ZR=_@BA-/<';X,X?"#>1J$L/W?X<0-Z9:'W^0!7)C= M>P';3DCW&5P$=A$0N_<&;M\>QEEB=H_>RMU1VGHA?'KC&K;3$#XW,7_PPP<8 M!_QB&X3;N[W8!2$]>.`241#"&>P.!Z?V=TO$04@/'[A($H0)>^'(?L.=WZTX M57\4W:F^]M:E.D)&P!T7)%'';@W9CX$?'![;`6[[QC/$&6YW*]B^X5[0MHYM M.X@?4+,C[XLW_P$``/__`P!02P,$%``&``@````A`(M]\8XE"0``@RP``!@` M``!X;"]W;W)K30/"0U1R/I_LF3WY\ M_/Z[^_?N^*G?-,TP@0C[_B'9#,/A;CKM5YMF5_=7W:'9@^6E.^[J`?X\OD[[ MP[&IUVK1;CO-9K/%=%>W^V2,<'?\EAC=RTN[:JIN];9K]L,8Y-ALZP'R[S?M MH3?1=JMO";>KCY_>#C^LNMT!0CRWVW;XJH(FD]WJ[I?7?7>LG[?`^TM:U"L3 M6_W!PN_:U;'KNY?A"L)-QT0YY]OI[10B/=ZO6V"`99\'Y"F]D\5-,GV\ M5P7ZNVW>>^__)_VF>__IV*Y_;?<-5!OZA!UX[KI/Z/K+&B%8/&6KI>K`[\?) MNGFIW[;#']W[STW[NAF@W7-@A,3NUE^KIE]!12',53;'2*MN"PG`?R>[%D<# M*E)_>4AR^.%V/6S@_Q97\^M9GH+[Y+GI!]EBR&2R>NN';O?/Z)3J4&,0\%1! MX%\=))U=I<5L@3'XNNF8@Z)4U4/]>'_LWB6#,-6(2!"0'K` M%!A96MG_0@NC("V3T-(`CF?`LC0>9DD5`B($I`<0#C`?86L*:&Y\S$PG<)$: M+:\3.:WSZ)E^B9-4"[A&%LGRX4A@B'21PB76\KE MX[E!9YJR1KRY84C%$,$0Z2,D/YS^L-@7;"(J#$W=0+3M-X<$AR2! M*"64KV!^TAO@>>8`I:,,PLYH4EL:B'*Z#CGIA:YKE5MH8@D.20)13BAG'J>/ MYR@=Q8]DKB&74VF\'%1Q2'!($HBF"87QT[QP&THQ3#!-&J*5OPDK;[U,F2L3 MR[$4')($HI10H;S*(Z7K\W>C5`N=/TQ6^WS]N0TI62]'B4'"A'EJ88IN^`ZUJ+IE][JJ%?Z M;!:6WGJYTC-(I`R2!**<4/0\3B=*KR72S]Q7374_7Z8,JC@D."0)1--$/?/2 M5*7/H<7G;J%:%WT"5BK]TJ=AZ:V7*SV#1,H@22#*"370XW2B]%HQ_)I<<;WS,KK\+0+=1`9`O-V%$+?Y]>R&ZA:8;@D"00 MI10(\L>5S[CL&LAM+B6'*@X)#DD"T30#C;VT\EQ\,RN^_LP'!\C2>9DR5QP2 M')($HI10#[]YYO'L&LBN@?S*I3"H\QSLL-DUUH(,&] M)($H)10ZC]*)RUC+HI\Y4\HR8U#%(<$A22":9B"QEPX3U][,"JU?^?!$X[Q, MF2L."0Y)`E%*J'->Y2_=F;1<^BVQ"NI3"@\TF?5RE!@DN):)R7K3R'!(<9YNC%=FGQQ5!O(+ MK6/IA].+>7H[NPXV`&G6J5=>E%,@Q^/6=(7/)H9-N_JT["!#R#/",8?'X>,K MIIRKM(;P#.M1#(\)QLN]QJD,I%X2JO#"0+?J^?O\.M!*J>UP=(#N4W81%<_3 M*T/NS^Z@R)W!E.MY/D)!,\/;XDLUH;W@5ER]I\-F+N;!?:8T MH2+-1#D-MH9T[III^$::"3=LMIM:E/V=@>ETF3.HXI#@D"00[5:@YI=J"I?Y MW&JZ/XU!84OG97:1BD."0Y)`A%(1*/_'E5?>5.`-Y*[XDD,5AP2')(%HFBB= M;'#.?EQ0:`7V)L=`5%/"`" M\.Y0PG.&\W*5U[$<<<&])($HI9A*XW//$=O/-RG.Q"`PGN MA5]NZ?#@-7(:O\0:/UO:-(Q M2P$6=7$PRQPLZH:'619@6>`%Q2S78%%WELQR`Q9U@QE:'O%/@=G+KQ8Y8,+.HN,;1DD`$\"HEDD$$&\/0A8LDA M`SC$QRR0`9R%8Q;(`(Z?,0MT#DYQ$4L&:^"N-6:!-?#,-F:!6H];(6,*W88; MTM@:Z#8\M(M9H-OP["MB26$-G$-B%E@#KZ]B%J@UO`2*6:#6\-XE8LF@UN,9 MA/&!6L,;@\B:%-;`-P@Q"ZR!,T7,`K6&E^)4;LT"M84/E M%OA4\RG^*[`@XK_$$8CA.#01_*FX>XI?A+@+1!8LH8_1-D(7HTV$'D9;"!U4 M#9S:/L$GH(?ZM?FM/KZV^WZR;5Y@\YJI@]-Q_(AT_&/0!\;G;H"//]79<0,? M^S9P=IOAJ?*EZP;S!U1T:C\??OP7``#__P,`4$L#!!0`!@`(````(0!^NG(G M604``+$6```8````>&PO=V]R:W-H965T&ULE%C;CJI(%'V? M9/Z!\*Y0Q44PZDG;G9XYR9QD,IG+,XVEDA;*`'W[^]EU$6L7R,&7VS;\]+SFOS(RJR9\S.KX,J>UV76PL?ZX#7G MFF4[>5-Y\JCOQUZ9%96K(BSK*3'X?E_D[(GG;R6K6A6D9J>L!?[-L3@WEVAE M/B5G<_RPK\63L[ML_>3NU?_.-W M5AR.+90[@A.)@RUW7T^LR2&C$&9.(Q$IYR<@`/\Z92%:`S*2?UR[ M03R/%GY``.Z\L*9]+D1(U\G?FI:7_RF0/%$7A.H@`;#7U^F<)A&)XI]'\10C M><"GK,TVJYI_.-`U\,SFG(D>)$N(?#F9XM&=]=91X8PBR(.(LG87K@.G:*`^ M[YLD67GOD-)<0[9]",&(QPM"5`+8=13AX";%X:1?F`BP8"**(*AMU1<0NZ-& MK>?V$7':01`32-!T)@(,A38>G%S#*FX*$AJ0J'NP1#R.(1`U"#*=F@"O73AW MEY/4QP_>*D@B:SD+4A\4QX(\FI`P0`!$#5KU5);!8ED]@*ZZ.?.!-`X-@&(&(R4F;MQ8@)L M$0NLLBJ((D:3T'RN:C@$6-PNJK`V0S?&B0FP12RTB"E(*#-F-YJZIDBC7*)4 MI?;B9K6_?(NJ_VMYMYJS%C_CT(P M32&^D^M)E%0C`8FM@FJ,SE$L6LVN*X8LTMNU)4*CI]-3BF[2"^Q^DQ'7[D!3 MJ3G`UPEBCS,G)-J@-K'`2M@1Q5Z!%4913)%&:(XF8);<'E8BI-K@.#ZM$HV' M([2U5V-T=8,X':BN\@<-(7XR4E[+(G["3\FZF;O0%F#Q=@8#KAX>#>@<`LQ( MG)@'P`6^RQQ(WQU"6X0U9EA:],5+VH+H-K&[S($,N,/"GEE3_6=$%+4WLR9D MK*1W&009<`A;CS5&)R8,@F"`G6D5,QJF(]F[RR^(4GP8N.YE([7?YC1F5)`O MIG(-C26=%`_C`D(&AP,+^[#(/V#8/XMJ9H MT/!8Z(N*_*CC4J'^AMA-$V1YEYU!6U4TZ`9#\=Q.2Y&8&?![.ZR#=JW#>+;KU0:-,9.A=&(,7:6=TP< MDKZ'$-\V$6HZQ"R,,`N=180)8B1%.(V6CTPDVO<3>`&Q]=`TBS@9^C5$3<@B M6:#7',S3LI.)/)4?X*&V?84JD)8^:7M79='Y-"&+B-P>:O'+^W[QD7?AWR.$ M6"2V&C0VW*,0E$]8YR&>X_XGT99Z$]M?-$CM-&#[9NBSRB("T"'S4QM"M4`K M67U@C^QT:IR5GN;9[X2VL"N6?1U@-,UAV^7,`[SEO+Q_$*JU; M-F_^!P``__\#`%!+`P04``8`"````"$`Q//_@N`+````-@``&0```'AL+W=O MTY2KBNBB7`'TZ>TG92FMP^^EZ8F^Z'IM?J-!OYV[YX/+P]/S3_\U?PQZC9.%]V;X^[U^(M?VC^R,_-/S_\ M^U_WWXK3Y_-+GE\:I/!V?FB^7"[O?KM]WK_DQ]VY5;SG;W3EJ3@==Q?Z[^FY M?7X_Y;O'TNGXVNYV.H/V<7=X:TH%_W2+1O'T=-CGLV+_Y9B_7:3(*7_=7:C_ MYY?#^YG5COM;Y(Z[T^+BV2:\N.XCV/V^,V*7VX?SS0'8AA;YSRIX?F1\_/ MNJ-F^\-].4#_/>3?SL:_&^>7XMOB='B,#V\YC3;%243@4U%\%J;+1X'(N0W> M01F!Y-1XS)]V7UXO6?$MS`_/+Q<*]QW=D;@Q__''+#_O:41)IM6]$TK[XI4Z M0'\VC@>1&C0BN^\/S2XU?'B\O#PT>X/6W;#3\\B\\2D_7X*#D&PV]E_.E^+X M/VGD*2DI,E`B]+<2\5I#KS/N#6_7H(0L.T)_LT9'=^1*XV/E2'\KQZYQ!U<< M/;KGLDGQ#^7:HP!<<^FQ"_V#N]EK>?W.0`S7-4\>(T\/TEVKW[T;CLJ1ON8Z MY$;I']SHL#6ZN^L/1F*$T;=[--2< M+E*B2J#_ES^4.$+EHY!Y:%)W*#7.E/1?/W2[WGW[*R7J7ME,T,:QF+*%R$HA M.W/!W`6!"Q8N"%VP=$'D@I4+8A>L7;!QP=8%B0M2%V0&:%-XJAA1-OZ.&`D9 M$2,>W0D#(VAVR*9LP2XS%\Q=$+A@X8+0!4L71"Y8N2!VP=H%&Q=L79"X('5! M9@`K(%3KOR,@0H:F5Z-HO,'8CL!$VG1-HSO;9%J95%$",@<2`%D`"8$L@41` M5D!B(&L@&R!;(`F0%$AF$BMH_=\3-"%#3T?ZRYCJNG9()LJ(^E(9N5&K3*JH M`9D#"8`L@(1`ED`B("L@,9`UD`V0+9`$2`HD,XD5-7J:_8Y2$S)EU'BT)XJ8 M(?*&/3N.T\J(W69`YD`"(`L@(9`ED`C("D@,9`UD`V0+)`&2`LE,8@6)5C!6 MD.K7FKQ6$-9V+!3I58^F*9`9D#F0`,@"2`AD"20"L@(2`UD#V0#9`DF`I$`R MDU@#3PLN:^#EZJTEUH"7E\/^\Z202_6:@/1HE2;7;D+$CH MD-4$YPW[=O7,*R.NGD"27KG]*1M?N,IAY60J.Y/GLC)BY0B45ZYR7#F9R@.[ MS^O*B)4WH+QUE9/*R50>VLII9<3*F:ELA57LQ7%1KL/Z5_%>KMQKPDJ[#HZK M4+'CJD@5QJD+9A+T!I7)'$B@G.3F42S3%ZY,"$Y+(!'(K%R9&)S60#8@LW5E M$G!*@62FC!4+VD5:L;@^YL+:'G-)/%K;&Y4RLG-CJHRZU;#/%-%3XER1?KF[ M\CH#VDMW;)E`F1B1`>&P$C;ZTW>J8"F->D.YDVOUG.L1-+2"AF))^OH.UD`V MH+,%G02\4B"9J6-%SZ/M^R^$KS2WXZ<0[=*Y;J>,]%9JQH[::JY0;UPY!FQ5 MGN#(^0^U0K;26DO4BMA*:ZU0*U:HKZ?N-:(-:FU1*T''%%%F:=FQ$/M;:V,(H)T9:.F1D+22AH)25 MJBBOU7,Z';&,;FS%2#<6*V06%:(-.VJM+2.ME:!CBBACQU++#J?8'?]"..5F MFC9.7$<3<PEE@<\RFEA\%7_=(MANQ(5[0C!E\ZJA+OM0;.`C!B&5V6*T:ZL5@A MJ\2ELH$V[*BUMHRT5H):*:*,'6M*7&S+KP7_MH6HIW;W9NE+9#U5%=+).V-' ML\ZEE?545?*ZJ!;*T2B$$+66"AE:$5MIK15JQ0H9U;A&M$&M+6HEZ)@BRBPM MNT#%KOQ:C&[:`XHW1&Z!2N04J#-73I6C5:!*2[X2$AN$.>MNK>=&,K;"S6C?'DLU9(*7LM1WC# M*EIXRTC?1:*%KTPH*5O)0>OBF&4L75.YXLC@6E;<6+GJY,&L7(FLRE7(K%SE M:%:N1$:U!>+)+[).5]M"(:MR06NIK`RM"+56J!6SE>[7&K4V;*7[M46MA*VT M5HI:&5N56G;EBOV_&Z->1V_S;ZM<>8I@K:LD4Z6_`-JVCA+2,MG&CA*W>1LI6J7`]FNXRE:RI7G$2X6>'=Z:RXL7+5@899 MN1)10O*@3,4;7[$"-RM7.6JKN;(RJBU0R*IR#O%%+"0SOD%(ZT=:NTK.;]45E7E]IV]5\3*NK$5 M(]U8K!OC)%W;RE[+&8X-JVCA+2,MG&CA*W>1LI4EY$9-6_DK"&GVDK'3?2)M(SS*[0* M$"T0A8B6B")$*T0QHC6B#:(MH@11BBBSD!TW<41B3LK7CQ>[\D3%G'T9Z5&> M(IHAFB,*$"T0A8B6B")$*T0QHC6B#:(MH@11BBBSD!T+<6)AQN(?G1J)KUZ< M32DCO8111*]S9DPHP/JX!EY.:BNNLD`A\_4D6U7MA4PL];&SFUUJ*U:/+'5[ MM,0!QK71NO')HA8??8J4U2O+N4*T>C:TQLY!9\".>N&Z4,A8!(=LI>67-\E' M[(AK6>KJ+PV6VHR;@R61O=T<.[DQ+=NAK89.A!DC,\FD%D7='"QWW(I:I23VQRS13[Y]-?&K3;0ZR1.(T0=\R MO"OI*BLS(Q4RCLO9RLY(9_D8*"NQ4-(MXB!#BR$[6EW%^I:.5!9RD+&^I0&U M3U.H/5^*G28,,GWC33T57[WP='G[)S#T03X\:=1VUIHZ1TXF3I6CE=5*RSA$ M87FYJ_#&WF#HS&8!"YE3I^J!F;\*_21_I54U=;HO(JRVY,C*GQ/(+\./^>DY MG^:OK^?&OO@B?BK0$W-^A=7O&+H=_R,I47"<*[0YH9\XE&&#*^+'#^7`P)4N M72GOU+E"CW-_3L].;(<>Q;YXT.(5^HW%QSJM"35?WSHU7J,SZ?E9K7[?_T@[ M16QXTO>SLFB=FYC<^5D96913UV-Z+T$^=5?BL4]?#WWZV@MY,O33.CX;^?0Q%-J' M(Y^^;D(>CWSZ7`EY,O+3DK>KT-+O;]YWS_EZ=WH^O)T;K_D3%9T\"#[)7_"H M4V'UW=>GXD*_O"D_`7NA7UKE](J%?AK3;#P5Q87_0PVWJ]]N??@;``#__P,` M4$L#!!0`!@`(````(0`(J\YZ3@X``-U'```8````>&PO=V]R:W-H965T&ULK)Q=<]I*$H;OMVK_`\7]@@48`Q7G5`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`X5XYCKO;+) M[%)'^?3VREK9J8[RJD-^NM10=J>PNZJAPR;ZZF!>K<_KCQ^.A^\]RI#DG-/; M6N1;9R'4.(R;VMO`_KNXIH`6*I^$S'V?;H!"]D3)Z(^/SG3V8?@')9"-M'GH ML#$MEFPALH607=G`M8%G`]\&@0U"&T0VB&V0V""U06:#W`:%#4H;5!H8DGM: M'U$4_`H?"1GA(^[=!P;*:2/+(6S!158V<&W@V<"W06"#T`:1#6(;)#9(;9#9 M(+=!88/2!I4&#(=0:OD5#A$R]WWZ4PN:N>F!A\9FI!O=FB;+UJ3U$A`7B`?$ M!Q(`"8%$0&(@"9`42`8D!U(`*8%4.C&<1LG]5SA-R-!LU("X0#X@/)``2`HF`Q$`2("F0#$@.I`!2`JET8GB-GL2&U[JGE_P8 M$M:U<[A3'QHRJ1])$RMPFFMBHM)ZR;F[:8V,=M!C_0?:(:S-=D@R;K/O$L@* MB`O$`^(#"8"$0"(@,9`$2`HD`Y(#*8"40"J=&!U/H M<^>TWJ\G(,O6B`?4"H@+Q`/B`PF`A$`B(#&0!$@*)`.2`RF`E$`JG1A.HHGC MKW"2D#&=)(GI)'N6TAJU3@+B`O&`^$`"("&0"$@,)`&2`LF`Y$`*("602B>& MDV@)9SCI(!\0'$@`)@41`8B`)D!1(!B0'4@`I@50Z M,3I>/&&,GO_)'%;KF#YA9`;(V,IBRJJ-$$0N(@^1CRA`%"**$,6($D0IH@Q1 MCJA`5"*J#&3Z32S(],7QY8AQFO4;30VYEQ\8:3&#:(7(1>0A\A$%B$)$$:(8 M48(H190ARA$5B$I$E8%,7XBUF.X+$4-C"BS8J#@_[S9?'PYTF?S1X;$QS07E MID6SOC,<)E'KPJ78@Z)$J)RZ8D(7M'FC-;ETE16/!D^B9E>V;H+/5FU]`1-3 MW5H]A,J*U2-4C]FJ54^8F.I3,U^DRHK5,U3/V:I5+YB8ZG>F>JFL6+TRU$V_ M4V8#OSNW`[%)7'OZ]\/;WWF:MOM:5PL9*W5*U#9_*;8,A5%+5I*,IRUR$7E< MKMGF%AM7/J.V7(#E0D01EU-2,:-6*L%R*:*,RRFIG%$K56"Y$E'%Y6HITSUB MX::'94?`Z6Z0ZSP530].@T3D:]%D+:B7;*7[1A94N=5EJV:YY]Q,Z5V"6L_5 M$>>QC>H6GY$2#QC1B%"MFEAQ$DJK\5V]O!P-QI9!Q#*JLIB1JBR1:*+N)$64 M<4&EE3-26@46+!%57+##H6)1_`,.;=;01@J5RVH5,TNQGTZ!11O<'/$KB4;* MRI5H/&^M/+:J7T7)C`E:`5LIK1"U(K926K%$6KL2B29JA*:(,M3*4:O`@B6B MRM`R@TLLBG_`%W(-K9K^(-Y&B(XW@\O:8URRE1I&*T9J2+J,Y%[*K".T9&UJ MA/I<2$D'C-X)K49+AI8S&%N-CEA&518S4I4E$AFAU2AK*.."2BMGI+0*U"H1 M55RP([3$\OD'W"E7V[H[&R2J4%EI9F6XI7B/9$>;U%(1XDHKBC9=R]K_\*35 MR-@CFUIS'1]K#+B@T51,H$V[J!'BE=%H,++JCUA&#UJXO41:&4';6&DH0ZU< M(OKAQ%2@5HFHDHCZA0J:02O6W[J7F\6>FK!<-S65JWC=^0TR8WEF[X6(=WC" M^6K:U'&5<,-G0\U!ESPG1!O"LH0'P^FUD0Q M8AD5EC$C=7N)1%H\IX@R+JBTK8R$UHGU&2CM@(6,&`'E86DTRU(6U!^MK*5' MKI1O!N%LZMS9SS6/A=28]QFI,1\H[0MC/I16*G*M?!.QLJHL9J0J2U1E*G*; M&Y'*SL!:DF>LHH1S1DJX4,(7[J)D*QFY#F2[BJ4[(E?LVOS_SUQQQ,(>%@TR M(E9^1&O,!M_.=9VY371NY$WOMP\JJLIB1JBQ1E:G(-92=@=4=&:LH MX9R1$BZ4\,7(-3JMZY';&-`N![7/3.=B)^<7!&ZS(43-Y0YX$.<\12RKW8LE MHA4B%Y&'R$<4(`H118AB1`FB%%&&*$=4("H1508R?20V2]!'':]=+F_\THH$ M0E1A\A'%"`*$46(8D0) MHA11ABA'5"`J$54&,OTFMDE^A=_D=HO^@)+(])NU-EZ.6BM^LJT0N8@\1#ZB M`%&(*$(4(TH0I8@R1#FB`E&)J#*0X3=Q*L#PV^7<5YN;ZT%&*F"6B%:(7$0> M(A]1@"A$%"&*$26(4D09HAQ1@:A$5!G(],5[VRI7;;:-FRT4_?'$J)WT+251 M4;9B0@M9-<.XL^;TKK+B*/,DT@]JL%5;7\#$4)];NW2ALF+UR%`W>TLLN3'C MJ`V.ZS:AQLW*W>BN!ID[''-KQ;&4!?5U$B,5"BZCYD7@>$Z+=?O-`9NH%8;/ M2*TP`D9&%K1W]4)IU;X)G%FMCE@&5QAC4C;Z\YU,(,RM3-`@\XW;G9VHZWK, M]]L2T0R-_>Y*1+L"VG"<6R]P/"ZH%N0^R@=LI>3#J^0C+HAK]+%8J.F#[YW. MD@L_%6\/M8+]MGENC8TE6ZF!L&*D#[)&GKRN=Y85NQX7O/R&BJU4C0&C=X9> MVXCZ?[0-['N)6*9CZ+VWN+TN\>':=MP@I)`A:12Q'DYG;-"I&+R$/D M(PH0A8@B1#&B!%&**$.4(RH0E8@J`YD^ZEI7BJD8'(E]QTFXKJ29C_2(%O)S M:Q]QJ:SX&;="Y"+R$/F(`D0AH@A1C"A!E"+*$.6("D0E(O'M!36H&[\UWU)H M_OOU?GO\LEUN7UY.O,*7>CD5'UG[0[53H?M.Y0<^E8% MY=>.*Z-;NI--TGJ-3JZ1V6ZKM!A_H4XJH^]0P?Q%^*8/5ZA M0_143]<5.@!/]71=H9/D5$_7T*"#X51/UQ4ZYTWU=%VA8]M43WUEV+J;/J[R MMOZR3=?'+[O74^]E^T1)I7DY?FP^SR+?E,L#\Y\/9_JL"DW7Z:,/]!F=+1T[ MH4^"]'M/A\.9_T$W/VP_S//Q?P```/__`P!02P,$%``&``@````A`%LXKDOL M`P``J0T``!D```!X;"]W;W)K&ULK%??;^,V#'X? ML/_!\/O%/^(DC9'DD+CH=L`&#,/N]NS82B+4M@Q):=K_?J1D^R39Z[5;7Y*8 MI,B/'RF:V7Q^KBOOB7!!6;/UHUGH>Z0I6$F;\];_^M?#ISO?$S)ORKQB#=GZ M+T3XGW<__[2Y,?XH+H1(#SPT8NM?I&S3(!#%A=2YF+&6-*`Y,5[G$A[Y.1`M M)WFI#M55$(?A,JASVOC:0\K?XH.=3K0@]ZRXUJ21V@DG52X!O[C05O3>ZN(M M[NJM'D;N:UIP)MA) MSL!=H(&.LP)&Q1S3]4J((#@>CTP^J`G]PKR2G_%K)/]GM5T+/%PGE7D!& MF%A:OMP340"CX&86+]!3P2H``)]>3;$U@)'\67W?:"DO6S]>^]Z1"/E`T97O M%51UZH./?V``:T,D>O6S]E>]!P@)* M^+2+P_DF>`+:B\[F,+:);(NLM\!J`;P!(Y#S`1C1"V+$"B+H0R\P0#N`>@L7 M$!#U`8#0R]:'3X.TQ$9PT#:Q:;2P3;+!Q$69?`A*]`(M#5\&3+>VG=%K,`<3 M%R;TJTGF]+7K&PV-%9JABEJ2Z)N)=9#XV"=Q,C?E%CY8SW,4&JZ+:$_WCO>T(^-0KD&D=GR<>BVQ7.B&G0F@$YD\F"*;!YQ"1C35$.O_T!#=-#-Q#`/.).+.)6*P&A&! M8\N`]@,B])"S*M&)3"),D4T$#BPC&A(1)]#F[[T9>O!9.#H1%,'HB+5+Q&`U M$*$W-+V=U(2?24:J2G@%N^+V%:U@\`YBO1H>HF6_&XXT(6C4XC?2X#ZIMK"1 M)@9-C+T]TLQ!HX@=:1+0J#88:1:@4:\E1P,+[7XZ"AR8B@ZP)NT!U!2F?9+N M]<+L!#X`UDFH@'0*Z&&5PKME@HZ[-+N;DJ_3;(WR8`@,BW*;G\GO.3_31G@5 M.4$IPQENMUROVOI!LE;MHD&ULK)A=;Z,X%(;O5]K_@+B?@"$)"6HR:D((H%UIM9K= MO:;$25!#'`%M.O]^CVU,C4_Z,5)O2GER_)KS^F`;WWU_J4[6,ZV;DIT7-AFY MMD7/!=N5Y\/"_N='_&UF6TV;GW?YB9WIPOY)&_O[\O??[JZL?FR.E+86*)R; MA7ULVTOH.$UQI%7>C-B%GN&7/:NKO(7;^N`TEYKF.]&H.CF>ZTZ=*B_/ME0( MZ\]HL/V^+&C$BJ>*GELI4M-3WL+S-\?RTBBUJOB,7)77CT^7;P6K+B#Q4)[* M]J<0M:VJ"-/#F=7YPPGR?B'CO%#:X@;)5V51LX;MVQ'(.?)!<4-%-/STB.S.^<9"J#H8E8XA@PCUBJ"CS:7C4RP M,4%L@JT)$A.D)L@TX(`MO3=0%5_A#9?AWJBL5@IH9AE&J`C5)#+!Q@2Q";8F M2$R0FB#3P,`(_VN,X#(+&_[V14+&1@FL9(RG!TT,<_J0WAU$-HC$B&P121!) M$PE44RV/'N;>$;%8BWESC4B$R`:1&)$M(@DB*2*93@:)POKP%://988. M(+)&))+$ASFN?VG(V!]6R*8/4A42=V3<3]];))WT1)_&"7M[R!39TRAZL,S>E(/\QK$T02 M^-,^9(-(W#62&U:^A=F:,@EJE"*2Z3*#[/D6;5`:-TI`2U.$#_/L$('RT=X# M<_E045Z?;*30<(J=&B^0BAJ+H0[NZPY!8A6@F*?3:7:+0N]VE*DIV-Y\1 MU%VF0D1W0S/YQD]_SSXP4^X386E65;KB+D(=$9CQ-#.#8<)K%?6Z!8PZY&G% MI%`@G"/SJ8]RB56,^+02K_D6BR^YTBL0S%2._V_2-,.$;0]TH M^97PBQ.24#&*4>XX><^:?\:'P[IK"!=E?*2T9CW:*#27_DW<&4HQ5DIZZ76/ M\"J>**57\52A3MPC<%I@U'4V$!\6&A0Q]F\Z4O.YFK,^/[G#E[DY@74(:E&Y MM%9(+SS9T(=Y1',C@FWTD@W5H^@UZ)L1E[[2[JH]_M+5537GS?! MTP8_C!`I:^4I#Q?D]VQ%ZP-=T].IL0KVQ`\."!^L'LM3C=4XA,TI&&3R20C[ MLQM\&L)V!O,D"&%!O\%G(2QFF&=!"$L:YM$\A%4$\V0>PK*`.9S*W(M*-9^? MG];C,8_K()P=2N!=1#"+@+'1T$(FZD;?!9N M;L7'00@["1R_#<*MX$Z?,9P"7?(#_3.O#^6YL4YT#X,-)R?P-M7R'$G>M-U. MX(&UJ:KZ\4S`"=8"1MC9[/[[CK%A M,6RCK=27$`[CXSDSX_%L/CY5I?&(6T9HO361M3`-7&_]NVXO-FA:G>;>H*FUGL0CL*B6U*1G"]BT<]'PF&8YH=JUPS25)B\N4@_^L M(`WKV:KL+715VCY.U#2J+/QRJ6F;GDK0_82\-.NYNY<9 M?46REC)ZYA;0V=+1N>:UO;:!:;?)"2@083=:?-Z:>Q0F:]/>;;KX_"3XQD;_ M#5;0VZ>6Y/^1&D.P(4TB`2=*'X3IEUQ`L-B>K4ZZ!'QMC1R?TVO)O]';9TPN M!8=L^R!(Z`KSYPBS#`(*-);C"Z:,EN``_!H5$94!`4F?MJ8#&Y.<%UO3#2Q_ MN7`1F!LGS'A"!*5I9%?&:?5+&B%%)4E<1>(-),BUG)6/_$"PW%D)7[OMX:FV M1YZU\GTO6"WOKPS42GCV*^_O:4OE72"CE*>[34MO!A0G:&--*DH=A<#61U!Z M/<3T3R&%6`J2O6#9FDO3@&@Q*(/'G8."C?T(N'Y01N#(83<4-)H.X&1+/D&2,:.)`R%2<"ZWL+\4)EDY<[]1! M(6,ER%WH9$7*\3K>AX*?+1> M+%=ZBA)ETUU`FA@QA]][U7):+K%[5=]ITJMXN4?#I M$B4R2=^DRQV5T2A]BDA>W^*"B17BO*0O\#T]5#"_B.VA7<$)D^F3\XB\1BO< M7O`1ER4S,GH5L\8*R`9T&(/VG1\3_`#C4>?-%'="N!5@ORGNAM!CY_C>"_?= MF#6U]T)H6W/[@Q]""W@%#T(X>H#;`Q&,2TUZP?^G[874S"CQ&20NNB)MY<`E M7[A*ZXER&)2Z#!&PO=V]R:W-H965T)0G2I4'#+7<^">EFC0,97ZB%9$!;V@-*PT5H9$T)(HT"]/ MK)$=6Y6_A:XBXO'<>M'Z[H M*Y8++OE!!4`7&J'7=UZ%JQ"8MNN"P0W0=D_0P\:_B],LGOCA=JT-^L'H10[^ M]^2)7_X2K/B;U13[7[0&?A'>`4]D'.I_N67+Y0= M3PK2/8,;X<72XN6>RAP6*%.&W\R#>)I M-`>TMZ=2/3!D]+W\+!6O?AI,W#(9CJ3E@-^.(Y@FL\4R1I(;&R?M1OCM-LZ# MV2*:O+(Q-.*U%_=$D>U:\(L'!0;Z9$.P7.,4R#H3S-&]+:^Y`G8@R1VR;/R% M[\&-):3R:1NO%NOP">S/6\QN!&,CL@Z!60-YO49PYP,T(@MJQ$RBZ%T7^%]T MX@CJ$*X@,.H#!"$+%(UEVM)6L#.89`B:V9"LA[@JIQ^B$EDV?@(_-W+;@F[) M["&N3"CTH9GCKU]7:`C6:OHLFLA4%YUKC5F+H36,:K>*;/X>&0BV9;01W:]T M>67#B'42O";#"^M7;@Y2W_G.(8VMH8T,LQ"O5DZY]"`W#_A=&W2"VWE`L'UX M&QD8,(Q8!JSLDTS/@22]TP"DL36TD:$!\%%U#.A!K@%8)V]W0*/MX[O0P`,K M9)D0CW3>!.'O=$'S.#I,([6Z1A+%C@_=1JW6EN8TW-NE$)LN"1VB?R>[T-"( M%C5R&C:P0>%A.?R6$AN?`=L&&." M(T;Q<("^L,L_3>_,U.4L[*9IIE/LQN M]AM@VFK(D7XCXLAJZ97T`.9'P0)ZI3#SFGE0O-&#S)XK&+3TOR>8JRE\Y*,` MP`?.5?>`!_23^O87````__\#`%!+`P04``8`"````"$`>JASKG$)``!5+@`` M&0```'AL+W=O(VQB5Q$+O7NW\_TM8;1:V]9/URO3RB*#XD+5*R M[W[\'[[^Y>Z_.G9E>6[0`T')O[X:YM3XOQN-GLRL.Z&=6G\@@C3_7YL&[A MY_EYW)S.Y7K;33KLQ\ED,AL?UM5QV&M8G+]%1_WT5&W*HMZ\',ICVRLYE_MU M"_8WN^K4&&V'S;>H.ZS/GUY./VSJPPE4/%;[JOW:*1T.#IO%+\_'^KQ^W`/O M+R);;XSN[@=3?Z@VY[JIG]H1J!OWAG+.\_%\#)H>[K85,$"W#\[ET_UP*18J MFPW'#W>=@_ZNRM?&^_^@V=6O/YVK[:_5L01O0YPP`H]U_0E%?]DB!)/';+;J M(O#[>;`MG]8O^_:/^O7GLGK>M1#N*3!"8HOMUZ)L-N!14#-*IJAI4^_!`/AW M<*@P-<`CZR_WPP06KK;M[GZ8SD;3FTDJ0'SP6#:MJE#E<+!Y:=KZ\$\O)+2J M7DFJE616B4A'R>U43&>HY8V9,-HM#W_U\B(;W4ZGV>SVYNV9,ST3_IJ9;Z\Y M[IEWCBS6[?KA[ER_#B`[@5MS6F.NBP5H,Q[LK;8^_2^7@B]1R1*UW`]OA@/P M5@-Y\/DA$=.[\6>(W4;+K+B,H!*YD%CACTTS(;*`G!8"4ZQ02,Z*6'(, MD0Q1/D+(`9$/((=:.G+&J)5&?":,;FZ%S+2"(9(ARD<(%]@"0BZ8S^ M_^P3??6&#=U8MC*03TB(@';NI,S$@D.20XI`E!)6X8#2_/(<%'TQ)Y0T1"G- M:21S,S&UOB@X)#FD"$0IP8H^I;<;!X'2]/$QD+,IYU#!(N<,12#*"0NLQ^D=U^MR[%NN(;=: MCK4+`^2@@D.20XI`U$RLG9Z9??=_1=;K&NP3L&79=SWK^*V4+JO8\@PK!(,DA12!B9A(IT%=X MOE-#]TL#D9T^"4Y?N9.RGN>0Y)`B$*7T,?4XL?78SYSP@&6D?)9AS^%D'$>M MW&U?DDLI`E&.D0*-.]N%36+""[2!?$(B"6CG3LI1LI7=0))+*0)12EARO0?F MRCT`#_)!Y380I<2BI">ZD!1NHJ/$I!21HI2P<`:4KHF2KK_PQY[B11(<0U9X M$]!71"?%.%H90ZAPTPPD.:0(1#EB(?X`CKJ>>QL@WA>&A!CMW$D9^PL.20XI M`E%*6&$#2M?LB;I0^Y1L[78Q$DEX!DNLE*/$(,FE%($HI:`/N/)F,[$-@F]_ M<"!9&2G_>6.9R)L(-\W0EAQ2!*(=X:I*S"YQPJ."0YI`A$S<0*&^0\>OX=B(0N8*HKO\^TAX)@AJ>)SA)8S`^F MUM6_IL07:5)+02N*[^:Z8,ZF08>KC*I(,+$6OQ%,PS<23.@Y;#1U1?2M@()\07#D&5R1. MRE'BK0"74@0BE+*@%<"F](I,[-30'L%`E%*PH^5.RE+BD.20(A"E%&D;KHA2 M9ML&/Q.#<\+*2/DLP[`Y&<=1*_?*&Y=2!*(<@S[BRK-$QAL,`_F$1!K0SIV4 MH\0Z$\FE%($H)5@QW-*OZ+,S5!-DHH8HI:!SR,U$%Y*"0Y)#BD"44K3EN+B! MS6S3X6=B<$Y8&2F?)!5,^I_U2M_\+J4)Z?R[S<[YO!IG[!S]"FV-I:6'\CEV6+)6@"%<$(Y!A\ M/M=U2VQD"B-=G\9&9N:3NV!DF=[".ETK&XQ`?5]@&8Y8D,YA9!X;R2:P3DS; M,A.P3N?+"D5FP,QA?=`D9$$8@JO4_C($I(J.@.6CV84+!Y= M&Y:.Z5F*"?@XMO(*1O"3"VX3?!0!(]$H"XAR?_1C7H$HPSOWF#:();RYYB/P MM>XRFC&X?$1^A2D6PV'IV,I+2*]H;'&;B^F!-(EF"21)IV=L2<-'O:?U<_G; M^OQ<'9O!OGR"W7;2W3:<^\^"^Q^M/I@_UBU\SMN=T7?P^78)9^0)GMZ?ZKHU M/\!!8_M!^,._````__\#`%!+`P04``8`"````"$`!%%M8^P"``!!"```&0`` M`'AL+W=OR'L+1/\^]?]U35&4I$V)S5O:8)?J,2WF\^?UDO*K*(-D0[O:`M?"BX:HN!5E*[L!"6Y6=34KK]8+-V&L!9;AEB\ MA8,7!*'LN6"[&O(^]D+239PFY*`?H7"OT/.<;]\8%ILTZ9Y"!MAT) M6B1XZ\7I"KN;M?'G#Z-'.7E&LN+'+X+EWUA+P6PHDR[`GO-'#7W(=0@6NV>K M[TT!?@B4TX(<:O63'[]25E8*JAU!0CJO.'^YHS(#0X'&\2/-E/$:!,`5-4QW M!AA"GLW]R')5)=B_I>//7HKR>R[+X/0O<>Y;( MB5:+P-,..*+)9"WY$T&`@3W9$MZL7`]G@@OWU MZ,O_;`$_-,E6LR1XA1$D+*&43QO?6ZS=)_`_ZS&[.Z9JNAY%JEAFA5I8=D78J-%24-*5U+5'&#WK\78.S8W2A$?Q*G1,<-OPWAK]NDLO@OC-+STWV4,;E_0L^I/$'D9)^ M)Z)DK40U+2#%A;,"^X4]`^R+XIV9C7NN8'2;QPJ.:@IS8^$`N.!<#2^ZH2J"5A;B?Q9OM<_)V;SYO'M^NO1YSCR M*$PNM#4PCU_`Q^?IQP]LY6P-#A7XB%P8/X]+Q/HL2;PLH1+^F,2&)(5UE4#: MNH?$%H62<&EE4X'!9#J9?$K@&<'DD!_5.X=Q[_%L@^]UFEO9\OF[]4M-P"G[ M4M=:28$497JCI+/>%A@MGR5HE@R%C.@RD(U3^)).6#+V#) MZP&[`M$F;264\RG;X-D&)%H7>?6'TC:-HWOAH<69QQOAE#!(6*U:O^G6NO;H MTI_6/?H2`#U+2*$_[)9#W>%:S=+IK-.@U5BS]="3D&#,N%:HP7\O5L)A"'DV M9.XH>N(>:%M%3KW!EP8I7_S:]-56=DB^BV%AC;=:Y0(AYQ=""R.!9UVD_-:\ MP^3D_S89TFUMMWEN"_Z]IJ+M>-KT]\&,R,8F"S$JP\[D0GC5^5PY\.2_ZZTN M&5E35<%;KLV&%*VCF0G*%[:J%/:P;5:)"JFE:![W661HY6-I=4X#S)=/#14A MZ/D&W`,X_EMAR=<656UIZ/#'KZ!R1DW>)HLF*&\D\F_*[`'.FGL/3PVYXLLV MM'!8AS,5KN%AFVF0>Y!>OA;WU-M!M8-9YD&30)H/W7`8_C1XQ1#^$E`H_1[Z M<#)#^(?NV-6COZW7]I(&?/L>CP]9 M5@H'.;U46_GK`;NBI]CIULFB%#1D^5;G7T'[>]SU7V1Z,CN>G$[H8QB3U M,TS_`@``__\#`%!+`P04``8`"````"$`Z]I;=S(!``!``@``$0`(`61O8U!R M;W!S+V-O&UL(*($`2B@``$````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````G)%!3\,@&(;O)OZ'AGM+::$;QNQ4`)HMW\O M[;HZHR>/Y'UY>+Z/:K[73?()SJO6U(AD.4K`B%8JLZW1\VJ1WJ#$!VXD;UH# M-3J`1W-V>5$)2T7KX-&U%EQ0X)-(,IX*6Z-=")9B[,4.-/=9;)@8;EJG>8A' MM\66BW>^!5SD^376$+CD@>,>F-J)B$:D%!/2?KAF`$B!H0$-)GA,,H*_NP&< M]G]>&)*SIE;A8.-,H^XY6XIC.+7W7DW%KNNRKAPTHC_!Z^7#TS!JJDR_*P&( M]?MIN`_+N,J-`GE[8/LWUR3>[RK\.ZND&.RH<,`#R"2^1X]VI^2EO+M?+1`K M)]-0#T*_)MX`K#!^^>?LR\```#__P,`4$L! M`BT`%``&``@````A`/K`UM.Z`0``UQ```!,``````````````````````%M# M;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@`` M"P````````````````#S`P``7W)E;',O+G)E;'-02P$"+0`4``8`"````"$` M1RN-_9T!``"&#P``&@`````````````````9!P``>&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`FEM*2]`"```["```#P`````` M``````````#V"0``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`.42 M54`O!0``LA0``!@`````````````````\PP``'AL+W=O&UL4$L!`BT`%``&``@` M```A`"FT:K:J!P``J"H``!D`````````````````_A0``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`.21!J19`P`` M`0L``!D`````````````````<2,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,:L8OB[!```]A(``!@````````````````` MNS```'AL+W=O&PO&PO&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`*[.K=UD!@``^1H``!@`````````````````W78``'AL+W=O&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`'ZZ2``!X;"]W M;W)K&UL4$L!`BT`%``&``@````A``BKSGI.#@`` MW4<``!@`````````````````CIX``'AL+W=O&UL4$L!`BT`%``&``@````A`$Q/ MI&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'JH&PO M=V]R:W-H965T&UL4$L!`BT` M%``&``@````A`.O:6W&UL4$L%!@`````A`"$`V0@``++1```````` ` end XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity
 6 Months Ended
Dec. 31, 2013
Stockholders' Equity [Abstract]  
Stockholders' Equity
4.Stockholders’ Equity

Stock Based Compensation
We recorded stock-based compensation of $115,000 and $284,000 for the three and six months ended December 31, 2013, and $129,000 and $272,000 for the three and six months ended December 31, 2012.
 
The following is a summary of option activity for our stock option plans:

 
 
Number of Shares
  
Weighted- Average Exercise Price
  
Weighted- Average Remaining Contractual Life
  
Aggregate Intrinsic Value
 
 
 
  
  
  
 
Outstanding at June 30, 2013
  
1,063,750
  
$
2.36
  
  
 
 
         
  
 
Granted
  
48,750
  
$
1.39
  
  
 
Forfeited
  
(6,750
)
 
$
2.21
  
  
 
Expired
  
(158,750
)
 
$
3.67
  
  
 
 
         
  
 
Outstanding at December 31, 2013
  
947,000
  
$
2.09
   
1.9
  
$
27,000
 
 
                
Vested and Expected to Vest at December 31, 2013
  
861,767
  
$
2.04
   
1.8
  
$
21,000
 
 
                
Exercisable at December 31, 2013
  
602,214
  
$
2.41
   
1.6
  
$
7,000
 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no options exercised during the six months ended December 31, 2013 and 2012.

Common Stock Restricted Awards
The following is a summary of restricted stock activity during the six months ended December 31, 2013:

 
 
Number of Shares
  
Weighted Average Grant Date Fair Value
 
Balance at June 30, 2013
  
390,003
  
$
1.81
 
Granted
  
--
   
--
 
Vested
  
(164,998
)
 
$
1.93
 
Forfeited
  
(33,334
)
 
$
1.81
 
Outstanding at December 31, 2013
  
191,671
  
$
1.70
 

In connection with the vesting of the restricted stock awards, the election was made by some of the employees to satisfy the applicable federal income tax withholding obligation by a net share settlement, pursuant to which the Company withheld 57,680 shares and used the deemed proceeds from those shares to pay the income tax withholding. The net share settlement is deemed to be a repurchase by the Company of its common stock.
EXCEL 14 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\V8V1B,SEC-5]D.#)D7S0Q,S=?.3(T.%\R,3(V M96)F8C=C,F$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=F5N=&]R:65S/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E M;%=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DEN=F5N=&]R:65S7U1A8FQE#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N M9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=F5N=&]R:65S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I%>&-E M;%=O5]$971A:6QS/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E M;%=O#I7;W)K#I7;W)K#I3='EL97-H M965T($A2968],T0B5V]R:W-H965T3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V8V1B,SEC-5]D.#)D7S0Q,S=? M.3(T.%\R,3(V96)F8C=C,F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO-F-D8C,Y8S5?9#@R9%\T,3,W7SDR-#A?,C$R-F5B9F(W8S)A+U=O'0O:'1M;#L@ M8VAA2!);F9O'0^)SQS<&%N M/CPO'0^)U1(15)-3T=%3D5325,@0T]24#QS<&%N/CPO2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P,#`X M,3$R,3(\2!796QL M+6MN;W=N(%-E87-O;F5D($ES'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO2!&:6QE2!#=7)R96YT M(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)U$R/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)S$P+5$\ M'0^)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V8V1B,SEC-5]D M.#)D7S0Q,S=?.3(T.%\R,3(V96)F8C=C,F$-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-F-D8C,Y8S5?9#@R9%\T,3,W7SDR-#A?,C$R-F5B9F(W M8S)A+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO3H\+W-T&-E3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS M<&%N/CPO3H\+W-TF5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XX,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V8V1B,SEC M-5]D.#)D7S0Q,S=?.3(T.%\R,3(V96)F8C=C,F$-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO-F-D8C,Y8S5?9#@R9%\T,3,W7SDR-#A?,C$R-F5B M9F(W8S)A+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'!E;G-E*2P@ M;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M7)O;&P@86YD(')E;&%T960@97AP96YS M97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0O:F%V87-C3X- M"B`@("`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`@<')O9'5C=',@1BY/+D(N('-H:7!P:6YG('!O:6YT+B!4:&5R92!I2!P3L@9F]N="UF86UI;'DZ("2!O;B!T:&4@3H@)R=4:6UEF4Z(#$P<'0[)SY2979E;G5E(&%RF5D(&%S('1H92!U;FET(&]F(&%C8V]U;G1I;F<@:7,@ M9&5L:79E6QE/3-$)W1E M>'0M86QI9VXZ(&IU3L@9F]N M="UF86UI;'DZ("3H@)R=4:6UEF4Z(#$P<'0[)SY2979E;G5E6QE/3-$)W1E>'0M86QI9VXZ(&IU3H@)R=4:6UEF4Z(#$P<'0[)SY4:&4@8V%R6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,@87!P6QE/3-$)W1E>'0M86QI9VXZ(&IU M3H@)R=4:6UEF4Z(#$P<'0[)SY792!O<&5R871E(&EN(&$@6QE.B!I=&%L:6,[(&9O;G0M M9F%M:6QY.B`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`R M,#$S+"!T:&4@1D%30B!I2`Q+"`R,#$S+B!4:&4@ M861O<'1I;VX@;V8@05-#(#(P,3,M,#(@9&ED(&YO="!H879E(&$@;6%T97)I M86P@:6UP86-T(&]N(&]U3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^4F5C M96YT;'D@27-S=65D($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+V1I=CX\ M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU"!,;W-S+"!O"!#F5D('1A M>"!B96YE9FET+"!OF5D('1A M>"!B96YE9FET+"!A"!A M"!C2!A9&]P=&EO;B!A;F0@'!E8W0@=&\@861O<'0@=&AI2`R,#$T+B!792!A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W=I9'1H.B`Q,#`E M.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[)SY);G9E;G1O6QE/3-$)W!A9&1I;F3H@)R=4:6UEF4Z(#$P<'0[)SY$96-E;6)E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@ M=&]P.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W!A9&1I;F"!S M;VQI9#L@=F5R=&EC86PM86QI9VXZ('1O<#LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[)SXR,#$S/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)W=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ('1O<#LG M/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/&1I=CX\+V1I=CX\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ M('1O<#LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=W:61T:#H@,24[('9EF4Z(#$P<'0[)SY287<@;6%T97)I86QS/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$ M)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE M/3-$)V)A8VMG6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXR+#`V-BPP,#`\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W!A9&1I;F"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F M=#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXQ+#4P."PP,#`\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI M9VXZ(&QE9G0[(&)A8VMG"!S;VQI9#L@=&5X="UA;&EG;CH@#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F"!D M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F"!D M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\V8V1B,SEC-5]D.#)D7S0Q,S=?.3(T.%\R,3(V96)F M8C=C,F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F-D8C,Y8S5? M9#@R9%\T,3,W7SDR-#A?,C$R-F5B9F(W8S)A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQS<&%N/CPO6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM M97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS M<&%C:6YG/3-$,"!C;&%SF4Z(#$P<'0[)SX\='(^/'1D('-T>6QE/3-$ M)W=I9'1H.B`Q.'!T.R!F;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B!A M=71O.R!F;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&IU2!N96-E2!O9B!!6%`@9&5V:6-E M6EN9R!T:&4@05A0(&%N9"!R96QA=&5D(&1I2!M96%S=7)E;65N="!P97)I;V0@97AC97!T('=H97)E('1H M92!F;VQL;W=I;F<@='=O(&UE87-U6QE/3-$)W1E>'0M86QI M9VXZ(&IU2`S,2P@,C`Q-"X\+V1I M=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU3L@9F]N="US='EL93H@:71A;&EC.R!F;VYT+69A;6EL M>3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^0V]N=&EN9V5N8VEE3L@9F]N="UF M86UI;'DZ("2`Q-2P@,C`Q,R!T;R!N86UE('1H92!#;VUP86YY)B,X M,C$W.W,@8W5S=&]M97(@0V5L;&EN9R!496-H;F]L;V=I97,L($Q,0R!A7-T96T@:6YF2!D969E;F1I;F<@:71S96QF(&%G M86EN2!A;F0@:&%S(&YO="!M861E(&%N(&%C M8W)U86P@87,@;V8@1&5C96UB97(@,S$L(#(P,3,N/"]D:78^/&1I=CX\8G(@ M+SX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU2!A M('1H:7)D('!A7-T M96T@:6YF6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M3H@)R=4:6UEF4Z(#$P<'0[)SY792!O9F9E3H@)R=4:6UEF4Z(#$P<'0[)SY4:&4@=V%R2!L:6%B:6QI='D@9F]R('1H92!S:7@@;6]N=&AS(&5N M9&5D($1E8V5M8F5R(#,Q+"`R,#$S(&ES('-U;6UA6QE/3-$)W=I9'1H M.B`W."4[('9EF4Z M(#$P<'0[)SY"86QA;F-E(&%T($IU;'D@,2P@,C`Q,SPO9&EV/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C M8V-E969F.R!W:61T:#H@,24[('9E3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE6QE/3-$)V)A8VMGF4Z(#$P<'0[)SY3971T;&5M96YT6QE/3-$)V)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXI/"]D:78^ M/"]T9#X\+W1R/CQT6QE/3-$)W!A M9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B&ES=&EN9R!W87)R86YT:65S(&1U M6QE/3-$)W!A9&1I;F"!S;VQI9#L@=&5X="UA;&EG;CH@ M;&5F=#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXH,30R+#`P,#PO M9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M#L@8F%C:V=R;W5N9"UC;VQO3H@)R=4:6UEF4Z(#$P<'0[)SXI/"]D:78^/"]T9#X\+W1R/CQT6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA M;B6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B3H@ M)R=4:6UEF4Z M(#$P<'0[)SXS-C(L,#`P/"]D:78^/"]T9#X\=&0@;F]W'1087)T7S9C9&(S.6,U7V0X,F1?-#$S-U\Y,C0X7S(Q M,C9E8F9B-V,R80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V8V1B M,SEC-5]D.#)D7S0Q,S=?.3(T.%\R,3(V96)F8C=C,F$O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQD:78@3PO=3X\+W1D/CPO='(^/"]T M86)L93X\+V1I=CX\9&EV/CQBF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^4W1O8VL@0F%S960@ M0V]M<&5N3H@)R=4:6UEF4Z(#$P<'0[)SY792!R96-O"!M;VYT:',@96YD960@1&5C96UB97(@ M,S$L(#(P,3,L(&%N9"`D,3(Y+#`P,"!A;F0@)#(W,BPP,#`@9F]R('1H92!T M:')E92!A;F0@6QE/3-$)W1E>'0M86QI9VXZ(&IUF4Z(#$P<'0[)SX\='(^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!V M97)T:6-A;"UA;&EG;CH@=&]P.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D(&-O M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O M;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[)SY.=6UB97(@;V8@4VAA6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F#L@=F5R=&EC86PM86QI9VXZ M(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C,#`P,#`P(#)P>"!S M;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[)SY796EG M:'1E9"T@079E#L@ M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!V97)T M:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE M/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&)A8VMG6QE/3-$)V9O;G0M9F%M:6QY.B`G M)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&)A8VMG6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)V)A8VMG6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&)A8VMGF4Z(#$P<'0[)SY'6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$ M)V)A8VMG6QE/3-$)V)A8VMG3H@ M)R=4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&)A8VMG6QE M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA M;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&)A8VMGF4Z(#$P<'0[)SY%>'!I6QE/3-$)V)A8VMG'0M86QI9VXZ(&QE9G0[(&)A8VMG'0M86QI9VXZ(')I9VAT.R!B M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!V97)T:6-A;"UA;&EG;CH@8F]T M=&]M.R<^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[)SXH,34X M+#6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&)A8VMG6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B6QE/3-$)V9O;G0M9F%M:6QY M.B`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`C8V-E969F.R!W:61T:#H@.24[ M('9E6QE/3-$)V9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)A M8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C M9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T M:#H@.24[('9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&)A8VMG3H@)R=4:6UE M3H@)R=4:6UE MF4Z(#$P<'0[ M)SXX-C$L-S8W/"]D:78^/"]T9#X\=&0@;F]W#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F"!D;W5B;&4[ M('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F"!D;W5B M;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD M+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C M9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T M:#H@.24[('9E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD M+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE6QE/3-$)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI M9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@ M.24[('9E6QE/3-$)V9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V9O;G0M9F%M:6QY.B`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`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H M.B`Y,"4[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L M('-EF4Z(#$P<'0[)SX\='(^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@-C8E M.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q M-C`[/"]T9#X\=&0@8V]L6QE M/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F3H@)R=4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O M=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXD M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T M:#H@.24[('9E6QE/3-$ M)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M3H@)R=4:6UEF4Z(#$P<'0[)SXM+3PO9&EV/CPO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&)A8VMG6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W M:61T:#H@.24[('9E6QE M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXQ+CDS/"]D M:78^/"]T9#X\=&0@;F]W#L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SY& M;W)F96ET960\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F M.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R M.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA M;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@)R=4:6UE6QE/3-$ M)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A M8VMG"!D;W5B;&4[ M('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F M.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O M=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@)R=4:6UEF4Z(#$P<'0[)SY);B!C;VYN96-T M:6]N('=I=&@@=&AE('9E2!T:&4@:6YC;VUE('1A M>"!W:71H:&]L9&EN9RX@5&AE(&YE="!S:&%R92!S971T;&5M96YT(&ES(&1E M96UE9"!T;R!B92!A(')E<'5R8VAA'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQD:78@6QE/3-$)W1E>'0M86QI9VXZ(&IU2P@=VET:"!T:&4@0V]M<&%N>2!S M=7)V:79I;F2!H96QD(&)I M;VUE9&EC86P@=&5C:&YO;&]G>2!C;VUP86YY('-P96-I86QI>FEN9R!I;B!H M=6UA;B!C;&EN:6-A;"!T3H@)R=4:6UEF4Z(#$P<'0[)SY! M="!T:&4@1F5B28C.#(Q-SMS('-T;V-K:&]L9&5R'!E8W1E9"!T;R!B96-O;64@969F96-T:79E(&]N($9E8G)U87)Y(#$X M+"`R,#$T+B!4:&4@8V]M8FEN960@8V]M<&%N>2!W:6QL(&)E(&-A;&QE9"!# M97-C82!4:&5R87!E=71I8W,@26YC+B!T;R!B971T97(@3H@)R=4:6UEF4Z(#$P<'0[)SY5<&]N M(&-O;G-U;6UA=&EO;B!O9B!T:&4@;65R9V5R+"!A(%1O=&EP;W1E;G126"!S M=&]C:VAO;&1E2!S M=6-H('-T;V-K:&]L9&5R(&EM;65D:6%T96QY(&)E9F]R92!T:&4@8VQO2`Q,BPT.3`L.#`P M('-H87)E28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX@ M061D:71I;VYA;&QY+"!4;W1I<&]T96YT4E@F(S@R,3<[&5C M=71I=F4@3V9F:6-E6QE/3-$)W1E>'0M86QI9VXZ(&IU2!T;R!R96-O;6UE;F0@87!P2!S;VQI8VET:6YG(&%N(&%C<75I2!T;R!T:&4@ M;W1H97(@<&%R='D@82!T97)M:6YA=&EO;B!F964@;V8@)#4P,"PP,#`N/"]D M:78^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\V8V1B,SEC-5]D.#)D7S0Q,S=?.3(T.%\R,3(V96)F8C=C,F$-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F-D8C,Y8S5?9#@R9%\T,3,W M7SDR-#A?,C$R-F5B9F(W8S)A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W M(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM M97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L@/'1A8FQE(&-E;&QP861D:6YG/3-$ M,"!C96QL6QE M/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA M;B6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L M('-EF4Z(#$P<'0[)SX\8G(@+SY/;B!$96-E;6)E6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O M;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SXF(S$V,#L\ M+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O M;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^/'4^0W)Y;U-E86P\+W4^/"]D:78^/&1I=B!S='EL93TS M1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B3H@)U1I;65S($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[)SY);B!*=6YE(#(P,3`L M('1H92!#;VUP86YY(&%N9"!!&-L=7-I=F4@6]396%L(%-Y7-I82X@5&AE&-L=7-I=F4@3L@9F]N="UF86UI M;'DZ("2!A;F0@07-A:&D@86QS;R!E M;G1E3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\V8V1B,SEC-5]D.#)D7S0Q,S=?.3(T.%\R,3(V M96)F8C=C,F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F-D8C,Y M8S5?9#@R9%\T,3,W7SDR-#A?,C$R-F5B9F(W8S)A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^ M)SQS<&%N/CPO'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=F;VYT+69A;6EL M>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL M>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ M(&IU2!T:&4@:&]L9&5R7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC M:65S("A0;VQI8VEE'0^)SQD:78@3L@9F]N="US='EL93H@:71A;&EC.R!F;VYT+69A;6EL>3H@)R=4 M:6UEF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^3W)G86YI>F%T:6]N(&%N9"!"87-I M6QE/3-$)W1E>'0M86QI M9VXZ(&IU3H@)U1I;65S($YE=R!2;VUA;B6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2 M;VUA;B3L@9F]N="UF86UI;'DZ("2!A8V-E M<'1E9"!I;B!T:&4@56YI=&5D(%-T871E2!I;F-L=61E9"!I;B!A M;FYU86P@9FEN86YC:6%L('-T871E;65N=',@<')E<&%R960@:6X@86-C;W)D M86YC92!W:71H(%4N4RX@1T%!4"!H879E(&)E96X@8V]N9&5N&-H86YG M92!#;VUM:7-S:6]N("A314,I(')U;&5S(&%N9"!R96=U;&%T:6]N6EN9R!C;VYD96YS960@ M9FEN86YC:6%L('-T871E;65N=',@=&AR;W5G:"!T:&4@9&%T92!O9B!I6QE/3-$)V9O;G0M9F%M:6QY.B`G M5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P M<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IUF5D('=H96X@<&5R&ES=',L(&1E;&EV97)Y(&AA&5D M(&]R(&1E=&5R;6EN86)L92P@86YD(&-O;&QE8W1A8FEL:71Y(&ES(')E87-O M;F%B;'D@87-S=7)E9"X@5V4@9V5N97)A;&QY('-H:7`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`G)U1I;65S($YE=R!2;VUA;B3L@9F]N="UF86UI;'DZ("'0^)SQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^ M3F5T($EN8V]M92`H3&]S3H@)R=4:6UEF4Z(#$P<'0[)SY" M87-I8R!N970@:6YC;VUE("AL;W-S*2!P97(@2!C;VUM;VX@2!S=&]C:R!M971H;V0F(S@R,C$[+CPO9&EV M/CQD:78^/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J M=7-T:69Y.R!F;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[)SY4:&4@9F]L;&]W:6YG('1A M8FQE('!R;W9I9&5S(&$@6QE/3-$ M)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@ M8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!B86-K M9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C M:V=R;W5N9"UC;VQO6QE/3-$)V)O6QE/3-$)V)O#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$ M)W1E>'0M86QI9VXZ(&IU"!M;VYT:',@96YD960@1&5C96UB M97(@,S$L(#(P,3,L(#(L,C8S+#8W,2!C;VUM;VX@3H@)U1I;65S($YE=R!2;VUA;B6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&IU2!!9&]P=&5D($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+W1D/@T*("`@ M("`@("`\=&0@8VQA6QE/3-$)V9O;G0M9F%M M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU3L@9F]N="UF86UI;'DZ("2!)'0^)SQD:78@3H@)R=4:6UEF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R<^4F5C96YT;'D@27-S=65D($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\ M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU"!,;W-S+"!O"!# MF5D('1A>"!B96YE9FET+"!OF5D('1A>"!B96YE9FET+"!A"!A"!C2!A9&]P=&EO;B!A;F0@'!E8W0@=&\@861O<'0@=&AI2`R,#$T+B!792!A7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA2!O9B!3:6=N:69I8V%N="!! M8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T3H@)U1I;65S M($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[)SY4:&4@9F]L;&]W:6YG('1A8FQE('!R;W9I9&5S(&$@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F M9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R M;W5N9"UC;VQO6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA M;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O6QE/3-$)V)O#L@ M8F%C:V=R;W5N9"UC;VQO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V M8V1B,SEC-5]D.#)D7S0Q,S=?.3(T.%\R,3(V96)F8C=C,F$-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F-D8C,Y8S5?9#@R9%\T,3,W7SDR-#A? M,C$R-F5B9F(W8S)A+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)V9O;G0M M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@=VED=&@Z(#8V)3L@=F5R=&EC86PM86QI M9VXZ('1O<#LG/CQD:78^)B,Q-C`[/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXR,#$S M/"]D:78^/"]T9#X\=&0@;F]W#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^)B,Q M-C`[/"]T9#X\=&0@8V]L6QE M/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W9E6QE/3-$)W=I9'1H.B`Q)3L@ M=F5R=&EC86PM86QI9VXZ('1O<#LG/B8C,38P.SPO=&0^/'1D(&-O;'-P86X] M,T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M=&]P.R<^/&1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@=F5R=&EC86PM86QI9VXZ('1O<#LG/B8C,38P.SPO=&0^/"]T3H@)R=4:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXW,#DL,#`P/"]D:78^ M/"]T9#X\=&0@;F]W6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@ M)R=4:6UEF4Z M(#$P<'0[)SXY.#$L,#`P/"]D:78^/"]T9#X\=&0@;F]WF4Z(#$P<'0[)SY7;W)K M(&EN('!R;V-E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXQ+#DV,RPP,#`\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@ M.24[('9E6QE/3-$)V9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O'0M86QI M9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@ M.24[('9E6QE/3-$)V9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC M;VQO6QE/3-$ M)W!A9&1I;F"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@8F%C M:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXQ+#(Q,BPP,#`\+V1I=CX\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@8F%C:V=R;W5N M9"UC;VQO6QE M/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)O#L@8F%C:V=R;W5N M9"UC;VQO6QE M/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)O'1087)T M7S9C9&(S.6,U7V0X,F1?-#$S-U\Y,C0X7S(Q,C9E8F9B-V,R80T*0V]N=&5N M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V8V1B,SEC-5]D.#)D7S0Q,S=?.3(T M.%\R,3(V96)F8C=C,F$O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E MF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&IU2!L:6%B:6QI='D@:7,@:6YC;'5D960@:6X@;W1H97(@8W5R2!F;W(@=&AE('-I>"!M M;VYT:',@96YD960@1&5C96UB97(@,S$L(#(P,3,@:7,@6QE/3-$)W=I M9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ('1O<#LG/B8C,38P.SPO=&0^/'1D M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@=&]P.R<^/&1I=CX\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@=F5R=&EC86PM86QI9VXZ('1O<#LG/B8C,38P.SPO M=&0^/"]T3H@)R=4:6UE2`Q+"`R,#$S/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&)A8VMG3H@)R=4 M:6UEF4Z(#$P M<'0[)SXY,"PP,#`\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M3H@)R=4:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&)A8VMG3H@)R=4:6UE MF4Z(#$P<'0[ M)SXH-S4L,#`P/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[ M)SY#:&%N9V5S(&EN(&QI86)I;&ET>2!F;W(@<')E+65X:7-T:6YG('=A#L@8F%C:V=R M;W5N9"UC;VQO6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD M+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B6QE/3-$)V9O M;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@ M8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SY"86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R M,#$S/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A M9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG M"!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[ M('9E6QE/3-$)V9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2`H5&%B;&5S*3QB2!F M;W(@3H@)U1I;65S($YE M=R!2;VUA;B3H@ M)R=4:6UEF4Z M(#$P<'0[)SY4:&4@9F]L;&]W:6YG(&ES(&$@2!O9B!O<'1I;VX@ M86-T:79I='D@9F]R(&]U6QE/3-$)W!A9&1I;F6QE M/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F#L@ M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D(&-O;'-P M86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B`C,#`P,#`P(#)P>"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG M/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[)SY796EG:'1E9"T@079E&5R8VES92!0#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/B8C,38P.SPO=&0^/"]T M6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('9E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('9EF4Z(#$P<'0[)SY/=71S=&%N M9&EN9R!A="!*=6YE(#,P+"`R,#$S/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE M/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE M/3-$)V)A8VMG6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!V M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@;F]W6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG3H@)R=4:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O M=6YD+6-O;&]R.B`C8V-E969F.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^ M/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)R=4:6UEF4Z(#$P<'0[)SXT."PW-3`\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXD M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!V97)T M:6-A;"UA;&EG;CH@8F]T=&]M.R<^/&1I=B!S='EL93TS1"=F;VYT+69A;6EL M>3H@)R=4:6UEF4Z(#$P<'0[)SXQ+C,Y/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$ M)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[ M(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)V)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXI/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG3H@)R=4:6UE"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F M=#L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA M;&EG;CH@6QE/3-$)V9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[)SXI M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG M6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG M6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!V97)T:6-A;"UA M;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\=&0@;F]W6QE/3-$ M)V)A8VMG6QE M/3-$)V)A8VMG6QE/3-$)V)A8VMG3H@)R=4:6UE6QE/3-$ M)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A M8VMG"!D;W5B;&4[ M('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F M.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V9O;G0M9F%M M:6QY.B`G)U1I;65S($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[)SXR+C`Y/"]D:78^/"]T9#X\=&0@ M;F]W#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O6QE/3-$)V)O#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A M8VMG6QE/3-$)W!A9&1I M;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B'!E8W1E9"!T;R!697-T(&%T($1E8V5M8F5R(#,Q+"`R,#$S/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG"!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[ M('9E6QE/3-$)V9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[)SXR+C`T/"]D:78^/"]T9#X\=&0@;F]W#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O6QE/3-$ M)V)O#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O3H@)R=4:6UEF4Z(#$P<'0[)SXD M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V)A M8VMG6QE/3-$)V)A8VMG6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V)O6QE/3-$)V)O#L@ M8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F"!D;W5B;&4[('1E>'0M86QI M9VXZ(&QE9G0[(&)A8VMG"!D;W5B M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E M969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F3H@)R=4:6UEF4Z(#$P<'0[)SXQ+C8\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V9O;G0M M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[)SXW+#`P,#PO9&EV/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@8F%C:V=R M;W5N9"UC;VQO3H@)U1I;65S($YE=R!2;VUA;B3H@)R=4:6UEF4Z(#$P<'0[)SY4:&4@9F]L;&]W:6YG M(&ES(&$@2!O9B!R97-T6QE/3-$)W!A9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E#L@=VED=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T M=&]M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W!A9&1I;F"!S;VQI9#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQD:78@3H@)R=4:6UEF4Z(#$P<'0[)SY7 M96EG:'1E9"!!=F5R86=E($=R86YT($1A=&4@1F%I#L@=VED M=&@Z(#$E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^)B,Q-C`[/"]T9#X\ M+W1R/CQT6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA M;B6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)V9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A M8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE M=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K9W)O M=6YD+6-O;&]R.B`C9F9F9F9F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S M($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXM+3PO9&EV/CPO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD M96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UEF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B86-K M9W)O=6YD+6-O;&]R.B`C8V-E969F.R!W:61T:#H@.24[('9E6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I M;65S($YE=R!2;VUA;B6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)A8VMG3H@)R=4:6UE'0M86QI M9VXZ(&QE9G0[(&)A8VMG"!S;VQI9#L@=&5X="UA;&EG;CH@#L@8F%C:V=R;W5N9"UC;VQO3H@)R=4:6UEF4Z(#$P<'0[)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W!A9&1I;F6QE M/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXR<'0[(&9O;G0M9F%M:6QY M.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC M;VQO6QE/3-$ M)V)O6QE/3-$)V)O#L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0M9F%M:6QY.B`G)U1I;65S($YE=R!2;VUA;B#L@8F%C:V=R;W5N9"UC;VQO3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\V8V1B,SEC-5]D.#)D7S0Q,S=?.3(T.%\R M,3(V96)F8C=C,F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F-D M8C,Y8S5?9#@R9%\T,3,W7SDR-#A?,C$R-F5B9F(W8S)A+U=O'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V8V1B,SEC-5]D M.#)D7S0Q,S=?.3(T.%\R,3(V96)F8C=C,F$-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-F-D8C,Y8S5?9#@R9%\T,3,W7SDR-#A?,C$R-F5B9F(W M8S)A+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO&EM=6T\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M&ES=&EN9R!W87)R86YT:65S(&1U M'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2`H1&5T M86EL6UE M;G0@07=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!I;F-O M;64@=&%X('=I=&AH;VQD:6YG("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`H:6X@3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\V8V1B,SEC-5]D.#)D7S0Q,S=?.3(T.%\R,3(V96)F8C=C M,F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-F-D8C,Y8S5?9#@R M9%\T,3,W7SDR-#A?,C$R-F5B9F(W8S)A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@9G)O;2!S86QE(&]F('!R;V1U8W0@;&EN M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA XML 15 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies
 6 Months Ended
Dec. 31, 2013
Commitments and Contingencies [Abstract]  
Commitments and Contingencies
3.Commitments and Contingencies

Financial Covenants
In June 2010, we entered into a License and Escrow Agreement which granted a customer a non-exclusive, royalty-free license to certain intellectual property necessary for the potential manufacture and supply of AXP devices and certain AXP disposables. The license is for the sole and limited purpose of manufacturing and supplying the AXP and related disposables for use by the customer. The licensed intellectual property will be maintained in escrow and will be released to and used by the customer if and only if the Company defaults under the Agreement. Originally, default occurred if the Company (1) fails to meet certain positive cash flow metrics for each rolling quarterly measurement period except where the following two measures are met, (2) failure to meet cash balance and short-term investments of at least $6,000,000 at the end of any given month, or (3) failure to meet a quick ratio of 2 to 1 at the end of any given month.

On December 31, 2013 we amended and restated the License and Escrow Agreement to delete all of the financial covenants except the minimum cash and short-term investments balance covenant, (2) above, which was reduced to $2,000,000 at the end of any given month. We are in compliance with this covenant at January 31, 2014.
 
Contingencies
On April 11, 2013, we filed an answer and counter-claims in response to the complaint Harvest Technologies Corp. (Harvest) filed on October 24, 2012 against the Company in the case captioned as Harvest Technologies Corp. v. ThermoGenesis Corp., 12-cv-01354, U.S. District Court, District of Delaware (Wilmington), with the complaint being amended on February 15, 2013 to name the Company’s customer Celling Technologies, LLC as a defendant. In the complaint, Harvest contends that our Res-Q 60 System infringes certain Harvest patents. The counter-claims are based on anti-trust and other alleged improper conduct by Harvest and further seek declarations that the Res-Q 60 System does not infringe the patents and that the patents are invalid. The Company is vigorously defending itself against the Harvest claims, while aggressively pursuing its separate claims against Harvest. The Company is unable to ascertain the likelihood of any liability and has not made an accrual as of December 31, 2013.

During the three months ended September 30, 2012, we were notified by a third party who believes that the Res-Q system infringes upon certain of its US and European patents. The Company is in the process of gathering information; however, it has not yet collected enough information to assess the validity of the alleged infringement or estimate any potential financial impact; therefore, it has not made an accrual as of December 31, 2013.

Warranty
We offer a warranty on all of our products of one to two years, except disposable products which we warrant through their expiration date. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.

The warranty liability is included in other current liabilities in the unaudited balance sheet. The change in the warranty liability for the six months ended December 31, 2013 is summarized in the following table:

 
 
 
Balance at July 1, 2013
 
$
489,000
 
Warranties issued during the period
  
90,000
 
Settlements made during the period
  
(75,000
)
Changes in liability for pre-existing warranties during the period
  
(142,000
)
Balance at December 31, 2013
 
$
362,000
 
XML 16 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheets (Unaudited) (USD $)
Dec. 31, 2013
Jun. 30, 2013
Current assets:    
Cash and cash equivalents $ 2,330,000 $ 6,884,000
Accounts receivable, net of allowance for doubtful accounts of $29 ($47 at June 30, 2013) 5,538,000 4,898,000
Inventories 4,180,000 4,259,000
Prepaid expenses and other current assets 136,000 232,000
Total current assets 12,184,000 16,273,000
Equipment at cost, less accumulated depreciation of $3,589 ($3,277 at June 30, 2013) 2,106,000 2,208,000
Other assets 48,000 48,000
Total Assets 14,338,000 18,529,000
Current liabilities:    
Accounts payable 2,737,000 3,106,000
Accrued payroll and related expenses 531,000 477,000
Deferred revenue 371,000 377,000
Other current liabilities 998,000 1,188,000
Total current liabilities 4,637,000 5,148,000
Deferred revenue 69,000 63,000
Commitments and contingencies (Footnote 3)      
Stockholders' equity:    
Preferred stock, $0.001 par value; 2,000,000 shares authorized; none outstanding 0 0
Common stock, $0.001 par value; 80,000,000 shares authorized; 16,692,372 issued and outstanding (16,557,627 at June 30, 2013) 16,000 16,000
Paid in capital in excess of par 127,709,000 127,493,000
Accumulated deficit (118,093,000) (114,191,000)
Total stockholders' equity 9,632,000 13,318,000
Total liabilities and stockholders equity $ 14,338,000 $ 18,529,000
XML 17 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation and Summary of Significant Accounting Policies
 6 Months Ended
Dec. 31, 2013
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
1.Basis of Presentation and Summary of Significant Accounting Policies

Organization and Basis of Presentation
ThermoGenesis Corp. (the Company, we or our) designs, develops and commercializes clinical technologies for the processing, storage and administration of stem cells and blood components for sale to users and companies involved in the development and administration of cell therapies.

Interim Reporting
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (SEC) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed financial statements through the date of issuance. Operating results for the six month period ended December 31, 2013, are not necessarily indicative of the results that may be expected for the year ending June 30, 2014. These unaudited condensed financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended June 30, 2013.

Revenue Recognition
Revenues from the sale of our products are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. We generally ship products F.O.B. shipping point. There is no conditional evaluation on any product sold and recognized as revenue. All foreign sales are denominated in U.S. dollars. Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet.

Our sales are generally through distributors. There is no right of return provided for distributors. For sales of products made to distributors, we consider a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are not limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements with us, the level of inventories maintained by the distributor, whether we have a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive. We currently recognize revenue primarily on the sell-in method with our distributors.

Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis. Revenue for each unit of accounting is recognized as the unit of accounting is delivered. Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Estimated selling prices are determined using vendor specific objective evidence of value (VSOE), when available, or an estimate of selling price when VSOE is not available for a given unit of accounting. Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer’s geographic location. We account for training and installation, and service agreements as separate units of accounting.
 
Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement. All other service revenue is recognized at the time the service is completed.

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

Fair Value of Financial Instruments
The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short duration.

Segment Reporting
We operate in a single segment providing medical devices and disposables to hospitals and blood banks throughout the world which utilize the equipment to process blood components.

Net Income (Loss) per Share
Basic net income (loss) per share is calculated in accordance with Accounting Standards Codification (ASC) Topic 260, “Earnings Per Share”, which requires using the average number of shares of common stock outstanding. Diluted net income (loss) per share is computed on the basis of the average number of common shares outstanding plus the dilutive effect of any common stock equivalents using the “treasury stock method”.

The following table provides a reconciliation of weighted-average shares used to determine basic and diluted earnings per share for the six months ended December 31, 2012.

Basic average common shares outstanding
  
16,519,078
 
Effect of dilutive options
  
576
 
Diluted average common shares outstanding
  
16,519,654
 

Common stock equivalents consist of stock options, warrants and common stock restricted awards. For the three and six months ended December 31, 2013, 2,263,671 common stock equivalents were excluded from the computation of earnings per share because their effect would have been anti-dilutive, and 2,622,712 and 2,577,712 for the three and six months ended December 31, 2012.

Comprehensive Loss
ASC 220, “Comprehensive Income” establishes standards for the reporting and communication of comprehensive income (loss) and its components in the financial statements. As of December 31, 2013, the Company has no items of other comprehensive income (loss) and, therefore, has not included a schedule of comprehensive income (loss) in the financial statements.
 
Recently Adopted Accounting Pronouncements
In February 2013, the FASB issued ASC 2013-02, which is an update to improve the reporting of reclassifications out of accumulated other comprehensive income (AOCI). Companies are also required to present reclassifications by component when reporting changes in AOCI balances. We adopted ASC 2013-02 effective July 1, 2013. The adoption of ASC 2013-02 did not have a material impact on our results of operations or financial condition.

Recently Issued Accounting Pronouncements
In July 2013, the FASB issued ASU 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”. This amendment requires entities to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward or a similar tax loss or a tax credit carryforward, unless certain conditions exist. This guidance is effective prospectively for annual reporting periods (and the interim periods within) beginning after December 15, 2013. Early adoption and retrospective application are permitted. We expect to adopt this guidance effective July 2014. We are currently assessing the potential impact, if any, the adoption of ASU 2013-11 may have on our financial statements.
XML 18 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Merger with TotipotentRX (Details) (Merger with TotipotentRX Corporation ("RX") [Member], USD $)
Jul. 15, 2013
Merger with TotipotentRX Corporation ("RX") [Member]
  
Business Acquisition [Line Items]  
Number of shares of Company common stock to be issued in exchange of each share of RX common stock (in shares) 30
Aggregate number of shares of Company's common stock to be owned by former shareholders of RX after merger (in shares) 12,490,800
Termination fee $ 500,000
XML 19 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Event (Details) (Subsequent Event [Member], USD $)
 0 Months Ended
Jan. 30, 2014
Subsequent Event [Member]
  
Subsequent Events [Line Items]  
Sale of common stock in a private placement (in shares) 3,336,800
Sale of common stock in a private placement (in dollars per share) $ 2.00
Issued warrants to purchase common stock (in shares) 1,668,400
Exercise price of warrants issued (in dollars per share) $ 2.81
XML 20 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 21 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories
 6 Months Ended
Dec. 31, 2013
Inventories [Abstract]  
Inventories
2.Inventories

Inventories consisted of the following at:

 
 
December 31,
2013
  
June 30,
2013
 
 
 
  
 
Raw materials
 
$
709,000
  
$
981,000
 
Work in process
  
1,963,000
   
2,066,000
 
Finished goods
  
1,508,000
   
1,212,000
 
 
 
$
4,180,000
  
$
4,259,000
 
XML 22 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Dec. 31, 2013
Jun. 30, 2013
Current assets:    
Accounts receivable, allowance for doubtful accounts $ 29 $ 47
Equipment, accumulated depreciation $ 3,589 $ 3,277
Stockholders' equity:    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 2,000,000 2,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 80,000,000 80,000,000
Common stock, shares issued (in shares) 16,692,372 16,557,627
Common stock, shares outstanding (in shares) 16,692,372 16,557,627
XML 23 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Tables)
 6 Months Ended
Dec. 31, 2013
Stockholders' Equity [Abstract]  
Option activity for stock option plans
The following is a summary of option activity for our stock option plans:

 
 
Number of Shares
  
Weighted- Average Exercise Price
  
Weighted- Average Remaining Contractual Life
  
Aggregate Intrinsic Value
 
 
 
  
  
  
 
Outstanding at June 30, 2013
  
1,063,750
  
$
2.36
  
  
 
 
         
  
 
Granted
  
48,750
  
$
1.39
  
  
 
Forfeited
  
(6,750
)
 
$
2.21
  
  
 
Expired
  
(158,750
)
 
$
3.67
  
  
 
 
         
  
 
Outstanding at December 31, 2013
  
947,000
  
$
2.09
   
1.9
  
$
27,000
 
 
                
Vested and Expected to Vest at December 31, 2013
  
861,767
  
$
2.04
   
1.8
  
$
21,000
 
 
                
Exercisable at December 31, 2013
  
602,214
  
$
2.41
   
1.6
  
$
7,000
 
Restricted stock activity granted to employees
The following is a summary of restricted stock activity during the six months ended December 31, 2013:

 
 
Number of Shares
  
Weighted Average Grant Date Fair Value
 
Balance at June 30, 2013
  
390,003
  
$
1.81
 
Granted
  
--
   
--
 
Vested
  
(164,998
)
 
$
1.93
 
Forfeited
  
(33,334
)
 
$
1.81
 
Outstanding at December 31, 2013
  
191,671
  
$
1.70
 
XML 24 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information
 6 Months Ended
Dec. 31, 2013
Feb. 07, 2014
Document and Entity Information [Abstract]    
Entity Registrant Name THERMOGENESIS CORP  
Entity Central Index Key 0000811212  
Current Fiscal Year End Date --06-30  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   20,038,547
Document Fiscal Year Focus 2014  
Document Fiscal Period Focus Q2  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Dec. 31, 2013  
XML 25 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation and Summary of Significant Accounting Policies (Details)
 3 Months Ended 6 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]        
Anti-dilutive securities not included in diluted net loss per common share (in shares) 2,263,671 2,622,712 2,263,671 2,577,712
Basic average common shares outstanding 16,682,730 16,522,310 16,672,811 16,519,078
Effect of dilutive options       576
Dilutive average common shares outstanding 16,682,730 16,522,310 16,672,811 16,519,654
XML 26 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Operations (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 6 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Consolidated Statements of Operations (Unaudited) [Abstract]        
Net revenues $ 4,468 $ 4,802 $ 8,112 $ 8,924
Cost of revenues 2,679 2,826 4,932 5,322
Gross profit 1,789 1,976 3,180 3,602
Expenses:        
Sales and marketing 713 735 1,428 1,391
Research and development 797 714 1,630 1,552
General and administrative 1,882 1,085 4,024 2,225
Gain on sale of product line 0 0 0 (2,000)
Total operating expenses 3,392 2,534 7,082 3,168
Income (loss) from operations (1,603) (558) (3,902) 434
Interest and other income (expense), net 0 (5) 0 (2)
Income (Loss) from operations $ (1,603) $ (563) $ (3,902) $ 432
Per share data:        
Basic and diluted net income (loss) per common share (in dollars per share) $ (0.10) $ (0.03) $ (0.23) $ 0.03
Weighted average common shares outstanding:        
Basic (in shares) 16,682,730 16,522,310 16,672,811 16,519,078
Diluted (in shares) 16,682,730 16,522,310 16,672,811 16,519,654
XML 27 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Events
 6 Months Ended
Dec. 31, 2013
Subsequent Events [Abstract]  
Subsequent Events [Text Block]
7.Subsequent Event

On January 30, 2014, the Company completed a private placement of the sale of 3,336,800 shares of its common stock at $2.00 per share, together with warrants to purchase up to an aggregate of 1,668,400 shares of common stock. The warrants may be exercised by the holders at a price of $2.81 per share starting July 30, 2014 continuing through January 29, 2019.
XML 28 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Sale of Product Lines
 6 Months Ended
Dec. 31, 2013
Sale of Product Lines [Abstract]  
Sale of Product Lines
 
6.Sale of Product Lines
 
ThermoLine

On December 31, 2012, the Company entered into an Asset Purchase Agreement for the sale of certain of the assets, rights and properties of the ThermoLine product line for $500,000. The $500,000 was received upon signing the agreement and was included in other current liabilities on the December 31, 2012 balance sheet. The company recognized the gain on sale upon delivery of the assets which occured during the quarter ended March 31, 2013.
 
CryoSeal
 
In June 2010, the Company and Asahi entered into an amendment (the "Amendment") of their Distribution and License Agreement. Under the terms of the Amendment, Asahi obtained exclusive rights to distribute the CryoSeal System in South Korea, North Korea, Taiwan, the People’s Republic of China, the Philippines, Thailand, Singapore, India and Malaysia. These rights included the exclusive right to market, distribute and sell the processing disposables and Thrombin Reagent for production of thrombin in a stand-alone product.

In connection with the above-described Amendment, the Company and Asahi also entered into an Option Agreement ("Option Agreement") and on June 30, 2012, Asahi exercised the option to purchase certain intangible assets related to this product line, including all associated patents and engineering files for $2,000,000. In connection with the notice of exercise, the Amendment automatically terminated. Payment of the $2,000,000 was based upon completion of certain provisions of the Option Agreement. As such, the Company recognized the gain on sale upon completion of those provisions which occurred in July 2012. The $2,000,000 payment was received in August 2012.
XML 29 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Sale of Product Lines (Details) (USD $)
 6 Months Ended 2 Months Ended 3 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Aug. 31, 2012
Cryo Seal [Member]
Sep. 30, 2012
Cryo Seal [Member]
Dec. 31, 2012
ThermoLine [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Option agreement amount       $ 2,000,000  
Payments received     2,000,000    
Proceeds from the prepayment from sale of product line $ 0 $ 500,000     $ 500,000
XML 30 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories (Details) (USD $)
Dec. 31, 2013
Jun. 30, 2013
Inventories [Abstract]    
Raw materials $ 709,000 $ 981,000
Work in process 1,963,000 2,066,000
Finished goods 1,508,000 1,212,000
Total $ 4,180,000 $ 4,259,000
XML 31 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories (Tables)
 6 Months Ended
Dec. 31, 2013
Inventories [Abstract]  
Inventories
Inventories consisted of the following at:

 
 
December 31,
2013
  
June 30,
2013
 
 
 
  
 
Raw materials
 
$
709,000
  
$
981,000
 
Work in process
  
1,963,000
   
2,066,000
 
Finished goods
  
1,508,000
   
1,212,000
 
 
 
$
4,180,000
  
$
4,259,000
 
XML 32 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Dec. 31, 2013
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]  
Organization and Basis of Presentation
Organization and Basis of Presentation
ThermoGenesis Corp. (the Company, we or our) designs, develops and commercializes clinical technologies for the processing, storage and administration of stem cells and blood components for sale to users and companies involved in the development and administration of cell therapies.
Interim Reporting
Interim Reporting
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (SEC) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed financial statements through the date of issuance. Operating results for the six month period ended December 31, 2013, are not necessarily indicative of the results that may be expected for the year ending June 30, 2014. These unaudited condensed financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended June 30, 2013.
Revenue Recognition
Revenue Recognition
Revenues from the sale of our products are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. We generally ship products F.O.B. shipping point. There is no conditional evaluation on any product sold and recognized as revenue. All foreign sales are denominated in U.S. dollars. Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet.

Our sales are generally through distributors. There is no right of return provided for distributors. For sales of products made to distributors, we consider a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are not limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements with us, the level of inventories maintained by the distributor, whether we have a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive. We currently recognize revenue primarily on the sell-in method with our distributors.

Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis. Revenue for each unit of accounting is recognized as the unit of accounting is delivered. Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Estimated selling prices are determined using vendor specific objective evidence of value (VSOE), when available, or an estimate of selling price when VSOE is not available for a given unit of accounting. Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer’s geographic location. We account for training and installation, and service agreements as separate units of accounting.
 
Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement. All other service revenue is recognized at the time the service is completed.

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short duration.
Segment Reporting
Segment Reporting
We operate in a single segment providing medical devices and disposables to hospitals and blood banks throughout the world which utilize the equipment to process blood components.
Net Income (Loss) per Share
Net Income (Loss) per Share
Basic net income (loss) per share is calculated in accordance with Accounting Standards Codification (ASC) Topic 260, “Earnings Per Share”, which requires using the average number of shares of common stock outstanding. Diluted net income (loss) per share is computed on the basis of the average number of common shares outstanding plus the dilutive effect of any common stock equivalents using the “treasury stock method”.

The following table provides a reconciliation of weighted-average shares used to determine basic and diluted earnings per share for the six months ended December 31, 2012.

Basic average common shares outstanding
  
16,519,078
 
Effect of dilutive options
  
576
 
Diluted average common shares outstanding
  
16,519,654
 

Common stock equivalents consist of stock options, warrants and common stock restricted awards. For the three and six months ended December 31, 2013, 2,263,671 common stock equivalents were excluded from the computation of earnings per share because their effect would have been anti-dilutive, and 2,622,712 and 2,577,712 for the three and six months ended December 31, 2012.
Comprehensive Loss
Comprehensive Loss
ASC 220, “Comprehensive Income” establishes standards for the reporting and communication of comprehensive income (loss) and its components in the financial statements. As of December 31, 2013, the Company has no items of other comprehensive income (loss) and, therefore, has not included a schedule of comprehensive income (loss) in the financial statements.
Recently Adopted Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In February 2013, the FASB issued ASC 2013-02, which is an update to improve the reporting of reclassifications out of accumulated other comprehensive income (AOCI). Companies are also required to present reclassifications by component when reporting changes in AOCI balances. We adopted ASC 2013-02 effective July 1, 2013. The adoption of ASC 2013-02 did not have a material impact on our results of operations or financial condition.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
In July 2013, the FASB issued ASU 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”. This amendment requires entities to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward or a similar tax loss or a tax credit carryforward, unless certain conditions exist. This guidance is effective prospectively for annual reporting periods (and the interim periods within) beginning after December 15, 2013. Early adoption and retrospective application are permitted. We expect to adopt this guidance effective July 2014. We are currently assessing the potential impact, if any, the adoption of ASU 2013-11 may have on our financial statements.
XML 33 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Dec. 31, 2013
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]  
Reconciliation of weighted-average shares
The following table provides a reconciliation of weighted-average shares used to determine basic and diluted earnings per share for the six months ended December 31, 2012.

Basic average common shares outstanding
  
16,519,078
 
Effect of dilutive options
  
576
 
Diluted average common shares outstanding
  
16,519,654
 
XML 34 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Tables)
 6 Months Ended
Dec. 31, 2013
Commitments and Contingencies [Abstract]  
Schedule of changes in product liability included in accrued liabilities
The warranty liability is included in other current liabilities in the unaudited balance sheet. The change in the warranty liability for the six months ended December 31, 2013 is summarized in the following table:

 
 
 
Balance at July 1, 2013
 
$
489,000
 
Warranties issued during the period
  
90,000
 
Settlements made during the period
  
(75,000
)
Changes in liability for pre-existing warranties during the period
  
(142,000
)
Balance at December 31, 2013
 
$
362,000
 
XML 35 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Details) (USD $)
 3 Months Ended 6 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock based compensation expense $ 115,000 $ 129,000 $ 284,000 $ 272,000
Weighted-Average Grant Date Fair Value [Roll Forward]        
Number of shares withheld to pay income tax withholding (in shares)     57,680  
Stock Options [Member]
        
Number of Shares [Roll Forward]        
Outstanding at June 30, 2013 (in shares)     1,063,750  
Granted (in shares)     48,750  
Forfeited (in shares)     (6,750)  
Expired (in shares)     (158,750)  
Outstanding at December 31, 2013 (in shares) 947,000   947,000  
Vested and Expected to Vest at December 31, 2013 (in shares) 861,767   861,767  
Exercisable at December 31, 2013 (in shares) 602,214   602,214  
Weighted-Average Exercise Price Per Share [Roll Forward]        
Balance at June 30, 2013 (in dollars per share)     $ 2.36  
Granted (in dollars per share)     $ 1.39  
Forfeited (in dollars per share)     $ 2.21  
Expired (in dollars per share)     $ 3.67  
Outstanding and exercisable at December 31, 2013 (in dollars per share) $ 2.09   $ 2.09  
Vested and Expected to Vest at December 31, 2013 (in dollars per share) $ 2.04   $ 2.04  
Exercisable at December 31, 2013 (in dollars per share) $ 2.41   $ 2.41  
Weighted-Average Remaining Contractual Life [Abstract]        
Outstanding at December 31, 2013     1 year 10 months 24 days  
Vested and Expected to Vest at December 31, 2013     1 year 9 months 18 days  
Exercisable at December 31, 2013     1 year 7 months 6 days  
Aggregate Intrinsic Value [Abstract]        
Outstanding at December 31, 2013 27,000   27,000  
Vested and Expected to Vest at December 31, 2013 21,000   21,000  
Exercisable at December 31, 2013 $ 7,000   $ 7,000  
Restricted Stock [Member]
        
Number of Shares [Roll Forward]        
Balance (in shares)     390,003  
Granted (in shares)     0  
Vested (in shares)     (164,998)  
Forfeited (in shares)     (33,334)  
Outstanding (in shares) 191,671   191,671  
Weighted-Average Grant Date Fair Value [Roll Forward]        
Balance at June 30, 2013 (in dollars per share)     $ 1.81  
Vested (in dollars per share)     $ 1.93  
Forfeited (in dollars per share)     $ 1.81  
Outstanding at December 31,2013 (in dollars per share) $ 1.70   $ 1.70  
XML 36 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (Unaudited) (USD $)
 6 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Cash flows from operating activities:    
Net income (loss) $ (3,902,000) $ 432,000
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 327,000 266,000
Stock based compensation expense 284,000 272,000
Loss on disposal of equipment 0 7,000
Gain on sale of product line 0 (2,000,000)
Net change in operating assets and liabilities:    
Accounts receivable, net (640,000) (797,000)
Inventories 7,000 710,000
Prepaid expenses and other current assets 96,000 (82,000)
Accounts payable (369,000) (1,087,000)
Accrued payroll and related expenses 54,000 (168,000)
Deferred revenue 0 (135,000)
Other liabilities (190,000) 87,000
Net cash used in operating activities (4,333,000) (2,495,000)
Cash flows from investing activities:    
Capital expenditures (153,000) (314,000)
Proceeds from sale of product line 0 2,000,000
Proceeds from prepayment from sale of product line 0 500,000
Net cash provided by (used in) investing activities (153,000) 2,186,000
Cash flows from financing activities:    
Repurchase of common stock (68,000) (54,000)
Net cash used in financing activities (68,000) (54,000)
Net decrease in cash and cash equivalents (4,554,000) (363,000)
Cash and cash equivalents at beginning of period 6,884,000 7,879,000
Cash and cash equivalents at end of period 2,330,000 7,516,000
Supplemental non-cash financing and investing information:    
Transfer of inventories to equipment $ 57,000 $ 214,000
XML 37 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Merger with TotipotentRX
 6 Months Ended
Dec. 31, 2013
Merger with TotipotentRX [Abstract]  
Merger with TotipotentRX
5.Merger with TotipotentRX

On July 15, 2013, we entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), with TotipotentRX providing for the merger of TotipotentRX into the Company, with the Company surviving. TotipotentRX is a privately held biomedical technology company specializing in human clinical trials in the field of regenerative medicine and is the exclusive provider of cell-based therapies to the Fortis Healthcare System.

At the February 13, 2014 Special Meeting, the Company’s stockholders voted in favor of the merger and the TotipotentRX stockholders have also approved the merger. The merger is expected to become effective on February 18, 2014. The combined company will be called Cesca Therapeutics Inc. to better reflect the combined products and services of the two companies.

Upon consummation of the merger, a TotipotentRX stockholder will receive, in exchange for each share of TotipotentRX common stock held by such stockholder immediately before the closing of the Merger, approximately 30 shares of Company common stock, subject to adjustment. After the merger, the former shareholders of TotipotentRX will own approximately 12,490,800 shares of the Company’s common stock. Additionally, TotipotentRX’s Chief Executive Officer will become President of and a director of our Company.

The Merger Agreement contains certain termination rights for both the Company and TotipotentRX, and further provides that, upon termination of the Merger Agreement under specified circumstances, including, but not limited to, termination due to a failure by one party to recommend approval of the merger, a party soliciting an acquisition proposal in breach of the Merger Agreement, or a party entering into an agreement with a third party related to an acquisition proposal, that breaching party may be required to pay to the other party a termination fee of $500,000.
XML 38 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 22 145 1 false 6 0 false 3 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://thermogenesis.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 010000 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://thermogenesis.com/role/ConsolidatedBalanceSheetsUnaudited Consolidated Balance Sheets (Unaudited) false false R3.htm 010100 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://thermogenesis.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) false false R4.htm 020000 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://thermogenesis.com/role/ConsolidatedStatementsOfOperationsUnaudited Consolidated Statements of Operations (Unaudited) false false R5.htm 030000 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://thermogenesis.com/role/ConsolidatedStatementsOfCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) false false R6.htm 060100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://thermogenesis.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies false false R7.htm 060200 - Disclosure - Inventories Sheet http://thermogenesis.com/role/Inventories Inventories false false R8.htm 060300 - Disclosure - Commitments and Contingencies Sheet http://thermogenesis.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R9.htm 060400 - Disclosure - Stockholders' Equity Sheet http://thermogenesis.com/role/StockholdersEquity Stockholders' Equity false false R10.htm 060500 - Disclosure - Merger with TotipotentRX Sheet http://thermogenesis.com/role/MergerWithTotipotentrx Merger with TotipotentRX false false R11.htm 060600 - Disclosure - Sale of Product Lines Sheet http://thermogenesis.com/role/SaleOfProductLines Sale of Product Lines false false R12.htm 060700 - Disclosure - Subsequent Events Sheet http://thermogenesis.com/role/SubsequentEvents Subsequent Events false false R13.htm 070100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://thermogenesis.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) false false R14.htm 080100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://thermogenesis.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) false false R15.htm 080200 - Disclosure - Inventories (Tables) Sheet http://thermogenesis.com/role/InventoriesTables Inventories (Tables) false false R16.htm 080300 - Disclosure - Commitments and Contingencies (Tables) Sheet http://thermogenesis.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) false false R17.htm 080400 - Disclosure - Stockholders' Equity (Tables) Sheet http://thermogenesis.com/role/StockholdersEquityTables Stockholders' Equity (Tables) false false R18.htm 090100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) Sheet http://thermogenesis.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails Basis of Presentation and Summary of Significant Accounting Policies (Details) false false R19.htm 090200 - Disclosure - Inventories (Details) Sheet http://thermogenesis.com/role/InventoriesDetails Inventories (Details) false false R20.htm 090300 - Disclosure - Commitments and Contingencies (Details) Sheet http://thermogenesis.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false R21.htm 090400 - Disclosure - Stockholders' Equity (Details) Sheet http://thermogenesis.com/role/StockholdersEquityDetails Stockholders' Equity (Details) false false R22.htm 090500 - Disclosure - Merger with TotipotentRX (Details) Sheet http://thermogenesis.com/role/MergerWithTotipotentrxDetails Merger with TotipotentRX (Details) false false R23.htm 090600 - Disclosure - Sale of Product Lines (Details) Sheet http://thermogenesis.com/role/SaleOfProductLinesDetails Sale of Product Lines (Details) false false R24.htm 090700 - Disclosure - Subsequent Event (Details) Sheet http://thermogenesis.com/role/SubsequentEventDetails Subsequent Event (Details) false false All Reports Book All Reports Element kool_ProceedsFromPrepaymentFromSaleOfProductLine had a mix of decimals attribute values: -3 0. 'Monetary' elements on report '010000 - Statement - Consolidated Balance Sheets (Unaudited)' had a mix of different decimal attribute values. 'Monetary' elements on report '030000 - Statement - Consolidated Statements of Cash Flows (Unaudited)' had a mix of different decimal attribute values. Process Flow-Through: 010000 - Statement - Consolidated Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: Removing column 'Jun. 30, 2012' Process Flow-Through: 010100 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Process Flow-Through: 020000 - Statement - Consolidated Statements of Operations (Unaudited) Process Flow-Through: 030000 - Statement - Consolidated Statements of Cash Flows (Unaudited) kool-20131231.xml kool-20131231.xsd kool-20131231_cal.xml kool-20131231_def.xml kool-20131231_lab.xml kool-20131231_pre.xml true true ZIP 39 0001140361-14-007918-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-14-007918-xbrl.zip M4$L#!!0````(`)R#3D08XA'FU%(``%:?`P`1`!P`:V]O;"TR,#$S,3(S,2YX M;6Q55`D``Y>*_E*7BOY2=7@+``$$)0X```0Y`0``[#UK<^.VM=_OS/T/J+-- M=V%\P8(O_KK]3!B8Z&-5/'KK>9V8XN).%"AC/NOMQ)3YR:0]NM M[08[4:.IEOV!9ID>1!_.)N:IV=]Q+].ATJC=5K.SC%DW(IL0CX6Q1=A&!-M]-=YQ[V!:LU5O M-.OM9CH)UKG/^2B;U>.F2QC\BXHIH9#52.!%%0:K%_)PN`-OTX%Q,JP>&%J] M8Z,![>5$P0U\&@>@*^J>#ABU)1-L$.A!ZJ/G@$ M(\UVH(8XH=UL9<-7L5"P;,9>H4D=&3*62]%C9&)'N'"OMXP@O)J*?(MJ]-N,5V'"#R#+"TL177ELGP]5:`XQJ=1M.JC#P:FXT6L95VZI]E M3V6(SWM2:$:$B0(WJ9Q.SG[:>M.`?PZ:S5:S]6JG/#E%M5.!RV,:@5:JL(P? MY*/M.W"U;Y#L>J,#*Y%"F;TK31)Q.)L"B]=NSA"'N0GITQSJ])&7W3)Q[C9: MC/DG[;JQ' M/QI/W?TT&YOC?EJ9.%M/4YRMVXNSM49Q9L'QR8KSUL%QK>)\@LZOM3[G]W24 MJB"/M07'QE/4C\8:@R/*X[?C"=?A)TCXCZ^E^>W*JN#+^8@:"C^+85?H1Q#8 MS-F(_E!DW&8O0B#C>A3)0%I'(PLEC'-]%%\W'Q7XVGJ3/IYG\-5.):>[]]C8Q,A;&'`>_)])(C%ZTR#\+W1?ZL[2#3\K*D;)` MOKX^47JD-,=1E]=/>^$7,+[U!G<W%M+!=\XA!A_%@=J**XL M.!&D^2V/#X23GB&5.Q$3]65X-'3UJ.'$997RZ+('D'W6O7&X;JZ1[/F9.,`@LXW M+?RFA0NSI#LU@AL'#[--\5"J^XEVY2,(8]^4=V7E+0OMD=1WD[:%=@'Z(:GO M+J:%OUTE72-^3X"WTS'\:];"*3Y_VDJW@,E*VT?1EET\F=,ZO(VVT)19 MG+YG;?FF(YN@(\43+\U[2LN26+JU_A5B6FGAAH*C]WWCZ1]P\,0IJ/1='CS" M6@2[M0"V/^-X].O5N[N";I=`AW(,^E$6'\[XB.<$N56ZK!XKTY,7<#7$'+IW M(E9#&2]'>)-PRQCG@:9O1[Q/1V_A12CD4?8&7S"O M)9=X'J_RC%V/1T:\VIF;F6$ZH;.2@`>B,X_8/P77[#0.&3JE/%X_S@W#4:?. M<=U,0CWMCBX#D]'S3@4),7Y!-E%)2SKF9D'S39B&8C)!3LG;V6411_4NL M)C&#Q-JH6(3LS)A$Z#Q%;C"._0F'IB/=P)LI^Z@<14O!E"G[NXJ2&`+.%-8N M$MK,TY.-<`-N2T=I>AE_JCF78J0TI'5]AGEB4D&''YD-=.-N)N>?:&8W@2F3 M1<2R$UC*OM+3>6+H??KZ9AJNACQ"@#,N3]1PQ.-IGK("S#)!EZ(OC=7@]=E' M/A3S%,T&X/N;2?KTX^GES^<_G'X\O3J[8B?GEQ=Y6HK0YA8-NV5@YV=Q**[9 M3Z)"0'X(C8`!-].3C_D+P\B\K[S/?PT%0Y MJ9FKHR$KN:G=HH,J@5A(B'>9-Y#B1JU(S"^M*E)R(.:)P5RL"CL^OQDA5%^_ M%%'BO%E@#.BC`/PN)1!RS+N1J+%86*9Z#`Q53;`^93T%2:-*NK:71(RG4V#( ML]8A>_YLM\.X97]+8L':C1I]"_,BI3C;??"S+C,\'X5-7=X<%^Z\?5[;6GEM MJT/>L[?7/@!#>;6S"H9-YY>.3RWG=_?@\&OXO>!3QZP?L8A>/^YK5J;5:7JF@-AWW+C<, M?HX$[<'$X?$08^!_Z/F%5E"VV.E%!*$&WF48[[0&[;V#PS)_]T+-9DIDE15O M=>:T\GXEE M%:\&OWYR5U@,('?WL'TKXZ%=/A[I=_YP?-N]*M\7VD-;H-PDUA= M)2!U[H-52!/KH<3O;,>"&1$D&K0`4M=86=!(;'4+TE(:`S]BK(X4*.F("D%* M>JF#P)Y+_Y.9#\:`)45RE>$XO7;@WVLUQ"(DL63HY[U3KF-(4`VD992U@AM( M*O6A^`7,\NRXM=_>[S1S\KH/FOX02!.R.&%=A]6"OG"<4,9[K/H]]WLEX'+*WW$C*RR[P_HC85J;7-.B\ MYX,N*-6%BF0P=?_^!$2^C53PY>:6P?>1?1G*,3-V&HG76ST87^_QH8RF1^PO MG^00K/BCF+!+->3Q7VJ,GM3`QK7LO60TVLC_B"/6;(SLRZWO^_9E"2*BK_-( M]N,C]N_$6-F;IA-QP!'#Q$\&_EF&>@[WC.6%=%H:-G-?DBU3M` M]JTX^`IJB32W:?^#NW^`X3&\;?;<#D3:)JVQB6"0`*I$OP"U,D`"0`S%6$1J M9(@9])Y"0SD3`6S0T$C&$MM95@2#6$6JCWX8DT@$.](*_ M_`NG,)KS?W/&YN?FILYF;JJQ1:*7&V0Q(2(4QU/%H$:E8 MK!I5N0KF7]/-/8Z^/:>$-IPG<4[.S!/-$ZL>CNA,C`G^X`[W`B5VP&;'>R__ M05PDF2'-^-F927^']*-L;%Z[TA^[FNTL&+)^7WD>L[\ET90U]UP3EGPC\"1GP0SQFQWTM1.9DL'N#KL4+!A]="I4/!^1LO^?#TLNA0QY+V4%(7.W00`&MA(!%8].P(+/>$@2\9RS'`VBY-!=\*B*"DM@+X M'X@(_+%40Q$6'?W4NU^`-!(N("!AX(`'"8@Y%QHTO#2I9^Y)!`CT:M%W5V-A M$D_0P>>1T(`"'"DPK37XUK'MV$074L>[I\*9]V:>V??843/L1\$C.P@PO[^: M8F29\^Z;HF3'UM$MNCK!S6%4,]Q28E=.I*!*PE+XS*UCUXA`L&JC[CZ<#QY``$%-)$F"G/1$(<[L(+W+H-V8DP`<>1 ML+("ZIS`L+,XV'98+%@?Z$TO`C1$6@8-R`V3P+JT`"]!DY!XI`*P$S5+%396 M%WZ%7`=#NDF&PRQ+F#'R]6_83:3&, ML+RIHV?`\3GP M/%J02M+]-ZTH*%Z(0D57N,V.>[C<>0F0_U!ZB&?;$&:JN&6N2!QX"J1(2K-5 MVSULU*`>RY&TR+#R)`(M60,Y`E]:B';Y22<#*7KL]!I*<[*#\UX/%%&G2DY6 M@E4`G;.C;4',35DH8>VLLUC(O5-Z-E95/V6KG8N`F(UR&8/D()G@Z.VAV$@3 M7W]!(6IC5Y4"$DE&OU[ZOLQ)'!;8PE:21YR0?ERY"0Q:BZ%)@@Y MX&^D#I*ANT/-U'R;B%QK-['4.8KD4#J'5BM@"!,J.SAX51EAZ@XF`F4);F/8 M*;[1@JHB7$KRF^"WYTS7#3:*3C*BT4"$Y+-OII!-.H>-QMO59+$+.*MAA98" MI(3$A5V7D?!,`!3P.8"0.O2CM7#[:'YH!?H:B=E3@'#=Q"%'PX?Y,$,[`",^ M3<.N<@M%(WE!=#U!+N?97J-1:S0:JU19*Y4^LQ-QW`Q<*8@_('D@?5&Q98$# MC^,0_W,Z&W5L3[C64V#T[SQ**DX\K+(KT\;.4J[?LA*J!^-@A9;1_D&I2[=1 M'+16X*!ST#G<8`Y6T*+.7G/_/CB@'W(3:NE!(\BBP*B-8,_?"??37,>[&J6; MGTY/)]]N@V".W?KNWMXJ.E>-?(/87MK/GV>[O=_^>JXAO]"!-%@707:!#G8" M2L&Q3R;Q]&E(VQJABB*NW9X'I3LOZK-S]HP.VK-_N3/UB%/M#. MUWM(V&-J6YTH\$3H(!ZE/#V+W?E9O(:OHFW+/D!LB(WK-9Z:0*M)KFZ<#"34 M7GUT;P)K\P!(4]AQX`RO1,^:DC6FU91'=EKOP50H'AU,0)#6OX`-[!P*^P0D M,O(G_%@L<$L,&V/9+AG5O2@V8#'I<9B@'7$F&8VB*0;XXW]6TJ+G.W$0>'I0*9%+D0[F$3)PPRKJTM3O/@;SD4<^#2M'G/X M"'YBJ"2FCI`75H&.<($DTL[?$!A!9ESK4K@%083I`$`L7,-7T?/$N+^FD,?( MI&NFJ!@$)@MM'1!?$%= M`$H8AD+8;"%`(I):/E1"]")@82CP[ALS:\%IR,A0J+\G4"H+#83Z#])(\=QW MA71,[:/)3K^'Y]1`SX.78]JROK`6LP@+;(#ZC\\;\\C MY<"8A'A,>ZPXL86OFLNA;6R/ZSQFD'B[;UK;3;<'A+Z$8Z,'/0-9A+&NH0+\ M+?4J((@0M-AB?SWK#O4R?QFD_C)=?FH>R5@.DZ%;S"6+F*YS"L2I!.\J=%+. MG4TXGO<,D\`9T;/6:DN]S3X+4C0\R0LF$$E"Y+>2I,E0TB<+X$;0K7EA[5:M M[/J7S;5CH9;>Z$@YGR,\@GH?0_D8L68SM[_9DQ&I-OS/3/R>$1UW$+H.2:H< MTC8>J/U(^6#G=V%&$3IQ]B/7J)?L4_XTB#]GXM^]\$B@PCH/K$+S:NT2"2W& M^]A`M@67Z[<-`ZK,.-T+B22:9;C&%'_*1UUJK-FJ!^,Z,+L'&'_=OMK&BH0N M*(,1B0;+R7X'8W@'\6Y"AP0_RPB,L6]5_"*WD3ICNRLH[I="UL7'VG4L[:9]V@)DT11[#G"U= M03#TC+B/X5KDIR:8'`'W;FNG.RWMI#.SVF*6;(!M M0K;_DHY/T&9N@:J'UR=7R3]D^/7MJ^FC*/QG++IZ5%#Z]N.4W*G+"]%99X<9 M\/?8A5E(_:>":X#M,\19%38;[Y,]D0)&BR*M@J66&H]L2'\`,@0%H>S.51W8 M]`!'EM,VT`(H4X)I2A/N<>IPUC*=N2/I2U*W=>\F#]TG1JA2:;F[L0X(37J. M*6_=LT\)7'@+_!GT/._>!X`?3T(JK=-\W.#-6SZ.NL,8?F@%MJQ.E]=%!SA? M@P!A=$1$`Q_9>==VQFFC\$X7NOPL1+>RJWHV[7&=SE87K\N!+'[Q4'-9!*$H?L>^"0(A> M+R-CI35=S`P]D3&>N#EB]>[_'OTS],T?Y]94E[@MIC#67WCE\5N0)1]WMG;["B[!IY?+.'V MEI[`EX-U]_B(M4;7JSBJ)^4>3JATIS*_6*Z/M*B+:VGH-/=D%O?OQWW<4;1K M,&;7`L@(^:Y!_R!!=)P]]`OR^'G"[0C=Z$SB>7.WM4;'M"[E>EK>:GM;W6V>>&YZJ!PKOKY>Z5LK*Q@\W>%+D&XXN=.UT8>Q3("0>M$;+&= MAR:J\ON?I43E/BWUWWGF;A]>K.;^_F&KW6D5E__&.XL?CH5Y MTD? M:3'`OT0T%NR#,O.?\N9'N#^=]A2NM'OXPU+SHGR48SK'5R>LU8)`E[L^J4B: M6\3<%4IX%`ZR<6D&`B_*@0#*=3C[)D9G?R4DO=@NP0N+L@OB"L`E`6?/\1K1 M%^Z6(OI0\__;^_K?QI$I+K9+;W M,#@,%+D<:T>6O/I(XOOK'\FJDF1;MB5;7W9K@>V)[?H@62P6R6*188:Z,+V1 M#+/S9"$^KZU,DH/HUM+ZB`@\&).@7#SG:#T8K'L8G8_C"P"6=:H!-`XL= MPF@?^%M66I)5DVHSQ?:GY_,D4"_,#EC"[O3\N]E7_FNVY,C;"1H&F\D!XH/G M!-+>/,/;((VT3:6J`)`R/4WO=V%'%0U2MB0!O7$W#4@?V8S18RWQ0TOYQ;&- MY%2RLJUH&C4\RB88K//5SL&+!C5-CH_NR:#NR,Z[,=0I^8*[0W4?E)O9>G,' M,4VEAXU"#P=!C(H_\"C96-6';3`/5XHX<4MUM4WP#T]9(C+91)8V&)R`3)2+ M0"0F@].+0_55/'1%<>.)>E"]ON+^KGWY"Z*A[V;Q@<6X-"P-^@''E$/6 M6N-L$AH$-%_TD8]^B"M'O[(BIX3'WQKP#/Q_4G5QK'QAMJQ MXVEG^20XC_ M;A0GE[.$NI3PAB/5O&DOK5,\Z#@'UD+/S+$_/\;,Z: MQ;^TQ9]@HH)G?`Y^"RMMVIYI*'1E5?N5SAC=5X+"<($O/8]"J2%/0YZ&/$60 M)[^76.<2L!P/3]L,9SHN2C8]3.Q?=DX:>WNH.'/XTR?DU:QP!.W(?R%$#Z_+!(EV(499B\S(T.E:1B. MG;R(_`C%;_UFN9OE+ES2IYJU"DG?$/X<"?_]^1I^XD4=&K?"F5ILO5'C4VA\ M"G7F4+7='3?\V9BV#>%K2/@UA4=..QBSX\Z8F:,B MU%B_9:>'&I2K"%6%Y[[D3Y?%H6>F7U6%D];6U)JQ?>/7:`C?$/[[="A]PH(J MM7-T:0C?$#X?;:R) MH*FO4ZD)J6B6^WM>[L;N;@A?.>'+J3_0U\ZH_L#&\ MH&(!#9^?@>/EDK:/UNX4%914'XZM#R3-&5$%DZOMAL=KRSG-^5#GK:-=DG:5 M>_GI5.97L2[0IL+S47492W::%2AMJUZ3AC7J2I[*UZ1AC;J2I_(U:5BC6O(T M[NDM5??OS/-%3;U/;TMFX`??4?#KQEW=N"+RL:=&`[4U+"PRJC[<51](&G?$ M!6T?K=WI-7OGXO?.]WU&J.U1P^-UY9SF?*CSUM'4QEW=N*L;[T)MR5/YFC2L M45?R5+XF#6O4E3R5KTG#&HV[NF;N:E&8BXKX->[IQO60B_TTZ&@M36U<;+7E MGL;]4.?MH[5[1:4@J@_'U@>2YHRHQCU=5&F4^G!6?2!ISH<+VCH7&DS]'U1* M?-.';.TN/;[#C,J_MKH>5C@UPPJG+UCA%&NM`\9&8.D4].-1O?JI.9LQE]D& M4YZ8_\J835\S60-YB360L?PU?@M$9:ZUHM>LK[H[]2AT"'_Y5^#@H&NM;YS% M4K=7G)PC31W^```XBX5C*U3.O:T`O"Y37O$?VQ'5W;UP[JDR#5R<"P?SS#<% M>OIS^!V@F&Y;?P0+_*&U$VA_Y/)P/N.TQE__K)@^_&21;O?)L:9\ M"6\X@1ZHWOU7YL$24EC6A.A=&5?-',MR7G$Q@(MTQ0L68+6O<*7="$9:544W M?//%]%?95N_/1RR:SST!7%KP,L'O%"X\__-=YYUB,,L2,B+\["UU0WX6E)/2 ML?/_-@FV2:]4Y#K68T.E@04L@T$YUU;[8#CE9$^3%N$LZD7_$A"7`I\_S'5@ M]9).LKS6H5GVTVK$AR7BJ5:*\A&/U<^ZZ99?,[SZF_4-+2J5B*J+Y_B#;NFH MXA1=4K?BJYERP:BUW=$==\#R.+#`162G*_5*\$SYKC:6]MFPL]H>E9CIO;;A M7&=UZ.1<7ZVY_C_I^K^`37E]7=Z6;").&I8[4Y;[ODT/_L:R,30NU="X4@>] MUGAFK;N=<^.#-^;@R8(Q*2G:$Q?F(0IK;C0O*2:'RH@RR ME@&J&Z"UUEZONMU6MUM6K&5>O%6;\[,^FZ>0K7%FAVH-]E.!7L&R>:V-K8HM>4CR>.E9;@V$3LMT8H-^=`3ILXE!+BAB\M17#L6UF8$`GH.O/ M*0KPA<$D<)B)^-#MR$&*<6SQ`%1+]M8].#*G3'E:@;VS"*-+V6)I.2L&T/F. MXNF^ZY:'\>%QM@ M""O%V#(8"H-C'6"`J:?,7&D\UAZ*7.P4^&E6)E$P'$@$PQ`8SR!/@# M80%F8ZY[1+0XM$`[T]^(PMW:%.+OO_Q'X%T_Z_KRSQ]-S[`<+W#9W0Q'8K9' M5/O**)3XQO%\C\+C/L"4TWM]A7!YC\!>'RR8X87IEVG#*6I;N>O0C??O^^IJ/*D'\I+LVD,F[ M9ZZ$Q#0F]O2CF`C8$=G]*YO]YSL#E2>UTU%]A_[2NNH[);!-_NNOG4[W'5#4 M,!>ZY6$HVX_7G;;:B/;3?$-ATO:T>@ M*]LIT)"'PK:4>P?D[$KY3?P7][M"&_Y_#F'$>X0"XB!&/^Y5"(Z.TJY-T/\O MP#JW@G5^#EF'2%7)^OOR4!MM8-`ZPD"K*D\WX"GP.;COL'-&+I MM;AYKSPZ2YA*&W1:BGPHHG5^V&:W\$?UAY8XAEWVK\#$ MTS/PY#L#783KVF'8MCA@X:_XH:@S:N(RKZ6Q!:T MY8J6`X+.9^["M/G2K$MG)CDJ6M*9XZ9[G'+4BZ+S?IQRV'H9CL[(E29.:\$V M.W?F=WZK?<%1&NJ@U5?'KE^$1*EZ/GOG%6G,K7;YL MZ`_+RNYP&9=H9R4II&Y?S-E?GUN&YC:M0K5BT+^4_&&UOUJXV64;@[$(YCCI M!,+$YPI!2WG577R)PYWR:[9U[`:"WSVTE<_"*/3G+F/4XW#N`OBWI0VZ>*^Z MVW:G+!?LS;`"'$-<`3#A5`A-W`0S]8D9.EBXV-ITI:?@U0FLJ3('J0:_,QL` M]"J,UD#36D-5$Y_ZPR%]FF7'<-L`WKXD..#CBSR)XM[FVN6W!\K/ MIOX$5KYOXM+?!*X+Y-IR((I.XL8AUD5T2'#P;[E"M;@K]+K[[L<^W@+$'?N' M9BD=B*X?@B"O;CV\23.8Y)')`GV$6VCW@./&Y/[M(0U^CV:A21Y7 M2S9Y,[W-[_G4^]W?6GN-5GN@"LD4O?='8GTV;6AKZI9R:X/P".BJ:Q-;[$(] M[F9A^UASX3"OE]=[74R7Y/A.0=O*7),&'!N4ZHBR)W$7LN[-^2F"?\2D>XO\ MWP'*>1=D)WP-1V?LRZ6^XNY`Z`M?N@&(#"O:F7AG[3IOP*:PZ69($YZQ:0K_ M]QTA^;VYX_J85(<.BQ02.147AFS^DPY;7-P^@#3X:'I+QS/EN73O.K#M_=4F MIV,O['-GQSKB(L7U';"#JTP\ MCVT+GFAH;'TWH[:\:;8K\'1+L35)6;#OO<^N.^R9>$?CYE&M,,AA$^^!G=D4 MLT.B2]L"V0>-'0)X.2 MD5?'PT%QH&3BNNZ@HQ4&2C;^Z:JCSD%0)ALZYB8XM[:!`0(,;'KZ[ZTM>]SS M#H\N1E>>!NEU=[#.2NEF+1J)C&H:2,SA*5C(YLJ5[/`>[>F/;,;`\IXJ7QF8 MJ4$*Y&0/T2&_`_C@5.7CDG6-NOT#2Y01HY#UOH:&6WKNB_J\&`@4K/SLE^OQX``! MT@!14U)D8X8-BZ@82MS:Z,QU7#,-W\<:G[K,A\14;*K24,CJ9U(/G2))2'`V MB[DC#\-,7>Z6#,T7^SD_@7JMC@]AL'/J*W MI#QE]<3W7?,IH-O<1V?KG?J5]&;-4XMATX#8>##51/`B:VR3C/KEIX M0V!Z:K"YL`-(F(#2YL'-E_U5^4+*`"N"2.G1P:ZA;U.7IEA9],,/31+-9@<7I7Q M2#T9$R5ZN*?\MN=Y3M@A:E_KMSE1)#NW3PY$TAN6[@%1/S[T3'1;EO7J4G1=PEWK,I:#)6HU[8=G;0S^D@`K0>^4Q[0(1D# M_I0X5%@(\"`AP&IGT%+N16!.?QB]INMAP!*^)^)/B**W,+K?E$,YAW(H$0@I MBV*D#IY^G9L^N\;5`6+RJ,'C8FYS+8L1CPM+N7ERG?]PUIO2BFZD6OJJV"RW MVBNEQ<*GKCD7J>[/Q]%T/ZYKCTN(22H'FYG6)GFNKX M@BO4J*WQH%ON#FUJ(S6V]8&DV4`7M8&T?I%^\;+9]F`,5$(H84*X M7U(XY"]LZXUC^"O&1AX1I]G;?-D8'S`7&`Y'6/:``3+!(%V8]]R%F3XP%#OB MVPCJ=GKT\1A02X1[]SR5H7-X&;3.8/-]37ITTJ1=RBE95&_070_FWY-9*2^P M4J1_ZJN]T1%@T?LBGOYH#V`3>_J`6:&P"`ES/=[^*.JIO6YW)YR)TQ0.=0KB MJJ.^-CX.:MQ,-Y@EZ)YG-)]B*9:K7SW*EO^>7@CQ8C@3PS=?$I^IP!`X@AS@ MPPI[\R<\U#7J>?*KF_ZZ1$D_Y1Z*[7I`C_G`)D.JL29BZ M)@AG%$9:;]P_%6',C&#[UDJ93)TEOAB)5=>!<6SXF^?I3,#S-6J[WI3G_ZMW M*:9*DE*FI_:F[Z"LXHJ?V9,;Z.Y*9!_&QT.?)P\?%-/S,)7$Y.&&?KGN:+)6 MDHFZLQ(LIYAA$J27N6::(@P^8XZO@SU*;@+3*$^ZA8E;O;;R#>:0JQ5A+[(E(WA_#6!!1;YF M7DR1VHN\D/$^4Q/=/CY/KJR'@;=(,AT?8D.'P,74T8'E4U90A^]0(Y*F6 M8$E@9I7S_1W;N&!BGFC_[073?09]ZW])$6F!^F53'`LO+('"_9YK7&&EB2C9 M^@-\*?*_Q!)&8)\'4%])-0-5+*X$HRZ"JMV^I!)Q>-:@F=C3."RQY.01(!$< MZ&6-H(CI2`*&NEHN3:**$Q-5J&>6J.*#K`:[MM%H%P6+!1IK\-N!#4485Y#A MHA(S.RX@B$Z)%*S$Q`;ST%TXF*T9(;IQW&5;N4)3F5NU*["J&=IZ8`B^!Z'M M`0@PXI2],,M91G6&F(M2#<:&D\`R;60IQ6?&W'8LYQGEIRS%(Q[%`"NTL`P+ M%2K;3%[-I;8'`I++#6KP9#G.-+*7^8B>SCV4`:`8`B.,<=-^<:P77K*9*A!S MF*G&2_*,.!DV=?4E#%!8,>&2F([L'7.A?)4^A:KXBVJ#$#.A``AL/9B:HKC[ M%#7.:;YPZ>;]XH;6**-&]+`D[5A$A9.7RYA M4Y`*$5\/4`9-!VN6W?)5=):P=?FF!5;4>1J]%ARM%FQK9&"._)5(/"02#V%"6E!"W_,,15/F4FET%%!XBB$$.B]2LXR?=!&UY"JT>4TH#Z@3 M5HGBU6RDXT[QYHSY"CDEH_X,B]^0GY%C"Z,1\02SKFV<`]O%G[M.\,QYDV8! MA$U1[JD=NRB0WKRMDN""R+LKOZ%W$[V%DD`FL>&4W)DO3*9VDN/[<]V'Q5D! MHI35!PEA[Y*SV67DIX1);XI:CDO4N0^=Q;)OAKQ.^U;A,10>IW/9_"W&;P7:%)A)%Z!O' ML'ONQXI,;OZ5&0YH>)4I+@(.+ZHOZ(G:+^BS!C5C"L*9N^1=#NK_PE*0EQT8 M'?8%N?(97DSA]D2W/TC(*"DG,"U(#M)U+&@)XF"N@\IFH.R`@:Y0^V#NBPE[ M(;:A75QQ^/U]2V@[\#O>2,S,-RY2IPPD&B@>HFH6:2R6!;N#!]NLL#$F3'6P M!1Q?'LK]*7G]HT/-FYO+",7/[;OVAS9]N21QZH#8I(WDTMRV$_GG@3&%S"'Q MB6?'2HZ$ST&F0E:'!-,1'*(T'%L@7H'+@25L(C:G+M#/083$(4N'BJB?!UT6 M/"\[(&?QW]D;2@]^_\(Y*3Z;6"UWRJ>>RAS\LJUC;PO5PG;4J2QZ%[@Q.D7+ M)T7U%+5/O&AWD%3Q]2+CD-/(#UQZ2LYO?U'(K'?[[,A)H'G($PNL$0'R*]Z6 M5'EYT,'!9@P`2Z/Y$]D)-@LY":7Q"?6#-<&3[FDHBZ^ZTM=5E;GJ46!0%PQ0F1(*(D>5T(&NY MX\L%X/%8T.,)ANGL"3P^LH7&!W6)I45<@-J'JA^_U=^BFL3TEK_%\7?>[/!JWV6`!*A$JN/(P0>DOI*?)-S9P@D,^4D_<0$OEV)R%%H(! M*C=>T%)'H%!+[);X7N66;C@)L"A;7(&"BX?7%;+1>U%P42R@`11P%KB!L1HJ M;0<@#IC8(&-!=6[+ZB?$6TP'W1^!W(31VS@R<.3D=@(VW/BQ#-CAYN3G$E[A M6Y9CZ'S3[YSW"?-I"T%$JJ?%55$,95Q09^0G86(87$1R+@.;"'DZB>"XH?FF MQ*4C\VI-+Q"_8]/$905;8-?T_+CD`A8!]ZCF)J@,*,-!149_F>(\_5-5 M$[YH5W]_N/OTOL6EJ?ZBFQ;7(U#$V2':Y#V)S\S;8U^Y2<.^PLAYAOGL!!*W MU_QXIKT,8J:#G"]&U_BD!,4>0@M1C^_D_V#<)X,=2="B'B7LQ)!%^8.0D:8. M?T`+WP$1N)P#P8A1,/:`0B/X^!Q&5ZP3CH/V.C"5N#2@6M!K.Q^EEG*]`^"3%)F$JYS\;/(VP-B0.?QH`GYD@A-Y:],CCZ`%FVY: M]W.#RP>;/TT1O@KT_9`M1ZO?(NW/XA[;:C+%0NP9)*?<*'RMNO>*X@G8> MA4I9+!*:9&=[_G8O_#:FJY^]4[2IPIQ;%>8S6_D']DSBIUIW^#,MD6KQ^Y$GW?XC]`5B."-N M\5?'M:8B.C+P3;RFX>=W*),I3)$N9K;N67)<]UAV^9(6?3NV'8BO4"V62I8? M[_T,$L4R],P*H?+F.K?_8=D-$7V:X+2/W:4^".,5[^VF85RIX&V>\0>&T)(10;KC1RSC0R[U_0@#LU&[T+LC;D>39Y;S"0"B"96E%7C" M+!7U@UA84@@=76N0QJ1I#-$8K7STPP7N2K3G)FF,7+75)Q[7*BSP@`SA00)9 M06H3G'IP',B+3[YQ&%A^@MB"MH''M8K09J&E,80PXFO+)$=%2[IUM>#MN%30 MCB'A>==^.)Q-9C@ZH]1E7*!)MMFY,X_+P7`QJ6^+RD18AY1,@U9?';@5@SZO9(D2-$,MC.LN2Y&X\TNVUC$ MT/&07#+QN4+04E[I6LR/HH##_OC.SC4IY$M_10\%CU,@%_W<9=PO>=`\[,*_ M+6W0;0V&ZF[;_17OL-F;\%F'T4#`I>*9PL"NC! MB^QKJ0OQ>R.M-="TUE#5Q*?^<$B?9MDQ/,H`KHUW[6;M533ZURKA7'K1K*W[ MN=9!XR[`F.L&KRYA$V+6;4_Q0C>:7,'H&;;D[,"6WC7N@$IX#QZEAV"T>'@'!FRUQ`A^=+>C M*YXQ9].`A\SM&VH?^.=X']JD5N"O`YK4"F>>6N&GA[`W>^H*0?J4H M1%UY,`$7W:7>V(`']]#'&V![TU_KH7RB*.7XK02P)858@,:QX)M#W.;`!W[Y M&]LYN)WC,/LPC8@>%!/3K@D1W-U8YU<+4_XD!N?0H_!=;`D;E/DBW(B"'$(Z M6/2`.(X5-?($);`S-:%O\9/!"6&LD2ZP+;R_#(/EHEA&BN06='D.3'Z9!G]' M^QK$&,9?X=^6>/?!`_TCJ2&>H"A7\J'`QML4$2WV'B@"!C0/.YI!B^AL5_M2 M<'S278SMEJ*#AUS[$0SR&0S_%23?$J]?\"D.R2C^G()(C$,`-''$-J05?U7Q MC8=Y1K&8N!I>>.NU='SDCE`^M3#LD%[_^5LR+MP,%!Y*\DU(LU0JPG9"F+*? M3T?OR.D`FB!?8DY8QS:2\Y=2.]XL:G1<9M6-M_A)`Q<%7HHDH$>`)Z>+!9Q\X-D*]L&;B@HWBDF0NSG-*O;L(L MNX%I'76ZF_$NU./$M`P;&6`.SUF<"1O$O5,051U*\5Z9SW;_OXI*L)CF_Y%XR%,F8PX"&/MB'4X M`#D?N&2H#U/]1*B7NHRC18C%&\C(X7P`^'O=O7-)L9W2'KMG+DV;AOS=."*W MOWP&5-J`WBYT=DU5/6K;:U0X:@EQA!D9[B[6-?^]$AN],B1.WCH[D%CJYE2F MOB-U8MWFV5%/0G04_>!$CQDJIQ@7:G>P*7,/S5,1,BD.<&TCIWHV9!R#L:EX M6__1I-H`/J9*`_W]`P;+,B\A5Z'L]AEZQ3K=S:(N^>7,3#%9%?AD+,^P?TE:HN/OZ#;L'`MS;LRV?SR6*<%_9AU!EU MU=_Y95KH@?G`O>LGUPF6WJU\MHIM'/32 MP+EZ%SK`)V^F]SOB@JAP1`X5UME#QF0TX[Q!R0^^\1"Y=)@<56IJ-$X!<&$`'B9H=[`I%X\" ML(6IV\BQ3*G,@*/QM0"H1Q\9_ROAT$V:*#:*'$..Z\6/==)!9=V^DV.*80'*_%T]G4+W;/4!K@:50) M$/S9`<<*9KIK\/>+L>1[F^#*=C#.QZA5/BG:A^/U0F9[YRH8\FQY>X<;7JU* M(<^DTZC]OE8;T#,Z3JE@SA&@BX01X>NZJTDLSN$CFYF&Z6\="+*;[!7K([H< M)6:N5774&7%X>WP)*PWT$V MT,7_-0\7%&UW7HC1-#1+')@8+!]641,!!X$A!HZ!$`)`\ZO)SIO?J?/C:LGH MEHN`%$.EN>E:=V<6!WPAR_5W.#O85%2,$!4!@'WQ:V@510BT0*;SA$3*1+PN M_\H60JS?Q%3O1SA42UIG#COZN@7DCPY^%8-:PBQ`#B&.`8SP)O#%NC_I,(?\ M>*_^]_B+.OJ8'R?DAU[Q&[U^S!$#KUPN&'X9Y,@$1Z!1R&K77!1DWQ1:/JNM M=KYHO1S7^PA$U@K32_U@B\#HF1(:0?)E:98[O%YOXQG"QO"Y@)3MPIQRH'N9AM1 M`>$@-,1Y7.WDD07R55+1,F-7#7%=W]GU0$J^^X\J,:W[W^GULRC[)9HFS)8Z M%607`?.H?"39=C+KP'H:RS]_=_DBLZ2&VN\W2)5#:$^:FVBV/:F)#`=I!^-J M.W/QI,*BF*0_)V&7,0?8A:7[$F&>Z'.))T'XSA-[%I#YZD]'D?1L$GOU1N,6 M*`47GRSTPO*"QF*AQ:.L:>"&V0,H`T)>HJ#X%)LUR?1Y-GD\QYURMVQ%63LO M[,1^8+YOB2LNB@PI;,>>Z>%]P5FYKX;]>I^R!>#\?@^V3:;O[7R?41:T=7-] MZ;)K^21$FO1X[N^ MOP3CM?%=7%+>\NZ@3/E66=+R[0"@K%=OWU2% MT]$-YX?-2]#X#>I$#/V=W?U$5R<8?"?N5E8\U>PVR3'>>IOLQ]^W9+M543LE M7ZLD:@HEW*^DFC?M@9+BLN6P[IA!0L;YE5^DY<2NOX2/4GBVF#+5PYQ/\V:! M$]W'LL!@&,4C8HTPJZ!I;!7C;!;\XA8\.6SK9W/6+/ZE+?[D^=EES_B<8B,F MN_8KG='R+D%AN,`HC*-0:LC3D*^6]%R&1T\Y%?FUUM'R+A:T5X6FHBQKTV7%GS,Q1$6JLW[*?;@S*582JPG/?PXS+ MXM`STZ^JPDEK:VK-V+[Q:S2$;PC_?3J4/KTM3;?V#J6<'M?6`KKZF?Q7:K^. M;JDZ:V.-M^LRO%W=]F!8,[9OG"X-X1O"YZ.--1$T]74J-2$5S7)_S\O=V-T- MX2LG?#FY@?K:&>4&VGC.T^0'JBH]XB4E\AGWAA>4R*?A\S-PO%S2]M':G:*" MDNK#L?6!I#DCJF!RM=WP>&TYISD?ZKQUM$O2KG(O#9'*_"K6!=I47S@J9W+) M3K,"I6W5:]*P1EW)4_F:-*Q15_)4OB8-:U1+GL8]O:7J[JEZWKBK&U=$/O;4 M:*"VAH5%1M6'N^H#2>..N*#MH[4[O6;O7/S>^;[/"+4]:GB\KIS3G`]UWCJ: MVKBK&W=UXUVH+7DJ7Y.&->I*GLK7I&&-NI*G\C5I6*-Q5]?,72T*%OY7?J)N" M_13J^#^["]*'W47G6I>=YVN<"Q-*O$WH"TAZ)H4]`3W]M6+TNG]\47G!L[Q8 M[3N%;^&PO'SZ%1EG>$XAA6=UAGUSW#\4TU:6KF,P+[=3K`E%.2D4 MI8@KBM9XT"UWAS9!4`WGH?W>Z@P&Y\EY)\98:>GN&\[JP/ALVJ8W9U/EV7&F MQYT71Y*IO)O$8TM]U`706BN*:JO?&95XZ5<==]4'DH;/J^!S3=4NB,\+BC<^ MQGC*P1-^)'@UCF;)"FEM7!RY1;/40-?MM=11IP81+<6S;7T@:3;016T@K5^D M7[QLMCTJ)&Q_&%88^/65>;YK4E(F#\/%%%T$BBG/KFZ+7$ULL;2<%6/>[J@O MBD![VHQ`BT:G6+2)/=WXYE?;]'?$IM4L4NR?@>>;LU5.\0B/:S%AIJ?HBA8<28NW-1IH&+'3"DS#/?E`6,/?<4!H;[=/NI4A-H=@Z!9FE/KD*"@/:( MXL)B<7X)B$N!STEH'/#_E!:74X2AWBQ[[):(HSJU_49&QJ4:&E?JH-<:CXM*UUM/;?O]=\[/C0%S1/W%,S3&"XJ'/&>K MYK/CSIAY[)%V)(4JC[RJ4B_/*42L!MKK5;?;ZG;+2BV7%V_5YORLS^:Y[/B2 ML]E/!7H%R^:UQ?XGJ_;4YZ)I\GN6K<@[;-,/Z:.U=9@V&2H;`S0 M[\X`'58=8UE]VKU<@QYC<9F&8QNF9=*0&"SU*N)GKG41/^-1]-3ND$P9<"/B M;7C8E0#:^VYC+7F`X])U7LPIP[A+-RVEE<#CX;!3YC-W8=H,&-(S#2IM.C6M M`(.;F.[:,(VG+$&KH'XPMYLN8%-K;VZFBP_8/+RCAZ,S4B\_<'X0;&,X"UAO MR3U.I'I^YY[>"[ZY4`>MOCIN=88UOKNHUC%[5OOYTVS&#!_/!)+OY@M3')Y/ M]\R=38VGMGS9T!^6E>#],AQ+9R4I/@K]KYBSOSZ6=^-AJE"M&/0OI8304>9V M!H,V2FS/GA>8P?XK6SH`)Z"X:2_S!N'O]W"J&"O^[WG8Q]3@SXKIPZ_&Z38S M_X+;P+B:UI3#LT7)!&.U>&/^&VI@L/P^PXQS.AC5]C/8OYX`CMOU:.,MD6K\QR?+<>!?W?X#?IP#VS_/06R3Y?[J MN-84\[8;$G;\NH3V#Q-#P8L;1N M"7S@=/J#)3.U9<'7$WOZ13;Y](8.*K;%R5K(R1IQLA+8)O_UUTY'>P?T,\P% MT.@_WUUWW_VH=L+LP?WWG[X1W"3JT47"T$-PUYA]U^Q=3= MD&L'N*&GC3+#B]+ZFIRF2MQKJDQ<5[>?&6X$V$0K)=[P7E_1-IN\ZNZTI8B: M)BU%!,X$J&.!.+@'P>'`[UM/#4511Z;TMYH#^(6O$ MTQUP)CAZ\7>1AP,7@XU`>P3(U@G'II)L&==]XS(A:>G5^-)WWOW8A?_U,JQ] M?KA5L.R_./8+Q8:=8:>FO",>#"I7IG3&O,_K^#]P0-+,X=GXD^MX7LXG M_*:8[XV&_3S683<"U6Y);O#7:LN)7"8YR>2M4ZYZ.? MJ6-U,"SW]*ULG?G;O7JIY!RF\O1Q==`;CT=EK/@RZ&BQ]MST8YKCT&9&KX+C>E`9U.!G6-TSQQW4IMNTZ4GFN M=&RC$R_A_5=IV_O@!@A!RK:KR'4KHQ;:^K@4MTE&Q$.VB@F+Q&>(%;@K8R!E<'9DW;N#CJ:I M>5Q%[8*Z$/F:>,UNZ;`L. MXL2>2@`?'?PJ]HZXP-TR&JC#3/9&3L@4LHEBL]1%^XR!E-&FW';O9]<^NX/\ M5C8E)LW"EF%6=+)XA\YE86]M4,)L?-[&U<[2%S($(/U5]J&ETS;DK39/H9"",M8=#7713\:N>*WL+A7+7WG9K@D MS^P+@#%R55HKL.D-9\$47W_C/SD6/2&)6YM)2^?=Z^84[-M'_>U; MU`V^2,8[6[#]YI;J#P>CS1V5$8!HTQ![WGI>@%DH>$DQZ77D`[?H80ZU\*X? M@B>/_2O`+?,)B\KM9F@%AUZ'54;$QUZ2)3?H_EHNH@9 MU[]/&?D,9(O3+16(ZY1"NC+7^W?IRIWX<&X_!3SS!K#0O8X%]A*)(;J*CHD[ M[L`;B_&@JW6V,%@;MRQH\;P^^#ZHJXY2@[O!5R`I\;630L^=MIEK??6]NC[. MHP>541(4(ONA)"R&I7M`P8\/]Y]_-CU>JW$S-0NHJ07E9MF89W3,0^FM5X1) M#[<3GA8J:\]O";YA>_MAZ\Z'JP)H/?"=\H`.R1C0P\@--B;H@X0'N@XR@6' M+>4\TH'[X6_,43MH@60(7\3/%-/WPF?RO,JEK_P)%(A.%(@&,SK/C&[+\&!6 M0#?@\0AX<`>N,8") M*4PH$%/4&1$!(;D0-D+3H,$!S)$:2_$$Z@@]W%3^&E@1O4@PF7;`*W;2B]*0 MIMJ8VHS3O`[=)?A"0?J!T@[M45?VOIR.J5-\H$Q/1+=C&_OJN#.,13=FFKPL MG/8^(]W&:3#2AMU.S7':^]8T89TT:%1WG#+IR+!.0VVDJJ?B))-Y9,=*]-P: MOR3^VS5]F9@5PX6UP"RS'!ST>V>!63&[["!F7QDF+(034YBB$\-P`IL.TGO7 ML>%O0X2R_L:3(2@)]L$?CF/]68[$!XK&61^FWED]N$);9DJ/U/2O1`.]M;DZ MA+4!()$I!%=QTIIYR MA4Y;9!$3$Z":B_`'-!M,^SU0Y-FT;4K[/H,646R)VN>Q)6WED^["-/J49_@C M-[#+_`@&15\N83MRSD*M?XE98'V0<&WE&YH.V(Y(C$,`-''$(JPD3_>H%XYC M!*[+]R&NAN=Q>P'&=WSD#D#8!)/+@.4T<;E7?#.$@`(/Q#8#63)S'3,5PD^! MJ\Q,&R#`44#^^GP_[[$ZCA>GH5B_%6L0YK,Y*+Y%CXT$.'45U)6D7]HB:B4R M&6UFW3"X"P!7-K#U8$HOR7!K8Z:7:2+'<99\8B!P01I<-,$>_@S-`._K_Z)F$W0+60R^P-WVE3T' M%A_CX?H?;3HV751L+-B:4M)MSC1S'-^U)J`P0G!1,:&,3Q`M0M8*IH`D7 M[$/D8K:-%`7(X7%JAY\0+=)ZUR@N,N?+`0`3Q4XA??AESO*%!5\\" MCEM$X>KAT\U[Q0UDLB$WI`'_G+QP0F*B"S2^'D(XMY5;OHK.TK2%)`-6U/G= M$!Q>E@52#AF8(W\%V'AP:.`DT)03#_-W@_PDR6X8+E#.>Z]0PRE#0MD,LW*A MRX4?D6H<%"H\ M>8`A0P*9Q(93.N!>F'3@R?']N>Y'3C)Q.2HG73%0"!@W+?X:V"ST@)&3#5UT M::6$-W<":XJ3N$PG+H<._X03AU8JW*VXOIC]E=,Z:2"I#^"60^B!%V`%X]L, M?YWPK<9E*AZ8F2*R%ZC^C;LD5P@. MG+>HNGEKAR5O>C>3#>]LV>SP.7FO_K<`;/:;4'6.7#?1>'L]#\![^ZQ MBP7TT#4B!CEE!I0\\A^VXBK68<1&)]YS;T$ZZL4`39R@$"#3YT&D0$&M$B#3 M)S]$/XW:KX:2J5,>(I#:.#60CR`%O!F/Y#!M/*$=5UC.82;.-8!EA[O9;=3\ MT?D4INT\+?UA?QB!?FBJ$I'(EM%34WM'8'&/R4X9V->NW MY.):L4R;K1\3HOMG:'T?=L9/F,[R;B;D_,]88^6T-9*899BQ#DAF6\-^7+B7 MA"DH=N["(>`WPX%.QWY=@OQ^2_%9#U*[^\!U\`=4P2?V=#+E+B7=^AB95A]6 M'WFR7^LG4*27WBUI?J"`81M^+#6!3I[1+>`KI-`,B(W;@1#H?&$I>=1^!@H]C)$3]1:.P_@51M M@5AM1VN#+D?YM?*J>^CP8>8+0!LL'3MJYP%+2<^Y'@),3C[=BUO^41>'(HN$ M^QV`T)],B[O!'.X?V"+;NO]G`TKAW5'BES'P]3,1R.8T0YCA'+$``7>U3C:1 M8-XQ`"#H.N5QN?C[OP+=Q4L+[G_XHL.RA(Z?+1OCV2SSP')<"-NW(> MF&[MWD=GAW.Y%1#I)A5V&#HUUC<^.;<]?6YNB8#HJO(*.[R;R,_OW@NV-5T% ME"D>7"R]W#^;!N65#R5&6_D5F)8+#:R:&$J!<+R6`,!Y0DF")13?R&_ZPJ08 MP9*+>$%RA/*P\D`G1'?>@Q/X<^5OCLMT3";I1A\>=?-5MSG>]\Q9PID@ M+F;5X0\>.O^")\LT$+";N6GKHN4<9,%RB8<-##'73=CW&!X/>U)?.AB:>&M/ M39VP_@)"8>69NG1W"KA#F4.U(M:Q0J1XPOY6'#D,<5,LG0/LKTY^E8!;25'C2?=F$U\G`V`O@+B>2NL=4FRR+74&AM=F&TU=_ M)5$5T/Q\^_EN`7NLG`FP_/;"`H6+"@)0559/+HK$B-LDKP-M*6[J/6U/'B2 MKL_GSQV/Q6>+G:CBTDS>OFL\_C>&B31YUU0,Z#$)GH&[D^NS[G'\[S'7=C], M0A$4A5='D='`+T],1KX`3$S>T.%JZH`B#T/&N\E_K/6\_L+<9QD]_0@P>G0^,!PKSKV^QUDFVJMK__0/(1J"1-S'^%<#BT3LQM,DY_/BZ*8+>?8L!__4MU3L@ M::CGC4ZXEM&C:GOWJOZ[E[2NSJO-`\[QQEC&E,O`<[ZF/&AE0<0X?4U#6'=0 MXV&#''<(X(?59P+O(08=$F."H`F0*EE;5>N-.Z/0%5,4&UL M550)``.7BOY2EXK^4G5X"P`!!"4.```$.0$``.U=W5/C.!)_OZK['WS9YR0D MW.S>4,-M91*8HHH9J#"S>V]7PE:("EG*23:0^^M/@'XQ/1J?!]R6-.27!'*:)Z#N8A"'$*1\$$XR#C)P'#'+(GF`T MZ/=E[QB1QS/YXQYP&(A1$W[VPM%Y;YDDJ[/A\/GY>?!\.J#L83@^.1D-__7U M^BY$)("'L!8+^C&=?7M,0))G*)?:7>X8+`:?#;5]:"OFI7Y#UY5?] MT;A_.AJ\\*B7#U$V.W12D+\TZ'.=A/4^#K/6+:D0A`RBMVH+ZP7!QGZ,8CB' MBT#^_C&_VG(G2\AB^B"\RQ$?A#0>2HKA%7F")*$,03Z#"4"8B\XS0?",-,NZ?C/)H\DO^];^O$;A'&"5B+DV(<"T- M'Y<41R*&7OPG1XC/>Z[D"4JD6>SDPZX4OY&^*HWO&R5ARIB`=4UE M.V&NK(FPJF8)7Q-6U1BPL!`K_JR`JQF1%H;LI8`9]:V4KX%?#W45F#ON1/["_%;*@ MF)2;.?P'P"FL`<-`D1M'2>&KZ^WJ./A:*21W[M_]<>XD$HF&4`/@6X"B*S(% M*Y0`7'.PA2JWBI;*5T>[J>7@;*T@_Q:Q*8UC2K136=>$_"R/Q'/X!$D*M2F]E2XWDX'N.(#@JFAK M/!@$^Y?7E!2:*O&@)VCN8Z=J!+SG2AZ&-"4)OP5K<(^A6B4S4;&.:XB\`'=] MR-11*1V6<^IL%=?(\2]KJ\TSM:_-1.I8YKVOG91R\+5.CG\)VT6\PG0-X1QF M&T5KU'*FSXWE0.\K&-JJZH`+!Y'^)3CU,IH:&!8J3;G2>Q"XJ>7@>JT@Q]3% MUVQO;]MHTSR#D3Q:)">[#7E. M++H&LV)=VD=;!;A+"Y2C1/\B M\2V#*X"BBY<5)!P*%;*EUC0%6G#L3ACL'!["I+VF9I`XR?.O&%-S&*J-_N]*B5C*'(121Z!Y#,5!SSYIM`.IKRKKI)XY/[7-30N%'#:EEE/@WK M6E^+S^]TW\YV6[$KP(E9?T7$B.$UY?6]J[(M]TRMK;L)L[$E>=!J8:`H)HN* MHC.-OC#1O]A>+AKWH10MN0:5EN[NJXD-`B^.XAIIE::UN*E6;^TN5*G,3&WC MKT2JDH3LU+K.Z5]Z-:4\N5GD8VQ]G5-J\H*5A4]%9(D?I7N'/M3_R!ZW;4^;93&_/K[?6(OVOO\%HLA\+?LM(R$WC# M-"LCY@.KZ>5$N[T,:Z3U`+@-Y]!V&JJ!7$C=7(`U2O.O+/$%("+GX`V1BX9( M%7>9;CT9L%,6R8&)TE,8N&MG!X%1EFJGJXKL[XF![&%$+#`[B6)$$$^D3D]0 M'1(AUK=],5)G*(8C/]A(3K/Z]_<"C&MPTVDU`D'MG=IF;YM27CKC;KS-CA M`6S50U>D=AWZ.P-1'2WMF+:'MFY,G0:[MIZF>QJC'A8=^]T<$;OUEP?0?WBT M8K[%(8?_`#&I]@H=LF(/"S]2K?S=Y=^7,&>(KRK,'P6\6Q85D M;9G82-TH%6NHCPUB[=1_!:JL'>5`^NT@A>;FNZ7D-YL7QGP6F(ZF-);;V4R5 M>GG02%1^<8R"Z-C\[Z3L*]RNDU\D1;_Y$S>:<2\["-DIICIE:L>D7;743,<& MIKV,<="52MU?`;83CPZQFF,OO2[1"C(%K19;%=KCAY1>]8,BJ=)-`:"Q1P": MP16#(+41HHUJ;D*.#9@',=9!XZ!;_P5XK>>@7A30=\]T.)?/ MFRS6XGF9Y?AQ:#7$FQ3.R[T5&//I*I(M`VU3]+)R.NX>?K*2EZM9WG`?H2IX M_?].Y/&`:L_+DOL6N/2W*'_UZ9K07C<+Z"N.W2O&;=-[?JCFW*M_IR.:T1[8LS[,M/FR5?M$=IF%R+,1E0X\BI M0(^5\YA1U,XL!T*3M=,<5;:[.T>70#/Z2T0`"??(VPR, MYKQ-R=AYWG9)V1RN4A8NA;=O%J47M&OR-3M#+4\S,7@7[4S>I7L8P27(*?HL MYV6FOE1/;OQDFU+[?'N+X*;LU;?')A3_G>_G>==8%X._E(])+F'TA=*(BS') MUR-D_\FR6?IUYJBK:N+H;M(JG43W4;0R&\MB*Z]@,XGS[Y55VV'/P?-7D(A@ M`K`;/JP,=7@8&#Q&AZN:;N`P2/,OO]R.^D_*'N5AJ]B:<#=PV#GJZ#!Q>`P/ M9T7=\&$29RD<:]?HO$'^D/_45WSS/U!+`P04````"`"<@TY$UQ*;.`T/``"Y M^@``%0`<`&MO;VPM,C`Q,S$R,S%?9&5F+GAM;%54"0`#EXK^4I>*_E)U>`L` M`00E#@``!#D!``#M7=USVCH6?]^9_1]8[C,A2;>[VTRS=_+9R4Q;,B'WWGWK M""-`4V-126[(?[^2L0@8V98MR1:4EWQ@^7S_CH^.9/'Q]^4\[/R$A"(<77;/ M3DZ['1@%>(RBZ64WICU``X2ZO__W[W_[^(]>[Q.,(`$,CCNCU\XMHD&(:4Q@ M9XC#F'$*M//X-+A_^'S7.3]Y?W)^ MX3G%4><)QHSS[EP%`0QC>M*Y"L-.,IQV"*20_(3CDUY/<`]1]/U"_!@!"CM< MZHA>+"FZ[,X86UST^R\O+R3PWKBH][9>>_=VO#FP/?)?V/6Y4;N=%9F)CB$ M3W#2$;__>'I8W\=FD,SQE`>; M$&.O"WC9I6B^"*'\;$;@Y++['>.P)^+A['QEM-_R*/4-A`,A'$P>"1['`?N, M^%43^?*)&8CX!9(I)'\A-GO&#"TPXZJ3I8&8)01-K,EP\'V&PS%'[=V/&+%7 M$VOF$S,0\0;/YXC-N9.&))ON2Z#^/Y')#7P62(IA&:H`!$C.=O'"<0A,C2U%;968_P9 MC$)H*<0E+3<17E]2#:)VXKN^B`HB+45W?1UL<&U):?F[:;7?^)J`>KNRL%&= MV*Y+[!0D#BH1>R6(Y;QL)R.[RL66L["M_&N8>5M+/TVG'<.PB"BG,Q9SY2%G M#!.7#B8W@,[N0_Q"_XA`/$;\:KTHT:?N0(G!0C0!Q'3?B19*\I;4N`:AF!,/ M9Q"R-_*/@'#6,\AX*(2FJFBQ<*J.&PV,A+[%02S$$Q"&S**."MEV)\1P@#6?7$3@E;4/>A%1O#N9"@"`F\\;+S^Q9CN.35WO@M#PEQS1*$0\95$U_C M[`N>'`YEJ?1`;DB.LO+&LACVBD?+@N56X];]H#D9L$I MN88XV&(5B@5\3)35;5+93@`=)>5M3'M3`!:\S#T[[\.04?F)F%&>]T[/TA7[ MW]*/OPUGO.+B00*Y,>8+7ONN0H00P.TB['3]^C;D$;PF9>L+(&.1R!]XM;)N M585@!,/+KCV"O#`6%K5!L%_=O+O3O!AA%05BS@(K1+V:8B=UPRQG'0CGEY(;:5UQT&$4'7;V(\C+1G28'KG8[XJUW=5V3Q$7)MXUYWD\X#.\Q$3?9*B.,F)N6'#69'P2X6O588_G>F3HIY/]YZ)#_ M"XH=SSSE_80$3.$G3IK=`@;O`2)_@C"&K>:$.M(UES2J27?,*LY]OI=IIYJ^ M:5YZWWY>HH\`C;EBC8*B*?]`;3-5\JA)8A/AE4D<#@S-K.<(*Y6% M2@/Z7^T'=,LP]_#IZN$C]9``W+HI?X&'YSK!_/M`$\R?B1T>HD=($/8HR]24 MRWFJJ2S7,=\X]/,^)9W*FJ:9YS\'FGEX43>!B,6\Z/,G[=01RGG.J2;4,>&X M\O`^99MJ:J:IYL.!IIIUO?<8."G?8+]CB9RK\3I M@4([R6945E6-(5O-UCFPLVR/N*[OI7V"=581B6HOMT!9GRNUU'1HJ:=P1+6) ME_8)U5E%)*KK[CKS'=7IG*0%8.=R;FKN?H2W-5_M$\(5NDB0[^ENP%2Q0[HM;U>[3&OO;@E)@"A\)"A( M]OU,7..RH@#V,:LMP!'/-CSG-=:U59)YH.XVN)S7.S+\GZ"("BZ7>#%1O`D0 M@_`SFL"<5SUJWITZIO+=!X$',YO9#^;*\LA(K+M_+2<2KZ93`J>`P0?.%T44 M!V\KZJYD4?.Q7YED^1P$ M+)KR@]=U1E9R"<4]W:FSU8T4AU@M%U"\QOB,Q4<;>N?D),M0-9;#$I0-Y#A" MW:(?_4L%!IK)5.'!3IM1N0%&.09(9U;BO)MM!<]4N<`IHTVP.V)T.&ANPA.. MX.I(='G.@P?;8PPTS.^!J&:@SY#,SRT#U4`"2PBN)<$1VE9\YQ_F:^DDDX$' MNVH,5"^O3C0M8OMA;E\P2ZG#IF#'C.+2T_XE&INJROSCP?X?.^562XG&0`+[ MTXECZFC8=_[EB%HZR61P,/N$BE9GV]F@T,ZNA$,">N,^\J\9J*V'!+3GFX]H MB;[;KR+8!+5]SKK`MLGYUP"W,U^U`'";NDB0>W#`EHG*&V\/MX'TFNQMP;TR M^R/FS;WF(?`K*R31[_EI9&5ZWRT7*/W6I#;07Y.]+?179G]$O[G7/$1_984D M^O=[1U[EAJ;+B;P=81K;$'3,$\UZU+]N@*EZ,H?L]U;"_(:GRV11D:NEK*#- M]0C_VC[R#^?:>DA`>[#ASTZ3T^X16F7T[;?FCT=B5;"[?\!32"R_7L>#/7P& MBFUW&3\13*U]%U\Y!TLP4W(X`DW+]OY!32FS!)L'>^0,5%-T]BR#K8"#);`I M.1S!IF5[_\"FE%F"S8,-84:U\DXCS?K,+Y>#M5F>@L,1;%JV]P]L2IDEV/9[ MPU5Y`\K)!*XJV\9:LL?IGKF7_`.POB(2U9[ONM)O-SF!;RY]^TW2(R`KV-T_ MY"DDEA!K><]3,(/C.(2#2?V5WV>A5A9:MNE*2-FCZQ)*(`R=`LB1=1T`QYZD M$C#)-B%V=A&$F`^\[#(BC@@0'^"(P26["Q-REUT*I^*/%M&U$I]SN5JB;%]2 M>4T>%K5]S66DSOB=)(A'L,<_Y5Y!;]]9F4:N]5C#Q)L\P:WM+"MG8;Q[K(B%TUI'!GMOO*70*N;5X6FT MWTO;EIOAOR6'V?:L(OY')-1G\4UY(L.^8@%.0!RR%L&P8\[&X?!MXTB#=@'! MIC/^,`/A7[OKJBN+#E&CYO@M$8KA0`132;ENQ?AU3 M/@&E]"KX$2,JM=V>0Z#X^O4>DSDDR=@9#KE@5,A[-6&0K/)0 MMKWBF$WV6&_K;#R/_(;L6P4![D0RG`_D(.$1DH`_,H%`H11Q0V0+('#((?6/ M$PZ>A[Y[JU:)>B?2R%Z[W8`79_2@**F*[V%VQ4A],35(]J+G$5*H2Q7G9@FE M?FEY67[=E%>(S^0#7-T-98&PQ%"%2@=%N.FFX+SX$ MXKGY2/`X#IBHQ&C;/?&'B`L'APRPUPEIM7QX->71+\3F<_7[6+S?M`JJ*THAR]JXRBVIE%<^$`81C>L^]NQ+O(6(@FB(^;U`&M/X-L@NI<<.O%J8C5TCM_W:"M9E1/HK=4:,.^^KY4 M@ZJV;\-<&ZL"VV@RMX3/=ES8(K8;4WAS76<_&N[N3:/HWS?+M+$4XL'J0M/0 M;B2;E*QQ-*1S,XG$HY662G+GOJQA2"7U=VTJ[:W5-(P+;,O4S4)+KAW4EOT( ME9WE&M_!HEJWVANT%"Z.>8\7=RMP-^05#R$(EG):I:\NHNE]9?"QK&(PI_ MQ#R-W?WD/]I>^\R(L]/8D+L22X;)W8>YP]I]3W3U7L=M3'C6QOC[+]MJ*=]O*1BBKB);.9!.IU@J MUT2[-%*2VK_W3+)ZJ,]V*QF5$P6>G/=6Y'1%4&@_UE#F3+6_2]O_.61SG.Y51][8[;L'@K7N>%7?W,3SA:WL.K[WY\RM M;0G5QVX5C5'[O.V#DDHAO.OM\M..\H@J/%W]U8ST<_%C!"CDG_P?4$L#!!0` M```(`)R#3D3RT3\ZNTP``(?'!``5`!P`:V]O;"TR,#$S,3(S,5]L86(N>&UL M550)``.7BOY2EXK^4G5X"P`!!"4.```$.0$``.U]:W/<.);E]XW8_X"MZ8AV M1<@N2[4]/=4SG1ORJU<]+DMKN;IFPK$Q03$AB5M,(IMDRE+_^@7`1_*!)WE! M(-/^T%UR\CY`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`NUUDUCU#U+!!HJ^N-&'[F/JB%X@VB%;86@O/; MC!;WZ5>D2_9-8YHEQJO+XIBA_,!R(QDZ[?7R,Z`N=(R%-Q-G,A@K]== M52*(R3S_C0FA1@I58GYY8%;1Q+(^^KQ0JC7\,+"]*$_^1M)=1KLW3^^2E/8Q MA?R0R/1X,9*9S8>!15@>B(VK\2_2:7#?/D/5PQ#0+JLV8OB51>@>B/=1+;2U M*)KK?.HCWI*\3+([VG$O=V)0JT5[V):)SH:XV#`LTI4^U(!7J#:X;Y+Z5@95 M0B'@7U/#Q*XF1&P0:_5)H;*\*#DP82,PF0,\>+.Y% MIM5P'VLT*.=/4/,H!&R+JXH8?5L1DGO"?0`+["R*VZO=39K$[U(2E4+4"I[W M,-M[/ANQ'6NP>!T;5J-U*-]@M?H=\0C@=BLR&:M\@+%J%MM6`%:@TF-T_0NQ9"+"55!@Q^\`B M\/:E^_@565HV<:8I2AZE%]D:/_X[%J<'$IE^JCR4F9\C]RT")\="XYJL6*#3 MIL/5,\0?(OHT!"C+ZHT8?F9AYML7'Z2\(EO+PIEL-B2[+DG\V_5]1#%VN2O9 ML@^V?D>,;0.%/M"5"O-1KS`/3`&])PT?=`9:')HOV4U3OZRW"(12,UF#`:20%,&0UL0D\:BQM21K`Z)\0<73Q\-%(832$)[7D!>367I82Z0$P*])P<&]8Y5-V`? M.S"#^U!O!/AZPC0XR(OJ4PAZR:=7P;ZC(@;^R.;"T/]$S4K0WGTT`'CU"`#3 MS!`TC#LV=]R?J[R;&(),:PFZO.1-IMU%QP]]K5SR_BZ)M M!3>L'.>/R3#4"I_5;S=X-A%^PE)`8%!E6`1$N?R* M_\2AB#ZS7_^OY]5_PDHA!M^RC\N>&`.F0M\?.N.8[+*R^(ACG#Q$-RG^@,MZ M=F<(5@/1!KM*T;E05A@'1;;>CQ+H.O55(X'R5N0$9;A$Y!9%:4J^L!T=Z);D M:$UV-^7M+D51HT)%?G?V$WKVN__Y1Q25Z*^[#*,?7Y[P'3??>^:/"4Z(?7T. MV*70ZI%-:]T[]ZZB)U8N->O$0@.^#86`F-8W:\NQ!YS?D.%V$C'5A(Y,2"90 MW--K6ST,@Q62>A3P0?[5Q4SHRXLX(++H#"*GT'%8[&(:.DX[\*B?GC3+/@X? M)Z?P0#GU&R=WFUW*]@"]P5O:6"9\.R?].\7LC_-L?;YAZU#^P7^_RLD6Y^73 M%<5%29^]_?LNV6Z$D174[#X6`YF=3TV0@@#G5)!ETI`?SM6J_><)R\$:P[2O MN;?L/6[`HIFX1=(H-(%X&`0SP%+[BW[K=<+*%Z574;*^R%Y'VZ2,TF$P4TLU ML4DF-3?4B.V"1@ZE"V4@4&BNV$\HR5!<_@Q2V?1(B/^W*TK&S.(3H=TZ^OD2WJN[R&*RP>])07]_'17WE-$/R1JO M7SW]4F!:_,LM.\\BR>[.XS)YH&^&B_,;MD`E'J4&#EVT5'3A8C:/X0L%&P2< ME4\=01RY774L,^+EC6T^#)12N^Q7]G=,K5->8AZL2&.6YB*-W3_YCE0.&4.6 M0^@P1L)[ZP=85V_C+SHW`Y?O2/ZF'K8+7GX#0)5P2@N@?AQ,9,+T[8^_<7`+(R62?LB+`'?(WC7K:)QM6U4JRC$#[M% M<:])#0&KJ@ZY[)LJ6E!IRPD8CYRL?Q%9MJKB-AB%LL;%NGJ5@("PZ"C7&,:8;7,Z#"2IRN.G"R!A?@('#0<0P#Q6]&!%^)2F#@;B6?-+_ M550DQ>5M/5Z;9'=7)$WBI^K_/^''\A5U_ML`'79*]8+[YT M%4JLOOZ`*6*%'C54-H/B`OLSQ_@-V41)9L`*H;R"'P-Y!TSI>7#-&9$S6_:, M;0AY=((:2?2YD@V04V(X:-@EK3$]SWJJ.L8)_'CGWFNRN4DRGFG(!M5-1`>, M$XL"D4UDW`7/%'Y,*"957_V,\SN8]H]S79DI)F>Q__(YBA7*,:%Y!* M5S-B/HFT1%226_?.H@[+W],?+DJ\,4CI1J+R=JLC"M]DM<8=MU9#/Y8-55]= MDNLQ(<2E`N&0LK[5#9.P7K1M4JNE:8X&UKUSJ$/O_660TN$+*R5YZR14@F^G M!&[`)XRMW%HV8#)#TJ8L#.X9HD/=DFGJ3MNF"?0UK9O4XV+`!!LIMG,)@\K3 M3MO0D>Y>,?N9*2"N$4@SX1*JDO%LEUCU.1[.]C.<9VOV'[;'\B%*V?Z'\_)U ME.=/27;WMRC=C>ZEL]&I/Z.ASDS2&GF!3-QL'*H(:VYGQ63X"#C?A83WTIYO MN+,"!9E19WUB&JEW>6GA;RDT6K4@6]GEM!.1J6M++`S)LV8-V=!WT1,B>04'V3`-93'__:L!ZMC18SX++ M>ZHC42^R.,=1@=_@ZK]&Z8]:59D%R52=,%GL#'QYT@3G]HQ6F%M]P"5:U[]4 M9TH<4-JD`9.6W?I*-N&XV(J>ZBKO"V,:K&\^Q3$DH+O)%?^CHW72G&_=**)G MC:KGC7-+H]LJWX*'M]>.?!H5Q>7MK[21C;+R,O^8W-V7;Q]Q'B<%OLJ3&+P6X#7? M6KLF:1KEU;Y;OLW6=["8`S\"!X=![)A@K1=#)IYP?GE[7[;[^LH M3=DA*%.BBKTU58"QL>8BUIC[=QYVK(MB'8$L/:PNJHC31B#*C2W]P/>LK6VV M^[-+A\+9[@^%6%U,F@8;@_!D;E@;J6S+Z"]H42@EU>E-+&4C?%$SSF):8OT, M^33E)B19*L^-0%;N;`..P?G@DPJ@##/V!E<=G:I/U-7R'#ZF@8E`5/$@.%C9 MZ<6""258'-=PG?M)KF$A?:K!=)@S\CZP+NOD+PAVKQU]D])*5B=/TK5IYL#6 M+UMY`\VJ)SB>'0D&Y^DHXT`HZYZG8S9A:'M4D]%E&1/_SACR?_?!;EHBAN6SAQG MF&W*H')5S45@;\:INJ,-9N! MZ)JLL:2LV>I*0C==>]M.FZ^1&ZLF;*`M;L;VN5_`39F@TE7-F;AV-$W:7DG9 MK`UM^^30-L?W."N2!UQ='F1RRIRMVIY=AFKSJ6;D")AW-CXU)#0WM>I)(W;W MDW?BV8&#S*NX$26-+`SX:>'5(UF+\O+V(W[`F6`00_"LI5WOV6QN=:S!$FAL M6,V2H?R*_<36D.;5C]Z)(*H38O`IAY#NB/5Q.]+W!LXW^!;G.5[7I?E`/XOP M_'2M7/WN"KF9`)9:=K``2>=+A6^U[JIYW(#=+];UU4HL:Z#/`:E*EP\:NRYQ M`[;`1^ME,F1..YBI!4[07N18\"-98'M&;K\PW)R_I,]E'4-%=I8ZB)RFRZZ)U`=K\L_*F) M9&AFU97D\\-11\0WLRPP0:;7V9!T>NT^!4V]^>-CNSKQ\I:-LN"LX,7ZB%,V MG<`ZL`4?$GT5%7A]%3U5=YI+AAV!K#4LGFMM+L'G^7>16X&42!D=`#RL^$#Z M/4G7."]^ST\7*)\\QPL@8!(GZ!A$F7F&>P$(HHS^6027?L*4Q3&!6$*[WZ!# M;E'7#JH-\4''X@1Q6\]OF#'46`MH4T^8Q),EU4$QSVN:;EK\FV[Q)3N%8(S9 M)@428TM%,Z%[T.X`1$E`(IG<@3`3"&;7$1`NIX0F+3HF!B:AW4EQ25%"GU%I M2XHH_4M.=MOB(HO3'5NKS-Z);P[9X?7E%N?5314?HHWX-J.95O9Q:)J5^0%H MBE_@R#.C")J0,]GRJE%&E?8):O51UP#:6SA!S$8@MRK-A24!Q<@H_DPQ.`@\ MT\OD+>*\C7)VRG#1K*AD5QW&Y]GZ39+N:+B4)#R66O6W-M::&4$,_4!&##N7 MJ@AA8VEUU:PF1NNHC/[DE]^VH""S:JS/7T,#7;Y:^0R5GW:\M..C:QXNR+_Y MO*OXQG_D,P7KZF>4X1(E?+T>>D;3SN)[OL(_KIV>4F3\;0@I7'K.#JR]J^KUOZ?ZO\$,2;O!GF1( M&19\/H>$A\4S[/L8=G:<]6Z6Z,[,Z+_T.RR_8G;\)=N-_T"[PG>XERGU3KD( MK#-CTWNQ[ZZ8]$]"Z9!LMBEYPK@>3WV?1#=)6IUU*EP2:BS?\$8O/Y=`.@\. MUC68^E0RR\C&ZCR.:.E2WEO)ZRE5_,C&PWWO2C&'!)E8:P.VZ51[ MM#/SLP0&X;(D4V^SX<0.ZCF0@RU;=`5"6)($CT&NBQ&'9C4\2NKWB@ M>$';-(HQF]0,<^#)!!#$ON(&?%-H]:BFM>Z-9.^B).=G75S>ODLR6KPD2B\R MF@+N^(1UU7<:H-U*I_YBACHS^6?D!9*(-@Y5C#2WLV*BJ#IABQ*TE48=<;_< MLX,'F5%[?38:J7=I:>'/&S__$B49&W&\S*J)WX3-ZU[>7N6$AMIRR$Q#Z?J[ M::5GLE%CWYB'/U4\S/`=3U04=#3SJ"*BB845$T"T65PW*R4H$=GMA=N-]YS3 M%`%D4C7U":=1[%+-R(=[N(%U=0Q]S40:[>8PJ6;.@2*N(\I`UP@?(^8D?1Q8 MT/GLW^R+Q[+MR]O+\A[GYT6!1]=U&4B.0KI`$HQ?(]M.0[G,FQFYQ-H5KUC/ MIN[H;'.RWL4EHD7Q/*5G4ME")BEK14:BD9*80!+;;A'E(%I+_IU MFPP';P5/&LITG\REQ]Z6]2HD4D:I,E<9V59B?R"]XC^P#(3^XAG9@JH@VF\X M0.Q>J(?.H2YL?<+E"F.[%I5YVM3FU<'5IJQ1-ZI.GXUVM3"/']O,QE\DZVDT M4O5+2Z5FHE5B%[)15KM085BEN7I-LH*DR9K/L;8R!4]OVWTFZ-DO6;1;)U3F M^V"V)>IJG%A53Y\5$H4N0Y0V0R'+JRAE4U+7]QB7/'%8\T&2*-WO;RQ>/5GM M.7I/>]`7U/IP$,.#9S&IW7J NR^HP^"Q0;(N`YKPTJWIM>.OQ!-4^$7?* M>S![MYUMR`6Z>6IW!9ION$2?60$0+T%847816LLC]U)\4;8&+@NA:&'(%6+8QZKSS$3=$YX_)\CVGKM/%FJ'*:?"M$"OF835"G1+[;8/:@@S. ME*F/BV&/C[Z1Z%%KT39B"-REFPCF?]D68O_&/AN('$<%?H.K_UYDYW',UGD7 M5]$3:\`^Y=%:T-&P4-H':".E^0'6P`UP@#3WJ`EPIH96S1.VGXT]\AZ6;`!! MYE37*"P8Z`]H;>PQ(%H.CO77,E(B+R7C2!ZI3%^7%]\3ZUA MQES2R**HVHO`YKO2_7$7GH^`FH`A)9M-:E=':9D--;'5G@-BM_SH$RV_]:I2 MAJM4P3DN=^:6Y5J_=CS7F#N`4Z@F04A)<+.JU5%<;D5--ME*R; MOFF]#^8\6\MWVLXS(J6^F1'P(&#B=I&^HT5![.*#L>%5+=E&!1XJ"-^@V=R/ M'06P47,F`)6!PQ8.NA!B8D\=3,Q+Y(T;#KNR-D5P0PMY=[>A2[//D+$EG.W, M(;#$N'^\'$T"ZT.SPK5]`L/F5J4D[SL+E>#[S0(WBS2?"L>6W6:9H57%[3!; M0"4FU'UA38UI^\$"?4T?6.IQ,3@Z;+%4+F&0*&^1*H2V*H&V0_!8-6YGX,`: M5CMRD3W0[)SD)L,S`EEIJ]&3!6=GQ_HB;<38GQTAA_JKS@^AD4Q4RTIN22I# MQZB.FII((_NNX>0PQ@L\S4*2/*(?,<*,@_94B(45HOL-B5XRDSC=D[*-1I*K_*KSKQ8:)S40\4BOYHX:BXU8I-H!39FSA;C1^EK?M([ M/YB\."_+/+G9E7SU+FFNR&NOL3[/U'7.#\0=`-,]881DJ5!A0[Y#Y0I`+5V&=9NB-PC%C4A?U M04$91)OP,?KR$3:N9BCJ`Q;%.?9\,Y@<.JV+-Y%7L60A.R;]YT5%%_:K3+HM9TK&2)N<*9M]_7;)?2?X;VT1% M8ER8#8+J-8;T46E`T4CNPV4VI_5JQ"Z-E15[SM8$;RN)0.AE@`,1S`N_Z0:(/!6CK405$GH-3ENZ"H]-D/[RR^?5WM^Q\@ M7RY0?QJ1P$R6C4W:1G1M-T[J0D4CB5+5H6O/30AFS;BBZHCIQ^[C?RS;A;O, MDA,T@(58N7E[*-``VGEP@NI'APL#21R<@H.PHIRDIZ@7E$8]L'ZBW#1D-U'K MQ0[]@UM2QZ'0\[%R!A6K)(.^@RC747,CD.YAIV#GV?JZ)/%O]R1=X[QX^_== M4C[I"6.D-J:/1@V.3$I'#KJ,EJX-^:8WM7I_GR M];__[\OW;]Y^O/X]>OM_?KGX])_!L-$,-6)N&M>HE*E*"Q+>&GA=$+0N\B`C MIU!X/?T&6.TZ?->(#20W$Y;3LL&Q;&B<<]5ESU7E<`X]N[W:3@K'3STK.M(( M<_&PJ3F%DM/;#AL&+M)6+-I&0+0-XWXTQ]W;(X;:Q*AOBS6?4?YG\L!WREYD MUR6MSBA?TV*^?2QQML;KJYRL=W'Y:\1VU)9/PP,#/I(T?4?R+U1I0`)@J_7G M![,ZD]I`Y7#0M8$MF2I:0'I:7+U+,9O%J`[$+^I)-F:F;>J>Z(_L8D6\ M9D^C^DSM;D/XF9E&M6W/D]_0'"!.`=B/<$`.NH$0M,SA$!BL"0G\G.!UR^CHI[6N"'A!;\ MU=,O!5Y?9.^2+,IB=K1D7"8/5:XF'E6=;J"NHBD&9@8[>Y>0TQF3O:L"V$2C M*Z:$;E/RI4",Y^BV4:#)1*/A>3YD!L((5)WWPXF]K6[DF%J2T&($6S)2E+T" MF\4&A:(Z)@@5W<0"@2OPX3%KUQ,"@,Q8==,6(_^VUD`W3^C9KN`]"7;(9ZW7 MB0-!A@$5F/3TUU2S$>T%-@SH+O6\*)[!`DX'T9J.SFEG9S*+IC"+M5LR5W#Y*V#9JMNJ80):Y#45L%G4IX* MD9].RTM=-E02=ZX;*H5;./CJ&ZI6,?2&R@F:[1HJ4#@'V%`)FE2[,1@#`];] M+==C,`J7"XS!Z+W#9*WJ,1A1WRO,,1@3A$U*6R>/P2AL3% M?8W+.T:&53[_5)N12;!C;826K:K[K")UO\J[5V*P;W,5^=_?:%_SDD-OS&O> MY[$WYBWHY&1U-T.0(K M<>=Z!%;A%@Z^^A'8SC7%7R&:[49@0>'L=P3VRWD-EJWZ;.+;.80=59GD6QT")IAPL]>/!E%+X"PJT@$VHJG+JMX];G!5#5FGE&IK+Y>;R M6689E+@:)TJ&*G5I7[W$]!5+OD:>\-MLFP$:7,E]?X(RW^>5ZNN96%;)@%HR ME1Z'U':]D:5MU.OBR*8AM'+U-U'(S22+U#(D671.5&11ZZZ:7SV/]NLKDEA^ M\SX;I"I=-FCLAL,&'0MTZ(='/?B@A,R#%=2[V_GWXPIU(^`Y$9-7F@KI%@A7 M(ANDQR^T"M:QEUJWA@#MIN_[X6\/O/8E?6K[ZO?90[[L)QV"&4:%Q#"J`>HY38A0]V=E.54K5.P.O- M8QTR('21SPH17J-??A=ER3\X15]3EI(T6?-_G&?K*PI$G)7\GY>W]?+2*+VF MOU1C&[*>$*3-)L+"V)Q+/8A2@/;&``ND)#>8G]6KJ$@*=OA'5X^/CUSO-ILH M?V+/KI.[++E-XB@K>Z.7;!@M">C2"UBH$X=(&P0J"/.]T`97WL.,A9VK1K)U M![Z=<>$:O+*Y%E_N(2+L)/<^@_&$`CLXPLG3*SB+]%.+!-(H''!+,(>]4(W& M3$8`MB\32@+6%$W^"@<8S.!ZC)X*'UH<8WW=CML3U'/,PUDOOM&8UCI'>^_= M>W5Y"-0EP\'-#QX(J+U:3B/5C8H.+IF3V`4=(E6ZT#)`=MU<18'@ MKIO35>>0!387STD41D0PO()N828P8D;%_7XC?+9N3\RXH'F/=#9CDG*7-Q;* M$'0R=@?.,EO/6O+9&5Q=[[;;E&>PM#^5D>PYW\W3.4.H$BR6Y)O>!+L M>\79-(@-N3RIX@44-[8S8KYE"8)I&M4]!J6@I(&$[CL(3;ML)NV[#W+ENK'D MC`R]P33('+5UH6XV%2FDPK(WKEQ%3WQ,X!W)/^(MQ>E]5.#+V]=DLR$9O^-D M@%MSA?H[F2C,Y)#>A3&7?JJXE.&[J,1K56?MTN[TP]+0)`L%Z_N;OYV#O];M4((II1H3X2*V%T?=Q(E`P< MN("BSR&%IH2?R'G\]UV2XZN<+?`LGZY2-CJB! MB?TK.CMY^?(E^Q\J[J.>:>HMJ) M<3T-R#06[K%&9LL-EN"BNMS^!""==I%T72&)/SQ!%T6QP^M#QH4LRDX"1CAQ M\YJS^;PELS*$RH2%T70L#$J&H7G(@5$C3^8$$1H8!]U18$7/DJS^U?/.*4,8 M2%FDJBP5GX9ZDZGFQ)51'64JFA,N$ M3:1!=6M(-*X8/8$J'1UYNI8#(=5SCG95622*(=B4K(@;%0RUBI)PTJ4\5/V7Z)(C!H M&D9)C>E;QXZBKHD<^?#)MVV4K.L35 MW*N&BD965K5@>_13YVC`9EE("(OM;1!")E?AB)`ZY0$IS7PM`TO(@3A3?P"( M/-U#LCF5D2&RO\3_=0CK^]U"4CZFYP"3?L?\2(SQNGA'/^J;A*_49#.^E[>O M=D62X6)\J)^%1MM:&&C,IJ76AX.Y%E.?:F::65DU@M596D64\B4UVYRL=S%; M0YEAWXPT!P:97'-#0FJ5^X0T]+4,&@$;"6-_`%`\'6*Q(\L@N9<^9D!*FP@7 MB`REB;BF4>?R]B*C79V[Y";%55NF:"'4"H(&0J8`R$BQ"]C.O*$W4S8JC.Q7 MP.0XQA1"WB=3C6M?0CI]_<@I)]:5,4[ER2??6(O^:Y3G458^G<=QOHO2^I^) M=+;(1FG/.R.E^=PS<..D,V_A6$-%4T.K_:_-'--ZE_,1I'O,1KD3XI^@-E`A MJ?(TSAE4 M/2=SG5+28NU/=Y'M>;91$38L,A50PHJ=.&]4E&[-&:LPLVII&LHYIU:`D))2 M7V$J1HJUY7Q4>5L(AXZ:#;5#"`B.FPS60'2$OQID&C46<-`,IZ%HFC.C7H=1 M+\-1OF8;\*N$_&VFWH^E7E-,Q,R^7K0-Q!S5]WZ1,Z&L!8Y>%F MB)E_&[S<-MBU\&H7TW!R)N_C'3Y0)%?%SP&*S\OCQ:6ZRC%^3(KZ>I`<1P6F MC03_KU$3;*"O;)V5^DY(I?"XV,B@O@SV?-397+V^IP;98&'6GH/SQ(].V.;X M>:.*ONP3[X,83C0!H);NAI@P"00*4_H8H2V'#T8X'H4T\`Y.!N789$?W!#7: MZ%FC[WVIJB\66"5.+FD07F^UF1DU:S('PNKVL15V0_W:O(NS14P<3F!VU\#J M&I=E6I]?OXG6^$#:K"$"]-04U),1#3N'5MAX<`XVUXW*P-4\G*F;BUKP^(!F M%_`G(_1"6*25&> MH!07!8KB>+?9I:R!06M,>R=QTMY<\KL?3_[P+S^A9_2_9W_\8S4ZE6'TX\MJ M>,I_%NL-?L`IX06K-T<,H&PD6W\BC>Q,,BFM0ZX9-7&D(I-> M?]6(2F#NA*)Q3^*60,`C*UFH;DTNGVF6;F:1'<@74*S-W-!]TI"]^5(&HDT;,N$&MASQU0 METB4]!A<0-%O[^$!9SO\$TSS([/J/SZFDO4H\9GW^)\O7EE@D6;Q]Q'B=%=)/BBXPFDEF1Q/PXJM,!+=P[ MJFO)I:.9(<%=T=%544BQ\Y7G>W=&4 M>$/[H/3WUR3C6Z!V4?H)YQOHQ!&^8$"))F3!/+=%<*\27"(+_FHNFSO@PJXJ M>]4L?&V114/V\Q$FS@XB!6"KZ(9CL(TH7!DA&UWH+W=4P3:8C@+\:QU.I`7N MB"C"-I7:%_$$-85$=2E16TS4*2=B!?T6VP\EMCOJ(7T-P?V0>V"=OJ6GKM:, M$L`/WA],YVE"F8/K)4U_AX5&_^SZ/5_-!('/1F\F[IT-__EHQ29_B\.,7<%T M.F:4/\#`Y7(^XZOI*1QV='0_.W)`X?&0LWG[#LP9<#8_HP1`V?RD$GAN$2>4 M.;AL?OH[N&P4IY9JU;W7[?BR^3DT!6RO9N(>MKF:4!C(YFKRMSC,V!5,-C^C M_`$&+N!L_NL<]S_LZ.@HFS_,\.@UFX]27-1K^<<'DTB>-EGP\.G<*-^W![F- M1&Q:&1L%&BMV2D%>_>;Y0!Y9S1"CSSE@75^PQPB1#7]@C>_Q>L>N.AH<_?.^ M.7#R$^M)R[92355OX&ZM/IEN31,`^C1B)T+1/YNGB7?63D4@@4'%@/>6EGJ!85(I/!`"+H>?Z!R: M"Z=],HQ.CFM5T6>NC)@VXNJ>CX+PA7Y9LKDP_+VF>6UY>0+[:ICC\B,RZBSV M/"Z3!_.V=*[!4>LZW2!8>)E:!-"4%:HT9@%HEI-5)4(;W$J$G_M=\%-H2/5D M2XL03.,[&[+"@`0!&EF$FFI;'+/FE32`(':1T1X)]?)4WSYO&*K,U$8!2:<& M%G;4CIRF]T:NS2*)@:E5(Q-01FX(#B'US2M.1G"U!3&-3;PNB$T'F;:94RA8 M#C+K5N$$U2H!9]1NT:O-H-W`-Z",>30J/#A>[CQ;#W[Y)4O*2;FT$U?B+!O8 M%6S^#5HXAYFYBW):Y.SP[KM'259)?)O7W[%.;K7I!F^V*7G"X33@#LDCS_>= M@539$P#UJN@C.'B[``+Z8&[NPXXMFJG?N#",U!-LC$*PE0VPV&KAU4W0M"^` M632TM;MB9Y=E<9+NC___4IMX'M6K!PJN'$J$FP(Z8>B:B`%93+(P)PXVUN4) M((J\VA5)A@L:[/Z^2PI^`E[QZJGS+UYN:0"Q4Q_%#E-UL+!AYM!-Q+#R;18L M+$SV.H6-'NHJGK"E2IT?ZGYB,)U#2ZP)0X9]_#5<4J8,'D%W#J1<+NXYG8(Q+LN1$C&VAYLS'V/GJ12Z3)9>% MF<[<<&;B!31463A4AB%C.ZM:%+6RGJ.#%1C(C+H:L-I$O<=8V9A2FW?G MV?KG*/\-LV**K[G2"[:\DPO.)IO,-"S#-%[4M%(JK_AJ6WZZT:9Y[IM-VGHE MMC4PY(U,IT\6M66_FV%5K:VLL647VI5/%UE1YCO>*E^6]SC_=!]E]0J,#R1[ MX"<`?21I^H[D3&G(.B_.NUM@%W0.L8-LL>*ZV?BZ=/&U6\>6+="J&A9L^S(% M^LQ$4"WCNUOBAXS#K5Q>("[8Q+58.4;[MQ;^`@<7EV`WM2Y>]+""$LQ6ULH] MZOA'O`"HI"78;W1M"T'__!8*PPJ%J@VM7TDL]'XHS:11K_JEZ'O8U?RY*-*J5J*M MVK,D0VL:$Z*\0%O:.O'%$YYOK/3&3)O6R"':+9LCX))8-4A.OL(!!JKE$G1' MA0\M1ADFZ>K)S\Z!,YTBL%WF52$$1\\T!4&\)-_BH%4.*.HL.NB]#W!MJOTM MO'F@S-<8WXXS:V['[P>=AK^PO9UO:+[U+DIR?G?O\NM-C(NTW"H4@R(%VPJ: MOX3M"/F6D^2ZC/+2\[H5TU?S/'%L5LS5JX@6,N:7,_UUEV'TX\OJ*/?#'%Q? M,B`L._UK1:C%YX2UI5MXIMCP:QU)'+7J9E2!]&WF:9##_LT.(8Z>*N_&^!9/ M#S2>^EMD@&T`#>Y"S\@1O[%SJ$0'KF:7WC:"Z5%P^Q\B%60,1+^"U: MAQRMAY>F?8O6NL]U>(--VHM/>C/1;,'H+>Q6IMD%F#N0-*,`OAKGR47VL8S2 MU4LX:7WG%6K5"#\7KR!BTQ]5^#R.Y?[SN0O1ZH&P`:B)FUP6D`9MYI0P`;D0CFYP::@H8W2Z:O(]AC9$?!2""R@%GMI/YMNSXQQC*BX]LU$?R M+3MFT7WO0PHX$Y;(A[#7J/\"P02=T_V^H6\1QQ^6O[:0E`G M8PF+[J>1$A1E5?WV-:3"$HXMTG#(\;M4L]$OP3*MANBM#RC$^%_N/+'0H427 M1<^^J@/9T1]\%5886[P_'T8<"W"5\@TM?A279BGK0%B=:+;";F)W;7Z!.>Z^ MIPE1LFM@=5VR6RI[0:VYC>]S(QGFE/.P]O6Q0U!'1H2O]0QHVO,0&K?@SLQC MYU"'UF6#0!+'K!J39^% MCUXU*M^BI[):?+%PFUG=K0[]E;!+7CYF[QGJWC$;S[YO\C$O:XBWC5F7WNDE M/I:EZ>T4.+B6S`']("_5F89KX.MTS`L!>I..[;L?5@P*YR(Q^W('%'Z@KP^K MO'\]-X<=5'QS=5_8002X`(>`S5_U[>,VR;F2ER1ZHGNH3-K:O>^FS++`MCEU MB7/'&?6T%W#:KDTITHHK'6MN/965D`W0#*0#-T*6)0%MB29]A0,,4N$DW1,+ M'UJ$@DZ_.T7X>G+P`XV#KK+Q`PN$0>?EDP?W^WV3Q2:(Q6Z=3P$/W08[R=LO MZ/)Y-VS!_L5Z#A&8Z^>CV@T+&>^D7SP&7P M-$^P.N!;:`"`[3'$AH/,ORS/@@AG*_?$>CW633"> M++QW\UM4/XRH[OD`N<,-ZP?9O1J/XL/>>*2S#[]^P_<-1K(2!7&DE*9P"TU^ M=B\<,EIB<22#W#(.N)F#=':KD,R5HVE%Q2U!AQ-@._=J">[;!HJR:B=`H5;F MQ'.\%1J-@^>Y_0,*HB'[(#CSAV+TN\EO0<(3CXXD:A]Q%[ISFZ6@%F,(#4.XF M].`YD`O*%.`*,'DI7<9QF=?!\A71\2D'MOQS,^3KYY0#PP(X&A,._I0#B[): M#6E4T>=MYG2@TK+P@02?T^]6W:DDEM[BK_'LE<.(2NYGI@(,2^.1DX#CTEDH M'6W+,@<2CLZDKAQ&_SK[&^'5V'%WTBZS,DZQ(8M#=O*9^X+OA0S_A MM#']DH6\DE)8TH6:$H'O?BHK2%V/)L9+2.(FJLOQZ"R,]UTZ"MRB]PHY"@0S MC:\MI;<0X&Z5Y0EJO1WTMLK@8HG[/JVG8'+<,_[G=W^B=^U!*JR62\N..RV9SZI%UUA8,"/I9<<2(JT[!H$Y7;HB?@Z2^+9,QY7.'T](==0=./R8>LC="=_L1;[+K\A:;&&O9`7O8'!XO-**KV,X]-6ZBRS+77#]K=.%MF8K:H/@=M`+ MGOK%7)S;PT5,1[TU207KB/TA$(M MNI%R>OEF1>FI;E?\.6("Z'/U>^A'$\*1*@@-/VX1_;;B6@(+#HG(^?'9?SRK7L MY$_P^S/GO\(!3:W[WL0)44)/D^Q'O=/J&&.OMTGWPPF^WJ??BZLH6;\C^:?H M\=>DO+\G*2LV_4'\;43=CHDFNIT%:Q,039:E4_!AFFG^M8W#%+.=(^.KV2ST MA:GBE,?B;?2$DBPF&TJ>Z+%Z5%D-;/YK*A*'47,&,@2ASM+:*$!-*HV_J%)& M)8^=E[>OH^+^74J^%.^>DW; M))(F:W9Z,FK%"T9KIH&X"GKV2Q;MUNRTX>_1Y\:`[U%5$R@0^RH;T%&AU:.= MUGH(]'J79%$6)U%Z18J$)RY:FFE5QG13J,#13NK$$?UT_@QIJ#;3IV-S&M?U M/<9E\"34`T5,1J.*E))2JBTAI\:;1Y*2^+>ZC_`S%JU,E0JT!!P+S*;;T"0L MN236U502*JWX[\T0`?IG5V\!D2T:IR!>34ZH\(:^AQ M,>3"C8Q;N80![6G3$E32J!)O[ZFN-$X0U:DDBN,'JVQ(U2%:O0Y1LE*R`0^< M%]4=S](^CDZPV[9(!"%8*33MJ@U1.=-24*Z\ZC[_/<)9R0&89=#Q/XT3)!Z7N:O\85<_19R:!N(CO43YM[1++BABP0J;2(X?:;C`4 MD?7%-&(2@L#UPR2&7=+#IO.E4A61(Y39(5VU*IAAT/N2:*AX$,^<3DY,C*X<+#/VEAU28^3$@AL#W1$Y@MH7IJU=.3_$%:$DR%Y%P9"AW5`H M\C[)\$6)-Z/9(HV8F"`=,5A^M(8=TF/HPX(=?551R\$D$!<)BQSCBI5S0U@) M2FJT&@IF#*R&0@R^S_$QT?!B*"5O-RHI^%:#V77<9G1<6+88K::LO6`"81%B M5*/JMF+X^;4M!5/0M!-[F\&0@8V0:)C0%9'0H!(!Y@`SZI(`'?LVZ&_5A)UL M]C0PW/?J3P'ZX?=6([X96M-;"P7KXE5B*ADQVJ'6BHFL.L2[^8HQJ=XXV`>R M;DQ9B7+(:U>/B<05H`]B#=E@.U2UZ^3RMEIUT-DV]2HJDGB`S4FZ]3>SU)W) M'BMOX/O]IWA74<[>WHK_B:)ZFV:SXJS:6$3V&GZ).0U/!*":^T2V,M,E^`3_ M2P,;;&)NDF=05)\VL`YF<>3R`)9,]2V'8)\3A)+"ODG2'?UU5&:SUDNGK6Z_ MY-INB"[SMU0;IO$_@>]*BRO^-'G`!]J4:<&ECP4F-6X4#&2&#,*!N@S+(]UU MHZ;S#0SSTQKG>!U\T^88T';-FR-$3VOB?B,D90W7CZ=G=;/%?OFOCSBF7;_T MJ5KH?1['9)>5;+%W3C+Z9[7=H[@B:1(_R1:\S+)1?\F)-B9R>_JKVS9D:Q+O MF!W1P1:S2R'B^4RCE.E%G))BE_.]0.4]1AG^@J+6!-KV;%")J$0;=O[#9LMG MXZD&?9"43[\OT&VS_1+E>$MRIO_";]R8AU4"!9U^_)ADCD61N87Q0I_9K>-\ M]_#$H6UDH]ML1MIKH[XZ^EP90,$L:O/,"DFSZHD6TT_IG^?7ZAA^:0=I?AG@ MR7%F08ZOF@B2P^T]$6':"?621/,BHY!--A^;/$"=4AI*UY])*SV'SQKCX`FA MF3\I24W45W7[L][G>K9=F._K1_6+2' M"+U`%U4F&*4%H?+K)&:;QI,JBTPRZF)3G5]5VQ(904F!=LW!)_S,QRA#^'%+ M7[;2I4DIM<+"'V)%SJ.LH&DG/P:"IZ+1[2VF:6A,:#J:1S=)RO854$G:D6+' M\-)/PF;^*#>HW5W&=AMIG0@]ICM1QJ-8AM3C!PX M9AU,'FGH:`[?:&Y82Z%6++PJ<:2Z,.M+!;+*Q@@:96G5]9IFHM_2R\`7'L>ILDLO;7R-V-'/Y=)G1WLUZ M%Y?#A=)ZP?K558)S6"2W"]Z3T+J2\D:CN?IT3]/TE.T=H&GZA@WNTE>NAX,Q MVB19LMEM4'4;*,NKO]1VZA0]JT>(Z:-;GLAGM,^0,L&$FMC6KCSGW`9((59U MVN>47*=EDLZL.QC"A'"]CXD`I.'ZJL56(\)0U`@="7(DX7@V=&9FS6KC5@FS MXAPC0U<3(736A="7#H2:Z'/2A+$CP9(D:9Z-)=!46>[JY^B1589Q:SZ0US;J MK;P;8M3F%VSB^QXGL*1K0-?@5Z)'V^`/P:1GG*"^37E7JQK0K^?$.6Y=YP0# M5_,0J\T04"U\E)"SSALF8^+>AG^W)^EV,^'249GC.6KS^!@?P<)FG-PX5O8U=2"AE:6-5RU7`< MET2M:#"#<>9`()/JJD\AK6Y+(5,OSE$'.'MB[&\>],Z^;NA)HCL'VQCFYX!S*R.V"=PRUKJ0LT6BNWF!:K\FV M78Q1#_;N%W.D^`&G!7K&EI3@QVBS3?$)*JFOA&VZSW")OE`/]YQ>]*_?V&QX M'&V3,DJ_KU9\Q/<)M<'IQNXCP'G)3C'J+"9FKTW3*"Z\OLR2]>T9UQ08\VBE[K7^Y"0-"HQ M7[%R&R4I'UMA=[$5MT]<+B8/F+Z<]RZP`4.(%9:'E]W)=-KPH3/KCGXP"9+> MQT3B\4MUJ0!B$F@O@GX.89@2##C2&V%G(F=FLJ,V#ICEZ!U-Q`_-:YHO%K.; M_F[JV\98#"V8YO.2`2MI=7W?E0&%*$E&,QM1L#D,.^U8>Y>N4JA[PCK[[*$FJPO(N,)R88M*_I'NUJ5 M?M@R3_BMY3VEX@4Z+_8E*9D[G%993\),T5QC36E*-;[<8YK31&F\HVD$2Y=8 M$L59?(=Y@:GMFR=:"EYX^IRMB'U(RH2F'+N"[SCD"UO72<[6QM(\Z)[X7M*J M`3,QAI[@4''AC;E:J"T^2T2O/8@B`%6N/'A!9ZDE\;02+`QSP%[E1.^06#_;8_WY-ZP;U;LWK(.V9*_YB4B\ MV?S8=H7.OT3Y6G8]B(5&_8F,-.;0U\`!7,MDX4S*4&,;JTJR2GO07A95PL$0 MT0849&*M]0EGH-V2S-P3'+'.FX&-"TKD)"N2^&]L=$)"*D/I^A-HI>>026,< MCDB&CJ0D,M)?M5*H%4-<+ACNF-8]F5!!?J-K/ M3U5SV@!1K.!&AHLQJ.*A3XCMD^0>OD(6'KRT[0#<5V M?,]FAPFUD7=4U[N\F<.M=ECYWB@U`=ID'N8&>PG,C>QW%=@Z7I!90%NK[)U" M<8IMMZHU*GITZ,/_W5"EW@+#MQ)^-2"6;<=RC^*Y6[3LO`'F81,\0V'Y;(CE M07/P#<^R'5[N\0R[YF[H07I=N5:P67NG$)RUAD1J%W"%D=:'?!&)1G5U7;.E M%D%<)IC148/J)785,5A0(E7:+RK1V76)>MD9K`:24MP#G;VJ,`R_^E3KRX(` M@_-6/]5[07(\/'/U+VR["KLP1M"@^%ZA:5#_?#!S0K M'5QQ=_NZ&DOJ+##X1%[AZBSWB^SM8WQ/:YN6[FT4WW.=R]N/CQWI`6!=F:\_ M*KSY.<2$+@UXSN&H@-(8X,3?ZF/_-*B,.^&;9.I;\&Y1[:B]'J^LZ76#45)= M")&P9>65/Z:`J<=*G_WKXW_T-#TG1LXX1!;`;3_Z07MJ0Z:;5P@M&,!DB*Y* MMF@8H+GH!^?$_\;[Z1`]8.+/S,]=%`DPJ7=5O$7I?[8$_<.Y?O0@0X&D!W10 MH0"TK_4SSN]P_FM2WG\B9;(E)X=!5+'6JS^XA=Z< M>&?L!KP_8^M9&J+L#`U[(.UEH^VI/7P)!X](&VZY6NBQMTT#3<O;=Q__X M[OOZ7!^<5RLZ4LQ6B(2V&,,>BV0.3/JAP]A$&Q,LG2Y&`YA,WMHE#`%H[OVS M!:P_5YJ>1X87`JXD_W6,W)D9JY4OT',$K#W#(/CL&X+U];LH@D$3K7:[CR0E MO![DA)=?,KQ^]?2.Y+2YYK+W)&5W-;*,\/R6]J>J=QEPQ[6;X>8X<#<@N^J` M2P6>)#HNJ'XWGPN_PQ1T?^J48CC\]X6H8TR87W:>TRWW7*G5KNM.<<2\5U1R7T$DIZ.XK=!8\J<'R+ M&W!0/J+`,;/[XK)H@`/OKHOI)7R<+1D^PAF0/XI0(NGI'70H`>U'LL-XDXSW M+-[A8>@1/VR.:!@\G+4GN6<+_O@%D7GYAN.Q]*@O4FU@K*YB0SQ$IRMV7G(.[]-:/K-9KV=V3L,G;" M?K'%<7*;L,,CDYR^]']D@1@G1UNU@RW)/;K]!6:`."S6@@Q6$=BU` MQ@Y-Z""!_GI@U2H[^\"T7N>>:S`R"'F*@="X1>V>]6OW]N!J5W;0@&GM0M]J M&K.`S^:VFQ:UT\("#'PZ]+"_.17>P\SK`Z$+!'_(@;,RJFXH=.)RF%-L6S_] M/L6^GW$4(YLNB4660?+H&D9H9]V+&]V\2(!Q`NPV7%>%6SI"5#?N.HP)(0Q8 M'G`XD-\)?&CQ8/Z]PRY*!7GXA;L2+AT5SI:)"GP<\GZ7K7.\+N]]CT4><)20 M7]Y\:%$"=MSQGO80"97#PO7`LL?-V./H\:R1@X$U^/%'L0/Y\(%(?M6L_$^R M!Y(^5`O]SXL"EVA+W^P^8O?K-@.&OH<$9=5'##[Y8(!A(+D?8A":@,8!T."@ MQ+(5`D[YJ1?TY_?LO)\P%NQ-JFC90*%-38.>X'+)+YMK1]MI-'RW*WHO^B-BO@?2/K&M6=G.6:=6V;6'WO6F'\3?Z8_,3_3]V M!2W]Y?\#4$L#!!0````(`)R#3D3HTN+3KR0``%J7`@`5`!P`:V]O;"TR,#$S M,3(S,5]P&UL550)``.7BOY2EXK^4G5X"P`!!"4.```$.0$``.U=6W/; MN))^WZK]#]ZTKQ9R:[3U,T!4G<4(0&)!WK_/H% M>)%$$G>"!$#K)1>QT>AN?&@T@`;P\S]>-O'9,T!I!)-?WKQ_]\.;,Y"$Y.G;(`VCZ,T__OO?_^WG_WC[]E>0`!1D8''VM#N[C-(PAFF.P-D#C/,, M?K\X^O/OKNP_O?CB[@-L=BE;K[.S]QX]_/7M[]N&']S^>/:[A M)H7)V3W(,USWV2P,09RG[\YF<7Q6D*=G"*0`/8/%N[=O2>UQE'S[B?SQ%*3@ M#$N=I#^]I-$O;]99MOWI_/S[]^_OOO_X#J+5^8TM^>OO^P]L? MW[][21=O*A')9XE*:O*7#GVE$[;>Q_/BZYX4,XHXK/=J8^N=G97V0S`&]V!Y M1O[^[?Z&6?KC.:$X3T#V.7@",:ZR*)[MMN"7-VFTV<:@_FV-P)+.)T9HSX98 MYR.QSON_$>O\Y<#YO(]X*X+%1Y@%L1DY"WY=63O5]!?ZUI1I>2+?FK0R[J=@ M!"L?5=-?Z#N`(KBX2A;#"]ZNRI3P#UF`1H!*M[+^"@POM8*HV1J@#5SA`2R- MTGL9_7((LB.)4+/0W"..W9"Q[_Z%T^']A<>HC7!"# M^?(.P44>9I\C_+6/?&QF/43\`M`*H*]1ML;^,=K"#*N.7GJ(*6#8QYH9#+^M M8;S`+N;JSSS*=GVLR6;60\0+N-E$V0:KG,Z2Q05,,AR'X7@LZM7R,EQ["'V3 M$+Q#U$](&I<>0GT*\'\)W'$4F61%K(=U?\@WFP#MYLN':)5$RR@,D@S'GC`O M3'('XZBGJ8U4:Q3CC\%3#`Q!O.8U#,+U)95@:@;?^B)2F%A"M[X.)FJUI'3] M]]AJ'^HU%Z.8B$Y,QR5F`I(!(A%S(8AAOVS&(P_EBPU[85/^MZ?GM>9^QG8[ M/6&1I)C/@DRP\(0P`T63SI<70;J^CN'W]+&Q]#^=R51PEL$S.F.(#IH&.#HUG\.#KV`!T:#P##%_'/D#I<*X`\I]^`*3RF/=@"Q%992`3WIR.$SYI,Y!AD'J&&BF- M>X4UC`HJ#/W5#PP5R+_`P^P*(GKP2Z5H(*9%X1E0>/KUP4>+;P6+O_D!B[O\ M*8["ZQ@&[14!YO<&)!K?/0,$6[<^<&APK<#P7WZ`@6P@P*38Y'A88V.G\SPC M.8PD&94^VD@4:(XYW`*>X4=!^U[C#[>:"F%_=QUAM,ZO\M8Z M/&*V#*`\\VNPM7[[M'_*@CV7IN4`6C3>($)&QWXNH<6Y1DC?Q=6?SSNF M_8Q_&'+W72)/H1]XET'Z5.B)#N,)!7BOTCBXW,0`Y)FF%T$".WP1/3W(,X[^Z4J9>K-4[DRUMPSO^V@ MGM)-_TRMHM@XE6-M.RVC1^Q`"K-Y3#&Y!5AFBW8%$]JGRFC-3^[B@*."9+LW.>AG63P#]`1;IX,M M-/<=`ML@6ER];$&2`NP1YR3>:VC?0H%"B9C&FK`P]_([4[!+<`9;N[."@7 M$G`\NB43R^X(+$.Z=[H\4@>QH:";"")\5OJQ6=:YS\,"7(X&B5N8A%2_RJ6I MC,B@<1`9,MJ((,'@X7W\5JI$'5:IXZF3#4R55VX;;8Q MW`%P#^+BYJV.%5JHD::O$_3$](YC255C%5A)\-:/T1U!V&4E\SUX!DG.<$9\ MHGI3G4'D.("D=%-!#8NA]R%\,341NB`!U?&DSD-W(Z>="ER8'&V?9S,9QPGC M-V'%[4L4>N28B:_#JS/+)"[. MJ_+)Q'?B>0(K>9WU<<6MP]\@5'H]57H%UZLK'<;^%3U=@.+RG%HR&FG@A`F1W\#L7MR$7X"%E-^4+5`:6*>`XDI1U5@&5#/,>200NC$GL&[F9 MP9@P"',>-$*=5$!"8_8*5P:E@W;]>1&O"GV+.[*4(S*$8LZ)8JZ)9V!3U-[( M8C2C(OW[QYSHZJI)9)JY3GKI9?*5F5W)=?)0=//Z^=,):>NILZ<3TNVS-B[H M%?BDC5/#;`^YJX;8.HSN84PG?_+;4.V& MES\=.LOAPQ$_A^/STR&/TR&/T[ZL>%\6SZ;FJ.@!BV)'Z0Z@XEI7[E:MJ!!U M]Y9=R/%54BW=]?=XV17X&P`V-2SO#9[EV1JBZ%^']0$JUEC$5(QUB;W"ED!7 M?4QU&?N[;TS3K'AI109'34(.AFI"#_%#U;$O=FJF_FXCT[1BWR@O2O#2/;Z>'4LT6Z,]S"/[R@91S**4BC137;R-GY2UUHS)4H8.5E[8,D(R`1A MDP1E%U3>!4SR6FJ"B!DJ67M9R2!XJ'&2@(H%&D\B)#GM>H&E%1M9>VO)(%#8 M@9'",S../J^CB1LS\9#4\SFF'FAR/'O%C52I5[`8/KED%9>N[M_;)9TOYUN` MBEHE"^5E1I?7&YJM@K2#=U@H;]`R\[#'?,D?SF")JOJ3F]6=J&0 MKC['SZ:S-W:!&/-CH2X"^@2/IVL.8D+`>T3B$UL`O;B*HH&*S-S!Y%V,= MAZ>_P]X]UA\;G;RY@R+%"@Z<*1H]X??N+1NPT=%404$"=AZ/)3BF0P* M8I)@M]A$2414SJ)G0(>1)'4]Y(JHW8:2FK(*8!(R]G=/]=<@2C[CX&.>D/D% MGO\>[@AO0TE,6<.(1^DXA*255($/CZG&[NG'$CH)6!57A[H6[XGB/%%\YSI& M1`HI((/":H@#MS;04,YV".Q9>.A2M!%Q3.$))IA*Z:#BF)GGIS,EYM&R$T+I M636'H;\Y*[W(*,Z8>IWVI0-+\Y M#02.&O*-WV0RA*\=\V;_ZI*7.GOJ4Y!&(9D(1W&.`T;&>IQBJ?J6?]E2KEI# MS0IJVEOL.:JM"555;_8MR>J*EP]$U?B[JR_AKO1ZF;0CDV;O;Z936T5)=R;I MOQQP6%]!M%J3QGK&X<@*W.:;)X#FRTZR4=&V+:VURE:F4"SKC&NC=;,^=N![ MMN/>IEB+OSL7#$4KKR)*.-0LS8ICMC*M] M\S\=RHB["-+U=0R_.Y`0=Y3`N)=*?%43D[1[11.%U.;/^>UB'GY#)*M]4AG_FROHB-F=O#I>[D M]S"H)XM<-3N-`V&A3!K):6YE&+V>'+7Q\*N6WC8\=J>8&8>-@P`>6RY!^?>1 M.:I'7=A'^A0+'D[Y21=TR"S=*W.%!F$789J"5L3FHJ5J$T,M.W36-"6K)=U3 MKCJ-H-SU?GJ3/&.;0=1]*5**E@G!!JWWV&-K;A9TC7HT(G/7T7:'P#:(%O7S MOE7>&9[\L@.=?DR8^)1CXCUP-6QE%M%R`G@?N%/,1/0[!(5RT.858@<^U$+> M0U?"%F:A2J]P@K%Y'=KM8A#?UR M%VEZ)C8[]-X#DF\!LRCLU*6?!NS$1KXH7%%QF,*2DJ'FM-REK%6&##IISM+# M"Q:'7MS77C4>9ZU?13S#,9PW:5PC9`V9R`8;1DQ_[V21MZ)VBJ9V:J:W?4'; M-H;R':4K'^*^-CM7T;(SI97:0_4RVDZU:BTPV'W`]CT(V?E(^R1[2S#@>Q0N M`WLOP02[:O29A7_F$0*R#XZJ%ZS?AU$HZ)K#E0$![&$;*8?+$:)X94:AXF20HG]@T82)7Q%JK(UC$!4IE;] M(+;G@@HC3?E8Z&+7L>AFY']EQA7^OLC#[#-6@`,YR9(4Z`E+3@"":M8Q#45A M[?Y>3BAO'.UH2#L*\A:YVK8Q`5R5RO7OZ)K"O$H^KY$_UY ME00#OD?A,K`^K[J&Z!YL-9$DD<`RB"B_;&9,N'Z!2MWRM2*NH\0GM80@V;:A4-,4^P M#LT9[IT([7!'+!Y"EL(DHPP7C)TRGJ*0K[L)^'5JT$]2V!9(QF*@;++H^^/# M:\9?1_LA$:B1.%HB\"JQ'MH7F5ZW,`FQJHPMH,G*R'()>814+N>`T]&``>YJGZ5B49"B6X!3K]M[Y%,D":QAC M-5*RT)'MK/F<@X&+3(;]O:S5X?D+F&9I\>["4Y""19T"P7!"9IC5UT?W9&;O M=FU9P3\="\[R6X:XJ1J5QLCYR@!OC"4][B9HL_R=#6L&&3VK-=U'$$H=6:H78!G`K ME))J3*BI?=-K\*HB/D&V"I,[)3;"HO:!"IVI&.L-@0YOUFM&0L+Z+0$.H<&W M#SJUL'JA!"535]][5?Z4@C]SS/.*K.C86]YH M"\+J@`*R&L1,,FN#9ULD9D\5T3%4=**7BEH'RNO7ZJ$,SD7_9',T=!&!9WO3 MISWJ5[)'78&DA8!=^28> M;,F[8;7$[`TY*>K]GIR`>CHH5#/,0/`3"F'ML@4S;K2ZA9-CJ053/,0&`5"J%_S,N),)=L&".P!DD:/8/R MAF`9GZM:[)`5)5EL.C#6--5`>):7QM`1'BLWDGP_6A5!,,'_#,%1A,3'MF[Q M_>TDJL6G@_6>IAL(\^I2&7['H,^:&7G,,\GBW4V:YF#!UX.]-M&#QWZ]0HO' M=+!MPHB#K6MHB5:A_.^>;E/WV0U[)&^2G?;"IKX7]A"NP2(GF1I?0;1:9[AS M/`,4K,!MOGDB)\B+F+Y$`W-YH0^/>KE!C\=TG*<)(PZU'*$GFK]9!,>W)MAU M@Z_G'.(!9'OY+G)$NI^D[Y$KUG$WHF*NGU74-(#2N47Y.KQ/E.>VN_K]O9VD(U$KWG$HLL7].\_8TT0]3S2JU^Z],^J>:;3L M@TXG&P=T6X<3:,<*%!B8;\D_T^I26UE'UI=AQ[7I,YS`$4?C=C5]RM&$@/X^ M0=?2_JFM_3W`EHI";,K"#GC,:?WR6Q)E6CULD*KH?<]P5=/KE4.VQ<#]U;#H MAAX]\6S5^A)D012?EJVGOFP]PZV^B.(<8Q\\@#!'Q57_5R]AG&.TD9?$2$_* M:R7:.2JS#<%-R\Y&>59V-L1S.LO<0QAYH&5O0Z+Z&U)Q5_OG>99F0;+`*A.' M';8ZDU;9JCT5RTZG<_0QVD"=0%$DSX^T%*]S$!L$I!+;GIJ\GEV`OU2W(1"I2 M2-JZ-4CL*W4??/\2D*/%09QBT>;+>XQ9]-QY/5*^0%MA3@'[Z1"T!H,:VC(R M(([8-ZYLYK`UN\]H$UI?(?IVDQ3/LZ=RV!*7:(.+5\)]=$GKJP@O'E_]295K M^,+!092NP>)7"!=R^!*7:..+5\)]?$GKJX@O'E_]F85K^,**<<9YSOCN`S2Z M&BABH&`PQ'.C[F5%2H1W2AF0='[>)QCQDK`LSU:FF^[(.,;V.0I!DI*7?JY2 MW`N^SU8(%/-GAI+2])5B$O0&KUA=0Y0]8LR53^&1:K[@$6B3;]JY%$+".A." M0VC-&\FW`510M>F9A'44N00DX@):PTXA-:ZD5)+0`5MF]U&IAK2 M6WCL+:ZG*&/D2_!"&=6DZ86(V=-/`#ATW4WC9U^+]\LF7^!S,8#<)`]D.R1` M"S*X5&%^ZQ!$L<,8I.`2E'_?PSB^AN@[+M3"IF&N52L:X^K(Z+:;A2'*@Y@[ MGK6)J"/8@("M5MH^L`5&&ID('>E\7XLHRM:I\5+@;E-S`7Q@7CZX&489F30'J30 MV$_X6((U`2MR>,)1L.+Y_$N4DG6`MH'D\"LNSXT6 MIQVW%.#_^'`*C%FFL!4::UP67(;&5PG=+3N\$C',3%=OO<*8+,-LUONPGJ^Q MEMQS25^N1K.QN1/73-C>_#W=,V'K8I\Y,$05]AKEZ!J/+X`#61114&')I]E=F4VDF"T89FXR#1X8DAFX-L=!T]/$4CC+"-)NL(4F9 MG#6$!(:]QYB]S'C("/GQ5*M+F:J^N"2B6:V_+EUH"Y8I\!04W&1@TPYPS3&4 MC>,D&!K,<"5NLR,-+11C$AV'8Q0B=T=!^9:#DC90'/2$`NQ#+DK%WA_78YB' MOOHA1\SO8@ZL7N@BH@JYCXZ4LS.CAJVDKQ<35#*%IBEO`QBN59K\S3=(S=\_ MSRV'8)EHNF=K&!H(N/I(Q>3J>DPB^:RO77XE.R7I35+FY_Z*8&HL+A378*A' M4VLX]>D>+>)+KZ9J8GA-Q*/.C"V[!%%&MCMKFQCNS)P:#'5F:@VGSMRC17SI MS%1-O,]-[&N5JY=MA(HR0_5I3@V&^C2UAE.?[M$BOO1IJB8:.9;3ZM.C3Z$[ MZ8RG2;352;0@O=3=_LR>1AM/5/6H/_\.4G)%)DD0W0*R1_L(R4]#=W/5:@WU M??EJ3R[!=-OYXB?DU:O%+ MSZ;H477AOWF8V2*WV6HV!)0]JL(7SG`T1SNSXNN]1P;-TKK^O`(_N$-16!SS M60Z],:TH@/GIG;0`4V]N.VULIV'=<\EC]!VS;EZA50<;^R4M8'@LX6O^.K;= MF9FHU)U+DW['?,V]S^5HU'SR/R.WKA<^R*3VWE_1T]M:E`W7,1V19O6FO)%R M]2>79*.=)^&7E$W@_1,/O4U&V3D>TSEI5F_*.2E7?W).-MIY$LY)V00FG_AS MT37YO%XT9*;'R0/96S$:+V/$X36C4XX);T=]1&=D1IC1\E%.CFL`QV44`U/P M9GT-HI\),XFPZBBQ8$1/IEBK^=29DV\:P#?IM>H4G)"TYOI).TZ\,F8E:JND*%579^\:Q59A".F0/ MFRG/:UBF?&_8=9@7S)!',2G8:W0T@S6L=?]C4C/]F&T2;HD]TQG+__20P)"C MT9+@-7J4_DUEW75HJ:"?1^+9++_?A$]UBJY;W]MOUV+L77!)K9E?VN&9N M71?.%]#P"EY;L"G,10?=8V,TS^@;X`(Y1MO[9LKQ&GJXJ68:W0/T$/PT+:S# MY*9E!IS],2HR/\GK5.1-)Q[#T'J]="#)7LW,2VURH#K3$G+73T9V]/()\1CQ MF?IL@UR##?A\@T``&]?R,F:_6,`-3(KW)@[O*A4:L=ZD5"A1F5BJA']Q>/G> MZ$V"-_7<3&&MKV:9_M'UJ3RYG MK#:=KL=IJSV%E:)!#%6NOHWN:NC5#NYJVM6>7,U8;3I=5]-6^_4^XR$T574W MB`5_PZQY<)=#J?GD=49LV>DZ'HKFK_>Y$5]6H2RL<]#NL MU1SC5U:,B%"538]Q8"5[=;J$Y"/!X72ONI*Y6HFUQ8K%)1Z#KX,(%1N_5G>5 M=*0;;T13D^Y5H\A!Z#B(EVD'1UJ=>9QA3A4LHX=5*K8;::"5L-EI@TUAS;5^Q2E0UWVD?D+T:2:[_=<:ZY19>-4# M^QE(OYLHUVLXLO0A9/A,.Q^I?H)OB$.24E)XW&3A&BSR&,R70G,Q7R5Z),>I MC8QX71Q0&]:4S+V&LB-9#8\^(S;_992&,4SQG'>^/-;_'L0DC^X"IEE:J/]T MI#[=QQH'$JWI^\E;M+XCZ5 MIK@YGJ*DT)9UNEN&M`(0G]1>W+?'82W@+,3!<1H5`G[:'?VOT2WJF$^S>!WO M*1>W9BB*@+.7*&4`@D'5PD*'RBGMR#\1`)>0W%$HH2>5GJ-QB][<+0UTMW(! MT1:6SQ7>OWP!E+1EY7*5<@KEK(VP\@T&]0W1'"2%59)Q4*$J_7&.]]2$Y38X M=@Y0O5^)+8XK(':68&PHCK`Z>U`/X(-D=3;0?X2=PDZ8YR6FX>@G7)""?+Z^"<%V4 MF2_O7XZH6QH/Q;ZRDGGV+KE%ZD+,P!85NM+&>HQY8:SE^(MN>F:H^M#2=?X] M`8M/NVN(-J!<5"1KC%@THNELB84LQ_I6/QFZFO;=TL:K<;[?C&1AM?XSG%#6 MDLH8_>@.H)#8904.RATI:Z`+#5A#U;:#U.!\QQG>KFI]9A!Y7'M@@+P_4:V/ M78/VMEL%8Y=#3%@OYW,(K:U2 MW"38J.`!MTVYCQK$01*"AS4`V2Q9S!:+`C!!?-C3PU#"_]G"-(A_13#?IIA% MG)-T"4(#DRQ*\*QNO@7E"F5*VQ@9N=:J`4:K=<*M2=G5&;?2T=K2\IZ3DJRW MP8:^$]632V5L;2X&[Q9'._@`@IBZ-47_6-\8WOIH,XVC5UM`@:*=)`R=VHIL MJE8M-M;@6?.?(A[`=(`*!-;G>@[4^>PS&`3*&H-#MQY_(_>1QRIHR@,W&W,< M+4C;:TOO[W;IV+$IM!1!C0VI_:K`6-KZNW4\O(4Z:SZCQ?*LU:91:S87D)0G M8F8K!`JQKR&ZSLGIU'*R/TM3D+5MK%*D,HY"KU M>0K[M1);=*/@1[S)RY9TG.;V?V?6,_[!]6JXE#G,/64!6[R`S MR>R=D&N*1#T%QR&A*V9[&[4M#JZ/LN\IH&*HMJ=R23OJWJ&0CJUAC_V_072D M;A9Q:>BZ6=\V$K<)E%.L->RPV!:)171V_J[PBSINUX1,[`O-6&^D?5MF M9=^"[\6GCKI*A6KE)0NYTE6HRQI:FG-[3V/Y09;],">)1X1==7\95H=,C^ZJ M%/_9!N9)._"6(:T,S2=U&E@*6LK#B<_4W[O>+N(@3>?+KP&Y8R:;HWMRQ=W^ M'!8(<=?)(I!>!'%,#I%4=&E%V/9FAKC5N6Q]N3D-4[.VDD=R[WK]O6:8JOK5 M"T!AE(([%(5@_U$)X9(L>+`6LO`/RVI6Z0E@867ZIZ`\FW?(+=M+3CRFL2`N M6F^D3-[$:]<,IK39VTC+S-47\@>Y:P[_\O]02P,$%`````@`G(-.1,YQ,TT' M"0``RU$``!$`'`!K;V]L+3(P,3,Q,C,Q+GAS9%54"0`#EXK^4I>*_E)U>`L` M`00E#@``!#D!``#M7-UOXS82?S_@_@>>7V[[X*]DLVV"]19)-BD")'5@I]V^ M%8PTMHF52"U))?9_?T/*LB5+UH?M-`9.;Q(Y,YR9WY!#4AY__G7N>^0%I&*" M#UK]3J]%@#O"97PZ:(6J397#6.O7+__^U^?_M-N_`0=)-;CD>4&^,N5X0H42 MR%AXH48)BCR.AK=W]S?DI'/6.>GTR+4(%I)-9YKTS\_/2)N<]/JGY&DF?"4X M&4&H<6QRZ3C@A:I#+CV/6')%)"B0+^!VVFTS^EQ=*&<&/B6:RBGHWZD/*J`. M#%HSK8.+;E?/0/IBBBHJICJ.\+MFK/[):1]M\L`'KF^%]+_"A(:>'K1^A-1C M$P9NBZ`3N+J8JY6LU]?7SNMI1\@I"NGUNW\]W(_MZ#'M=R&\2B-'Y.A)O0A@ M/<"$JF`1O;_"YP/)5PXZD7AAQA)B8HYP+34ULVZ9E8Q`P/A'+ M%FPSOKV(\1C!A%AO7Q@M!BW%_,`SKK1M,PF30:W:\'CD50Z62D9*(!A8@`I&88?>M@ZA[,+(=Z=I]&TXM0AS!ZU"BM7H\?AKW+[T,`OT>IB_8@G)1\I=$HDC"7F?NYM" M-N6'"MPA_V*?-R?TDGM)4L2Y,6>J,Z;#,I]OV1HCL2=`U[A%$!YSS1;BBGHF MQ8QG`%K]P6GH,FURL8&I`ETA6`B5!6N,_H0E6DF99"F41%+)AY7>>*T*:`Y](9ZG M]?`TXHF5W^!9B.<5Q=?AY#%A*VZ#QJ'O4[D83L9LRO$X[%#<'3F."'$_PZ>/ MZ'0'-VD1PGM)*,3\4[R[6M\IM(D=SD"<'-!NMI9#FK[$H&0]*HF';>(@$P=W M>`KG6L@5K,F&$I1.LB@EN!MGYRRBOL^T7:QPJN`R9J(3^'I.%1&4@'&:!2,A MS4Z4E+P&G@P\8RV<[S/AN2#5S8\03W`1*CGM)6!\S(*1%/)?$HEI,,A@\`!R M"O(;T[,GH5D@-%HLYQ$.6_I*L#C+8A$)(J\HB:Q%C?YJ\,C.">J!2?+"#1V- M@\8K54Y["0Z?6/2:PS!9FL)`#_G`+`2 M02(9C?,/NE,^W(XY=^>\>35RB#URR;W)SV^U-RW"\#(P";\"D^)R6C*-A<%1X*Z%./BHV4#U4YGS"1TY63%=_`%)\M2 M<.L>51NXZYQ9DRAO[2T"-^^D6HIIQ1-O`^7;Y/BOH"GS#I#D8T'OG.7/WR[+ M+RUL(K`PS:<"*J?],(G^O#31-VCMDNE3Z%6@>ZM=:<0+28I0G7;%7^%88>GZ@%S&+GA:Q2WMM:C.7+GQKY@+U2DJ/2A49Y/' M/.RM0$Y91A4=$FS+Y[TUL6.G#*'%NJU*^CQ)HK>FRO!>RFAF).;25B'O.PBP*;91#G49+@,*7V M)Y!;=$BQ>5*FN-I&3ALAZ7_:7P]=6P>]R_AII^I`UD6 MQ;RU8S[CB5/CB3VT^-B5I@RFH@*6V@S[L=W[I=WOU0,@4WU7<=28P0Q\MINE M^?5U5<9/,>X]`[(5@O4TV5V-XA+.W3<55M8N*W5V95C68J&JCF[#//`H MIUK(Q2V^5U\MDE)NUD(*?+8LM[4Z#EHCH4O1"Q^UW&GRSM43S<2NMF;:%R[])$0:# MEJV+O6!(TB*<>9[Y<#%H:1DB.45JB1X8M";4LU6WECC`\!'NDQW+#>6RUFR; M*^ZX1GI_!`;"^`X^U^A2RF,TKZB\[G(Y0,+&:N21H9$ZV(:^.("1T?LN-CY: MZN'D&Y62642.9[A$/('T[^PIS/0\X$D[C5L14=(>7^"^D,K% M6P(6;;IT@47F8OF**G"OA1\@'(D2WLB:+03_M"5K<**^YZB$$#O@F148^`W, MGUQ@,GL!2:M3F/+%C-IR#!+7XC,/HXQIA7 M*EV58VTEZB.S\'***X8YWF$*1V7PN/DG]<(\+$LIC\RR)USQU03D<)+\&9@P M'WX"0Y8PK9ST:*:J(\$MFJN8WQP`5]U*X3]*".C"_I4,OF5N])-YL@[7T?BB M9-G*?L+(B>HBHB,+Z*RJ>5OQ0JICW(;CV?K93+WQC$HP%;B8(RE?)!;3)W$% MT7'JCM_,G1GE4S3QACHSRS.CG!,VOD MC+PL=_`ACBQTS.Z:<>OP6TCF@LV.=]MOU\U\(,W-"S43.`8K`=Z>=?QOJ4$*4#B^5@M251S7R M8PG]DHW.M5R(,5`O`]MFQWN"9K^"1Y>X^/8_4$L!`AX#%`````@`G(-.1!CB M$>;44@``5I\#`!$`&````````0```*2!`````&MO;VPM,C`Q,S$R,S$N>&UL M550%``.7BOY2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`G(-.1`A19'#_ M"0``8'D``!4`&````````0```*2!'U,``&MO;VPM,C`Q,S$R,S%?8V%L+GAM M;%54!0`#EXK^4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`)R#3D37$ILX M#0\``+GZ```5`!@```````$```"D@6U=``!K;V]L+3(P,3,Q,C,Q7V1E9BYX M;6Q55`4``Y>*_E)U>`L``00E#@``!#D!``!02P$"'@,4````"`"<@TY$\M$_ M.KM,``"'QP0`%0`8```````!````I(');```:V]O;"TR,#$S,3(S,5]L86(N M>&UL550%``.7BOY2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`G(-.1.C2 MXM.O)```6I<"`!4`&````````0```*2!T[D``&MO;VPM,C`Q,S$R,S%?<')E M+GAM;%54!0`#EXK^4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`)R#3D3. M<3--!PD``,M1```1`!@```````$```"D@='>``!K;V]L+3(P,3,Q,C,Q+GAS M9%54!0`#EXK^4G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"```CZ``` "```` ` end XML 40 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Details) (USD $)
 6 Months Ended
Dec. 31, 2013
Jun. 30, 2010
License and Escrow Agreement [Abstract]    
Minimum cash balance and short-term investments $ 2,000,000 $ 6,000,000
Warranty [Abstract]    
Period of warranty on products, minimum 1 year  
Period of warranty on products, maximum 2 years  
Schedule of changes in product liability included in accrued liabilities [Roll Forward]    
Balance at July 1, 2013 489,000  
Warranties issued during the period 90,000  
Settlements made during the period (75,000)  
Changes in liability for pre-existing warranties during the period (142,000)  
Balance at December 31, 2013 $ 362,000